

1-1-2017

Mechanisms Of Hormonal Regulation Of Invasiveness And Metastasis Of Luminal Breast Cancer

Thomas Mcfall
Wayne State University,

Follow this and additional works at: http://digitalcommons.wayne.edu/oa_dissertations

 Part of the [Oncology Commons](#)

Recommended Citation

Mcfall, Thomas, "Mechanisms Of Hormonal Regulation Of Invasiveness And Metastasis Of Luminal Breast Cancer" (2017). *Wayne State University Dissertations*. 1844.

http://digitalcommons.wayne.edu/oa_dissertations/1844

This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState.

**MECHANISMS OF HORMONAL REGULATION OF INVASIVENESS AND METASTASIS OF LUMINAL
BREAST CANCER**

by

THOMAS MCFALL

DISSERTATION

Submitted to the Graduate School

of Wayne State University,

Detroit, Michigan

in partial fulfillment of the requirements

for the degree of

DOCTOR OF PHILOSOPHY

2017

MAJOR: CANCER BIOLOGY

Approved By:

Advisor

Date

© COPYRIGHT BY

THOMAS MCFALL

2017

All Rights Reserved

DEDICATION

This dissertation is dedicated to my family and friends, who have been my role models throughout my life.

To my mother, who has fought cancer and understands the true trials and tribulations of this disease. She was my first teacher and was instrumental in my decision to study biological sciences.

To my father who has taught by example to be resourceful, patient, loving, strong, and independent.

To my many siblings who have taught me how unique each life is.

To my lovely wife, who has been patient and stood by me through my winding path of career discovery.

To my close friend Michael Matthews, who has taught me to explore, wonder and appreciate my surroundings to truly enjoy the little things in life.

To my close friend and teacher Manohar Ratnam, a man that never stops pondering and pushing to learn more.

ACKNOWLEDGMENTS

I would like to thank my mentor, Dr. Manohar Ratnam, without him this project would not have been possible. Dr. Ratnam has taught me to think both critically and creatively. Dr. Ratnam has devoted a majority of his time to my needs, making my future and education his top priority. He has acted as a leader, teacher, friend, and sage. I am forever grateful to his wealth of knowledge and generosity.

I would like to thank Dr. Mugdha Patki, Lilly Huang and Dr. Rayna Rosati for their patience and friendship throughout the years. They taught me how to think carefully and acted as expert consultants regularly. Without their support, many of the experiments performed could not have been done. I would also like to thank Brooke McKnight and Dr. Viola, who both gave countless hours of their time to teach me how to perform *in vivo* mouse work.

I would like to thank Dr. Stephen Patrick, as he acted as a life mentor and remained highly involved in scientific discussions with Dr. Ratnam and I throughout my time at Wayne State University. I would also like to thank my committee members Dr. Matherly, Dr. Podgorski, and Dr. Yang for their participation and guidance throughout my PhD.

Finally, I would like to thank my funding, T-32 CA009531 from the NIH and the Rumble Fellowship from Wayne State University.

TABLE OF CONTENTS

DEDICATION	ii
ACKNOWLEDGEMENTS	iii
INTRODUCTION	iv
LIST OF TABLES	vii
LIST OF FIGURES	ix
LIST OF ABBREVIATIONS	xi
CHAPTER: 1 BACKGROUND	1
1.1 Clinical pathology of breast cancer	1
1.1.1 Histological subtypes	1
1.1.2. Breast cancer staging	2
1.1.3. Molecular classification	3
1.1.4. Breast Cancer Etiology	8
1.2 Estrogen biology	9
1.3 Estrogen receptor Structure and function	11
1.4 Adjuvant therapy in Hormone receptor positive breast cancer	13
1.4.1 SERMs	13
1.4.2 Aromatase Inhibitors	14
1.4.3 SERDs	15
1.4.4 Luminal Breast Cancer: Resistance to Endocrine Therapies	15
1.5. ER+ breast cancer dormancy and the role of anti-estrogen therapy	17
1.6 Progesterone Biology	18
1.7 Nuclear Progesterone Receptor Isoforms and function	19

1.8 Role of estrogen in invasion and metastasis	22
1.9 Role of Progesterone on breast cancer invasiveness and metastasis	24
1.10 The Role of EMT in ER+ Breast Cancer Metastasis	26
1.11. Current status of treatments for adv. breast cancer and their limitations.....	27
1.11.1 Survival of patients with metastatic breast cancer	27
1.11.2 Treatment of metastatic breast cancer.....	29
1.11.3 Molecular subtype-site specific metastases and overall survival	32
1.12 microRNA biogenesis and Regulation of mRNAs	34
1.13 miRNA Mediators in Breast Cancer	35
1.14 Current challenges of using miRNAs in cancer treatment	37
CHAPTER 2: ROLE OF THE SHORT ISOFORM OF THE PROGESTERONE RECEPTOR IN BREAST CANCER CELL INVASIVENESS AT ESTROGEN AND PROGESTERONE LEVELS IN THE PRE- AND POST-MENOPAUSAL RANGES	39
2.1 Introduction.....	39
2.2 Materials and methods	42
2.2.1 Chemicals and reagents	42
2.2.2 Cell culture and treatment	42
2.2.3 Western blot analysis	43
2.2.4 RNA isolation, reverse transcription PCR and real time PCR	44
2.2.5 Boyden chamber transwell invasion assay	44
2.2.6 Migration Assay	45
2.2.7 Lentiviral transduction	45
2.2.8 siRNA Transfection	45
2.2.9 mRNA expression profiling	46

2.2.10 Statistical analysis	47
2.2.11 Expression values from genome expression profiling	47
2.3 Results.....	47
2.3.1 Estrogen dose dependence for inhibition of invasiveness	47
2.3.2 Dose-dependent dual regulation of invasiveness by natural and synthetic progestins	48
2.3.3 The distinctive role of each PR isoform in the regulation of invasiveness by progestins	54
2.3.4 Effect of RU486 on PR-A mediated induction of invasiveness by progestins	57
2.3.5 Hypersensitization of PR-A to progestin through overexpression of the receptor	57
2.3.6 PR isoform A-dependent regulation of E ₂ target genes by progestin and their functional role	60
2.4 Discussion.....	67
CHAPTER 3: THE SHORT PROGESTERONE RECEPTOR ISOFORM SUPPORTS INVASIVENESS AND METASTASIS OF LUMINAL BREAST CANCER BY SUPPRESSING REGULATION OF CRITICAL MICRO RNAS BY ESTROGEN	
3.1 Introduction.....	68
3.2 Materials and Methods.....	74
3.2.1 Cell Line Models and Breast Tumor Specimens	74
3.2.2 Cell Culture and Hormone Depletion	75
3.2.3 Western Blot of Cells and Breast Tumor Tissues.....	75
3.2.4 Boyden Chamber Transwell Invasion Assay.....	75
3.2.5 Isolation and Measurement of Micro RNA and mRNA	76
3.2.6 Affymetrix Profiling of Micro RNAs Regulated by PR-A	76
3.2.7 Lentiviral Transduction.....	77

3.2.8 Transfection of siRNA or miRNA Inhibitor	77
3.2.9 Metastasis Pathway Gene Array Expression Analysis	77
3.2.10 Mouse Metastasis Model	77
3.3 Results	78
3.3.1 Identification of micro RNAs that are uniquely regulated by low dose progesterone through PR-A.	78
3.3.2 Regulation of micro RNAs by PR-A is sensitized to lower doses of progestin by overexpression of PR-A to a level observed in tumors.....	84
3.3.3 miR-92a-3p and miR-26b-5p are functionally linked to hormonal control of invasiveness.	84
3.3.4 miR-92a-3p and miR-26b-5p regulate genes associated with invasiveness and metastasis in luminal breast cancer cells	89
3.3.5 miR-92a-3p and miR-26b-5p profoundly impact metastasis in vivo.....	93
3.3.6 In primary human luminal breast tumors PR-A expression correlates negatively with miR-92a-3p and positively with miR-26b-5p	98
3.4 Discussion	100
CHAPTER-4 CONCLUSION	103
REFERENCES	106
ABSTRACT	150
AUTO BIOGRAPHICAL STATEMENT	151

LIST OF TABLES

Table 1.1. Treatments steps for molecular subtypes of breast cancer	30
Table 1.2 Patient relapse rate, overall survival and frequency of distant metastasis.....	32
Table 1.3 Metastatic site based upon breast cancer molecular subtype.....	32
Table 3.1 Data corresponding to heat map in Figure 3.1C	81
Table 3.2 Data corresponding to the heat map Figure 3.1D	82
Table 3.3 Data corresponding to the heat map in Figure 3.1E	83
Table 3.4 Data corresponding to heat maps in Figure 3.2B -D	32
Table 3.5 Data corresponding to heat map in Figure 4E.	92

LIST OF FIGURES

Figure 2.1 Dose response of regulation of breast cancer cell invasiveness by estrogen and progesterone	49
Figure 2.2 Inhibition of invasiveness by estrogen at different concentrations.	50
Figure 2.3 Absence of hormonal control of migration capacity of ER+/PR+ model cells	52
Figure 2.4 Regulation of breast cancer cell invasiveness by pre-menopausal concentrations of estrogen and progestin and dose-dependent effects of medroxyprogesterone acetate	53
Figure 2.5 PR-A vs. PR-B mediated effects of progestins on invasiveness of breast cancer cells.	55
Figure 2.6 Invasive capacity of the isogenic T47D-A vs. T47D-B cell lines	56
Figure 2.7 Effect of RU486 on regulation of breast cancer cell invasiveness by R5020 in relation to estrogen, PR-A and PR-B	58
Figure 2.8 Effect of overexpressing of PR-A on the progestin dose response for rescue of invasiveness from estrogen regulation.....	59
Figure 2.9 Effect of low dose progestin on the gene repression profile of estrogen in relation to PR-A and PR-B	62
Figure 2.10 Validation of gene expression profiling	63
Figure 2.11 Functional testing of selected tumor progression genes.....	65
Figure 2.12 Effect of low dose progestin on the gene activation profile of estrogen in relation to PR-A and PR-B	66
Figure 3.1: Possible pathways and candidate miRNAs that could be involved in the hormone-dependent cross talk of PR-A with ER that regulates invasiveness in breast cancer cells.	80
Figure 3.2. Higher doses of progestin do not enable PR-B to mimic the actions of PR-A on 15 miRNAs.	83
Figure 3.3: PR overexpression in primary luminal breast tumor specimens and the effect of PR-A overexpression on hormone sensitivity of miRNA regulation	85
Figure 3.4: Effect of inhibiting miRNAs hormonally regulated by PR-A and ER on invasiveness of luminal breast cancer cells	88

Figure 3.5: Roles of miR-92a-3p and miR-26b-5p in regulation of invasiveness and metastasis genes.	91
Figure 3.6. Hormonal regulation of invasiveness is not mediated by epithelial to mesenchymal transition	94
Figure 3.7 In BT474 PR-shRNA cells, progestin cannot rescue invasiveness from estrogen repression	95
Figure 3.8: Roles of miR-92a-3p and miR-26b-5p in regulating metastasis in an <i>in vivo</i> lymph node infiltration model.	97
Figure 3.9. Correlation analysis of PR-A, miR-92a-3p and miR-26b-5p in primary luminal clinical breast tumor specimens	99

LIST OF ABBREVIATIONS

AF	Activation Function Domain
AI	Aromatase Inhibitor
CK	Cytokeratin
DCIS	Ductal Carcinoma In Situ
E ₁	Estrone
E ₂	Estradiol
E ₃	Estriol
EMT	Epithelial to Mesenchymal transition
ER	Estrogen Receptor
ERE	Estrogen Response Element
FA	Focal Adhesion
FAK	Focal Adhesion Kinase
FBS	Fetal Bovine Serum
FSH	Follicle Stimulating Hormone
GnRH	Gonadotropin Releasing Hormone
HER2	Human Epidermal Growth Factor
HRT	Hormone Replacement Therapy
Hsp	Heat Shock Protein
IDC	Invasive Ductal Carcinoma
IHC	Immunohistochemistry
LBD	Ligand Binding Domain
LN	Lymph Node

miR	micro RNA
miRNA	micro RNA
MPA	Medroxy Progesterone Acetate
PR	Progesterone Receptor
PR-A	Progesterone Receptor Isoform A
PR-B	Progesterone Receptor Isoform B
PRE	Progesterone Response Element
RISC	RNA Induced Silencing Complex
SERD	Selective Estrogen Receptor Down Regulator
SERM	Selective Estrogen Receptor Modulator
SFM	Serum Free Media
SHBG	Serum Hormone Binding Globulin
TNBC	Triple Negative Breast Cancer

CHAPTER 1: BACKGROUND

1.1 Clinical pathology of breast cancer Breast cancer is the most common type of cancer diagnosed in women and the second leading cause of cancer related deaths in the United States (1). Due to the dependence on female sex hormones for growth and progression, this disease is diagnosed predominantly in women; however, it is still observed in men, accounting for less than one percent of all diagnosed breast cancers. Herein, we will discuss the biological properties of breast cancer from origin within the breast tissue to developed lesions and what factors drive this progression.

1.1.1 Histological subtypes: In order to understand breast cancer as a disease, it is important to know the biological composition of the breast and that not all breast cancer is the same. Although being classified under the umbrella of breast cancer, the origin of the tumor within the breast is critical for diagnosis and treatment of the disease. Breast tissue comprises lobules, ducts, adipose tissue, and connective tissue. The lobules produce milk, and the ducts carry milk to the nipple, whereas the connective tissue and adipose tissue provide structural support to hold other tissues in proper orientation to deliver milk (2). Breast cancer usually develops in the lining of the ducts, which comprises differentiated epithelial cells (3). The predominant histological subtypes of breast cancer are ductal carcinoma *in situ* (DCIS), invasive ductal carcinoma (IDC), and invasive lobular carcinoma (ILC) (4). Ductal carcinomas (DCIS, and IDC) are the most commonly diagnosed breast cancers. DCIS is intra-ductal, confined to the duct structure and has not yet invaded through the basement membrane (5), whereas IDC is invasive and has left the confines of the duct (6). DCIS is commonly treated by surgical resection involving lumpectomy (minimal tissue removal), or mastectomy (partial or complete), followed by radiation (7). IDC is the most common type of invasive breast cancer (80%) and its prognosis is variable, depending on

histopathological grade/subtype, tumor size, lymph node positivity, hormone receptor status and HER2 status (4). Treatment for IDC includes surgery (lumpectomy or mastectomy) followed by radiation, chemotherapy and hormone therapy. ILC is less common (<15% of invasive breast cancers) and predominantly occurs in post-menopausal women and usually maintains hormone receptor status throughout progression (7). Treatment of ILC is identical to IDC but the metastatic tissue profile is quite distinct. IDC preferentially metastasizes to the lungs, bone and central nervous system, whereas ILC metastasizes to gastrointestinal sites and organs located in the peritoneal cavity (8–10).

1.1.2. Breast cancer staging: After determining the histological subtype of the disease, it is important to diagnose the stage, an indication of how advanced the disease is for both diagnostic tools and for therapeutic intervention. The most common classification of staging for breast cancer is the TNM system (T= tumor size, N= lymphnode status, and M= metastasis). Tumor size can be denoted as “tis” (which represents ductal/lobular carcinoma in situ) or be given a numeric value. A value of 1 represents a tumor size less than 2cm. A value of 2 represents a tumor larger than 2cm but less than 5cm. A value of 3 is a tumor larger than 5cm, and a value of 4 is any tumor that has spread beyond the breast. Lymph node (LN) status is divided in to 4 subcategories; N0 (no LN metastasis), N1 (1-3 axillary LN are positive for cancer cells), N2 (4-9 axillary LNs are positive), and N3 (10 or more axillary LN are positive, or a supraclavicular LN is positive). Metastasis is subcategorized into 3 groups: MX (cannot be assessed), M0 (no metastasis), and M1 (metastasis). Based upon this classification system, breast cancers can be subdivided into stage I-IV. Stage I is classified as early detected breast cancer whereas stage II and III are defined as locally advanced breast cancer. Stage IV is any breast cancer that has metastasized.

1.1.3. Molecular classification: Estrogen has long been thought to be the primary culprit in breast oncogenesis, beginning with the discovery in 1902 that removal of ovaries in women with breast cancer resulted in regression of tumor size (11). Furthermore, it was discovered that estrogen was one of the primary hormones produced by the ovaries (12) and this led to strategies in the early 20th century to focus on surgery and oophorectomy which resulted in positive outcomes (30% survival). In 1968 the estrogen (ER) receptor was discovered (13), paving the way to classification of breast cancer on the basis of hormone receptor status. ER was used as a predictive marker for outcome of estrogen ablative therapy (14). This early classification was the foundation for the modern molecular classification of breast cancer, which also takes into account, expression of the progesterone receptor (PR) and the cell surface tyrosine kinase protein HER2/neu (human epidermal growth factor 2). A majority of breast cancers are hormone receptor positive (60% premenopausal, and 80% post-menopausal) (15). Hormone receptor positive breast tumors rely upon estrogen for growth and survival; hence anti-estrogens and estrogen depletion by non-invasive methods have become a mainstay in treating ER+ breast cancer. Breast cancers can express HER2 either in conjunction with or independently of ER and PR. HER2 is amplified in 30% of all breast cancers (16–18) and is associated with greater morbidity (19,20). Due to the high incidence of HER2 amplification, HER2 targeting antibodies have been produced and are used in the clinic. Humanized monoclonal antibodies targeting HER2 include pertuzamab which targets subdomain 2 of HER2 and trastuzumab which targets subdomain 4 of HER2. These monoclonal antibodies inhibit dimerization with HER3 and HER2 and ultimately cause the internalization of HER2 (21). Combining these antibodies with chemotherapy improves median survival from 20 months to 25 months (22). When ER, PR and HER2 are all absent in the tumor, the breast cancer is classified as triple negative breast cancer (TNBC). TNBC has a poor prognosis and can only be treated with

conventional chemotherapy, surgery and radiation due to the absence of drug target receptors (1). Taking into account histological grade and receptor status, breast cancer is classified as Luminal A, Luminal B and Basal like, which is included in a broader classification as triple negative breast cancer.

Luminal A breast cancers are highly differentiated and strongly resemble the cells of the inner lumen of the breast duct. Luminal A tumors tend to be ER positive, PR positive, and HER2 negative. This type of tumor is often classified as a low tumor grade. Roughly 65% percent of breast cancers are luminal A (23,24). Luminal A tumors have the best prognosis, with 97% 10-year relapse free survival (24). These tumors frequently have low histological grade, low degree of nuclear pleomorphism, low mitotic activity and are associated with good prognosis. Luminal-A is characterized by very high levels of ER and lower levels of high mitotic genes. Genetic profiling has shown that Luminal A breast cancers have high expression of cytokeratins (CK) 8 and 18 and other luminal associated markers including ER regulated genes. These genes include LIV1, ZIP6, FOXA1, XBP1, GATA GATA3, BCL2, erbB3 and erbB4 (25). Luminal A subtype is defined as ER-positive and PR-positive tumors with negative HER2 and low Ki67 index by immunohistochemistry (26). Recurrence is common in bone, whereas liver, lung and central nervous system metastases occur in less than 10% of patients and treatment is mainly based on hormonal therapy (27). Luminal A breast cancers are often treated with surgery and anti-estrogen therapy. Chemotherapy is not commonly used, as it has shown no additional benefit (28).

Luminal B tumors comprise of 15-20% of all cases of breast cancer and are considered more aggressive than Luminal A breast cancers. Luminal B breast cancers are also highly differentiated and originate from the inner lumen of the breast duct. Luminal B tumors tend to be estrogen receptor positive, progesterone receptor positive, and can be HER2 negative or positive.

They have a higher grade, faster progression, and worse prognosis than Luminal A cancers (29). Furthermore, these tumors have a higher rate of relapse (30). The largest difference between the two luminal subtypes is that Luminal B has increased expression of the genes v-MYB, GGH, LAPTMB4, and CCNE1. Furthermore this subtype also expresses HER2 in a third of the cases (31,32). Histologically Luminal B is defined as ER-positive, HER2-negative and Ki67 high. Also, Luminal B breast cancers can be classified as ER and HER-2 positive with low Ki67 staining intensity. It is important to note there is currently no standard way to define Luminal A and Luminal B by Ki67 cutoffs alone (33). The overall survival of untreated Luminal B cancers is similar to TNBC and HER2+/ER- cancers (34). Luminal B tumors tend to not be as sensitive to hormone therapy as Luminal A tumors. Furthermore, this subtype is more resistant to microtubule targeting taxanes when compared to HER2+/ER- and basal like breast cancers. This resistance has been attributed to the fact these cancers rely upon alternate growth pathways through PI3K, FGFR1, HER1, and Src signaling pathways (35–40). Fibroblast growth factor 1/ and 2 (FGFR1 and FGFR2) are amplified in Luminal B breast cancers and is associated with a higher resistance to endocrine therapy. Diagnosis occurs at a younger age with advanced stages of disease (40). Patients tend to have larger tumors and more lymph node metastasis. Furthermore Luminal B subtypes are more likely to relapse (40). Treatment options for Luminal B tumors include; surgery, chemotherapy, immunotherapy (trastuzumab) and anti-estrogen therapy (41). Once metastasis has occurred, patients are usually aggressively treated with anti-estrogen therapy, followed by single agent chemotherapy (anthracycline or taxane) (42). There are few proven standards of care in metastatic breast cancer management, resulting in variable treatment regimens depending on physicians and patients (42).

Basal like breast cancers account for roughly 35% of breast cancer cases (45,46). This subtype is associated with a high histological grade, poor tubule formations, and has necrotic cores. Furthermore, basal like tumors have high mitotic rates with solid growth patterns. They are marked by their high aggressiveness and high rates of metastasis to the brain and lungs (43,44). Basal like tumors also have high expression of myoepithelial markers, such as laminin, CK5, CK14, and CK17. Furthermore, these cells do not express high levels of ER, PR, or HER2 (70% of cases) and are also grouped as TNBC (44). Though not required for basal-like identification, this subtype has frequent P53 mutations, inactivation of Rb, and dysregulated integrin expression (44).

Oftentimes it is thought that basal-like breast cancers are triple negative, but the two classifications are not synonymous. Roughly 20-30% of basal-like breast cancers are not triple negative. TNBC is a classification used for immunohistochemical (IHC) identification of disease, and only relies upon the three markers ER, PR, and HER2. Basal-like breast cancer are identified by their gene expression, via microarray or realtime-PCR. It is important to note the basal-like classification is currently not in use in the clinical setting. This is in part due to the fact that all therapies currently used rely on the three markers identified by IHC for indication of various treatments. The classification of “triple negative” is considered to be a reliable surrogate for basal-like for all treatment purposes (45). There is a large amount of research to explore putative biomarker candidates for basal-like breast cancers, however, there have not been any reliable complementary biomarkers used in the clinic thus far (46). Researchers have also added the subtype of basal-like cancer as claudin-low. Claudins are needed for tight junctions between cells, and are commonly found in epithelial-like cells. Claudin-low basal-like breast cancers tend to be more mesenchymal-like and have much poorer outcomes when compared to other basal-like breast cancers (47).

Next generation sequencing, microarrays, and IHC analyses have shown that basal-like breast cancers make up roughly a third of *breast cancer 1 (BRCA1)* related breast cancers. BRCA1 is a gene located on chromosome 17. When BRCA1 is expressed, it plays a pivotal role in the DNA damage sensing process, and facilitates DNA damage repair. BRCA1 deficient tumors tend to be triple negative with P53, EGFR, and X-chromosome abnormalities. Basal-like tumors and BRCA1 related breast cancers both behave similarly and have early relapse and similar pattern of metastatic disease (48). BRCA1 is specifically involved in DNA double strand break repair. BRCA1 deficient cells are highly sensitive to agents that create double strand breaks, when used with a poly-ADP ribose polymerase (PARP) inhibitor (induce synthetic lethality) (49). PARP is an enzyme that repairs DNA single strand breaks, and inhibiting PARP increases the chances of creating multiple nicks in the DNA to create double strand breaks. Thus, inhibiting PARP in BRCA1 deficient cells can increase the number of double strand breaks, creating a lethal phenotype. PARP inhibitors are currently indicated for BRCA1 deficient advanced ovarian cancer, with several clinical trials on breast cancer ongoing. TNBC also includes secretory, adenoid, medullary (BRCA1 related), and high grade invasive ductal carcinomas. Triple negative breast tumors are treated with surgery, adjuvant chemotherapy, and radiotherapy (50). Triple negative non-basal like tumors have 93% 10-year relapse free survival, whereas basal-like has an 86% 10-year relapse free survival (24). More importantly if relapse occurs, it happens within three years. Women with BRCA1/2 deficiency have shown to benefit from prophylactic use of tamoxifen, and showed a significant reduction (10%) of contralateral breast cancer incidence after initial diagnosis (51). The benefits of tamoxifen have been attributed to the possible role of ER β in TNBC (52), but further investigation is needed.

1.1.4. Breast Cancer Etiology: Despite the fact that the etiology of breast cancer is not well understood, reports have described it as a culmination of factors such as hereditary-predisposition, somatic mutations, reproductive physiology, and environmental pressures. Germ line mutations account for a small proportion of predisposition to breast cancer, and are primarily attributed to BRCA1 (1% of cancers) and BRCA2 (4% of cancers), and carriers with susceptibility mutations have an 80% life time risk of developing breast cancer, and women with a primary family member with BRCA1 and/or BRCA2 mutations are twice as likely to develop breast cancer than the female population (53–55). More importantly BRAC1/2 mutations are more strongly associated with developing TNBC, resulting in prophylactic measures such as mastectomy, tamoxifen, and oophorectomy (56).

Increased exposure to estrogen (earlier onset of menarche and later onset of menopause) has shown to increase risk of developing breast cancer (57). Furthermore, exposure to estrogenic like compounds, aromatic amines, polyaromatic hydrocarbons, tobacco smoke and radiation are risk factors associated with breast cancer (58). More recently it was shown that hormone replacement therapy (HRT) which is used to mitigate menopausal symptoms plays a role in breast cancer risk. The women's health initiative study of 2007, showed women receiving estradiol (E₂) and medroxyprogesterone acetate (MPA) had increased incidence of advanced stage invasive breast cancer when compared to non-users. Furthermore, women who received hysterectomies and received estrogen alone had decreased late stage IDC breast cancer when compared to non-users (59,60). These studies were essential to the decision to decrease HRT in the general public to reduce the incidence of IDC.

1.2 Estrogen Biology. Estrogens are the primary female sex steroid hormones and are responsible for the development and regulation of the female reproductive system, secondary sexual characteristics and development of the central nervous system. There are three naturally occurring estrogens in women; Estrone (E_1), Estradiol (E_2), and Estriol (E_3) (61). E_3 is the most abundant estrogen, yet the weakest in terms of estrogenic activity. E_2 is 80 times more potent and plays the predominant role in estrogen signaling during sexual maturation and development (62). The lower circulating plasma levels of E_2 when compared to E_1 and E_3 is because of E_2 's high affinity for steroid hormone-binding globulin (SHBG) (63). In pre-menopausal women, E_2 is primarily produced by the ovaries and has dynamic concentration ranges depending on the stage of the menstrual cycle. Plasma levels range between 1.4-1.6 nM during the follicular phase and 3.6-4.2 nM during the luteal phase (64). During pregnancy, estrogen levels increase about 40 times in the form of E_3 due to heightened production in the placenta (65). Synthesis of estrogens is stimulated by the secretion of gonadotropin releasing hormone (GnRH) which is synthesized in the hypothalamus. GnRH stimulates the release of follicle stimulating hormone (FSH) from the anterior portion of the pituitary gland. FSH then acts as a signaling molecule to increase estrogen synthesis in the granulosa cells of the ovary (66). High levels of circulating estrogen acts as a negative regulator on GnRH production, creating a negative feedback loop (66). Biochemical synthesis of estrogens starts in the theca-interna of the ovary, whereas androstenedione is synthesized from cholesterol. Androstenedione then passively diffuses to the granulosa cells where it is converted into either E_1 or testosterone. In an additional step, testosterone is converted to E_2 by the enzyme aromatase (67). Both E_1 and E_2 can be readily converted to E_3 by redox reactions in the liver or placenta (68–70). Adipose tissue, smooth muscle and liver express high levels of aromatase which can convert circulating androgens to estrogens, and this is the primary source of

estrogens post-menopause (69,71). Though circulating E₂ plasma levels are profoundly low post-menopause (~0.1nM), breast tissue estrogen levels are significantly higher (1.4+0.7 nM) (72–74). Higher breast tissue concentrations are maintained by local *de novo* synthesis and what is believed to be a retention capture mechanism that is not well understood (73).

Estrogen plays a diverse role in vertebrate development which includes sexual maturation and cognitive health. The human female relies upon estrogen and progesterone for the development of the breast in both pre-pubertal and post-pubertal stages (75). During the development of the breast, the ductal system is primarily under the control of E₂ and progesterone. Duct elongation is stimulated by both estrogen and progesterone whereas ductal branching is stimulated by growth hormone and progesterone (75). The proliferative effects of E₂ also occurs in the endometrium, where E₂ acts as the initiator of the menstrual cycle. E₂ is required for endometrial wall thickening during the follicular and early luteal stages of the menstrual cycle (76). The endometrium then becomes much more vascularized to support the implantation of the blastocyst and for placental development (76).

Estrogen functions are not limited to reproductive health and have critical roles in maintaining bone mineralization and density. Estrogen signaling alters population pools of osteoclasts (responsible for bone resorption) and osteoblasts (responsible for bone formation)(77) (77). Estrogen limits osteoclasts formation by decreasing their population through apoptosis, and increases osteoblasts by supporting their proliferation. Post-menopausal osteoporosis is primarily the result of low circulating estrogen, causing a shift in balance resulting in osteoclasts outnumbering osteoblasts (77). Prolonging estrogen exposure with exogenous hormone has shown to be beneficial in fighting osteoporosis (78). Estrogen also acts as an important regulator of cardiovascular health by maintaining a lipid profile that is high in HDL-cholesterol and low in

LDL-cholesterol (79). The shift in lipid profile has had a significant effect in lowering risk of coronary heart disease (79). Furthermore, estrogen is known to be important in cognitive memory, mood, libido, and obsessive compulsive disorder (80–82). Estrogens have diverse roles in human development and the need for their stringent regulation is essential in normal human physiology throughout a woman's life.

1.3 Estrogen receptor Structure and function. Estrogens have great potential in changing physiology and cellular phenotypes in relatively short spans of time. Estrogen signals through the estrogen receptors. Estrogen actions can be mediated by non-genotropic estrogen receptor proteins which are primarily membrane bound G-coupled protein receptors. Many have been identified, but the most significant one is considered to be GPR30, which is expressed in most cell types. In general, when using the nomenclature “ER” henceforth, reference is made to the nuclear receptor subtype coded by the ESR genes. ER is a ligand-activated transcription factor which preferentially binds the more potent estrogen E₂. ER is a nuclear receptor that belongs to the steroid/thyroid/retinoid/orphan receptor superfamily. There are two main isoforms; ER α and ER β . ER α is encoded by the gene *ESR1* located on 6q24 and spans nearly 300kb with eight coding exons (about 140kb) and seven introns (83). ER β is encoded by *ESR2* on chromosome 14q21 and comprises eight exons (84). Both receptors comprise an activation function domain 1 (AF1-A/B), a DNA binding domain (C Domain), a hinge region (D Domain) and activation function domain 2 (AF2-E Domain). They are homologues with 17% similarity in the A/B domain, 97% in the C-domain, 30% in the D domain, 55% in the E domain and 18% in the F-domain (85). The AF-2 domain of both receptors is responsible for ligand activated functions. E₂ binding creates a unique conformation change resulting in repositioning of helix 12 in the AF-2 region. The change in position of helix 12 is what promotes dimerization and co-regulator binding. A ligand's ability to

alter the position of helix 12 is what distinguishes an agonist from an antagonist (86). The ESR1 gene has at least seven known promoters, and none of them have a CCAAT, GC, or TATA box. The diversity in promoters is thought to be responsible for tissue and cell specific regulation by distinct signaling pathways. The ESR2 promoters have not been well studied, but two (GO and ON) are known to strongly regulate its expression (87). The two receptors are found in the breast tissue, cardiovascular system, bone, and ovaries. However, distinct tissue specific regions of expression have been reported. ER α is primarily expressed in the liver and thecal cells of the ovary, whereas ER β is the predominant isoform in the smooth muscle and granulosa cells (88). In normal breast tissue, ER⁺ cells are largely non-dividing but utilize E₂ signaling to upregulate paracrine factors to support ER-negative cell growth (89).

The functional canonical signaling of ER is primarily based upon location, ligand binding, and cofactor recruitment. Initially ER is bound by chaperone heat shock proteins (Hsps) Hsp70 and Hsp90 (90). Ligand binds to ER in the ligand binding domain creating a three-dimensional structural shift releasing ER from Hsp grasp. A heterodimer or homodimer composed of ER α and ER β can bind to estrogen response elements (EREs) in DNA directly. EREs are 13 nucleotide palindromes consisting of two half sites separated by 3 nucleotides: GGTCAnnnTGACC (91). Once ER binds to the ERE it recruits cofactors for expression or repression of target genes. The majority of co-activators belong to the p160 family which consists of SRC1/2/3, ACTR, A1B1 and GRIP1. These proteins then bind to the AF-2 domain of ER by utilizing their NR-box (92). This complex in-turn recruits and binds to the core transcription machinery to express ER target genes downstream. In contrast, ER can also bind to the co-repressors SMRT and NCoR which recruit histone deacetylases (HDACs) to keep downstream genes inaccessible (93). Most of ER target genes are targeted through ERE specific binding and regulation, yet a large minority (30%)

of genes do not contain EREs. ERE-independent regulation is due to ER's ability to bind to other transcription factors and regulate a distinct subsets of genes. ER binding can be mediated by SP1, Fos, Jun and NF- κ B to target a distinct sets of genes (94). All of these tethering mechanisms still rely on P160 proteins for transactivation.

ER can act as a transcription factor in a ligand-independent manner. Growth factors signaling through insulin-like growth factor-1 (IGF-1), epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor (IGFR) activate MAPK. Active MAPK signaling results in phosphorylation of ER at ser118. Phospho-ser118 causes ER to act as a transcription factor in the absence of ligand and stabilizes ER by decreasing proteolytic turnover (95). Rapid non-genomic signaling does play a role in ER signaling, but most long-term ER functions rely upon classical ligand-dependent canonical signaling.

1.4 Adjuvant therapy in Hormone receptor positive breast cancer. When initially diagnosed, breast cancer is generally localized. However, after metastasis has occurred patients are virtually incurable and succumb to metastatic disease. First line therapy includes surgery and chemotherapy and is usually followed by adjuvant therapies to minimize growth of cells that have already spread. In hormone receptor positive breast cancer, anti-estrogen therapy is a critical tool and is divided into three categories: selective estrogen receptor modulators (SERMs), Aromatase inhibitors, and Selective estrogen receptor down regulators (SERDs).

1.4.1 SERMs are a group of compounds that bind ER and act as partial agonists/antagonists. SERMs are primarily used because they repress the canonical signaling by recruiting co-repressors at ERE sites in breast tissue. The most widely used SERMs are Tamoxifen and Raloxifene. Tamoxifen is indicated for use in both pre-and post- menopausal women and was the first SERM used in ER+ breast cancers in the U.S. (96). Tamoxifen has antagonist effects on

breast tissue but acts as a partial agonist on bone, cardiovascular and the uterine tissues (97). The agonist or antagonist effects of Tamoxifen are based upon the promoter context and cell type (98). Tamoxifen at a dose of 20mg/day reduces mortality in breast cancer patients by 26% and decreases contralateral breast cancer incidence by 50% (99). Benefits are reported to persist for an additional 10 years after treatment. Due to the estrogenic effects of Tamoxifen on the endometrium and cardiovascular system, women are twice as likely to develop endometrial cancer when treated with Tamoxifen for longer than 5 years (100) and are at increased risk for vascular thrombotic events (101).

Raloxifene is a second generation SERM initially used to treat osteoporosis. However, a large comparative clinical trial of Tamoxifen and Raloxifene showed the efficacy of Raloxifene was no different from Tamoxifen in preventing hormone receptor positive breast cancer (102). When comparing the two SERMs, Raloxifene had a lower toxicity profile and less side-effects when compared with Tamoxifen. Patients using Raloxifene have lower incidence of thrombotic events, and lower risk of endometrial cancer when compared to Tamoxifen (102). There are third generation SERMs available and studied, however, there is no additional benefit when compared to Tamoxifen and Raloxifene.

1.4.2 Aromatase Inhibitors block the activity of the protein aromatase, a cytochrome P450 enzyme responsible for converting testosterone to E₂ and androstenedione to E₃ (103). Aromatase is expressed in a variety of tissues and plays a necessary role in estrogen production. Following menopause, the synthesis of estrogens by the ovaries stops but peripheral tissues can still maintain low systematic levels of estrogen through the expression of aromatase (103). There are two types of aromatase inhibitors; Type 1 and Type 2 inhibitors (104). Type 1 inhibitors include exemestase and formestane, which act as competitive inhibitors of androstenedione. Type 2 inhibitors include

anastrozole and letrozole, which reversibly bind to the heme-group of the aromatase enzyme (105). Aromatase inhibitors are able to decrease intratumoral estrogen levels 30-fold (106), and virtually ablate circulating hormone levels in post-menopausal women (107). Pre-menopausal women have an intact hypothalamic-gonadal feedback loop which can compensate for the reduction of estrogen by aromatase inhibitors, thus aromatase inhibitor use is restricted to post-menopausal women (108). Aromatase inhibitors are indicated for postmenopausal women with local ER+ breast cancers and have been shown to decrease relapse by 40% (109).

1.4.3 SERDs are indicated for ER+/Her2- tumors that rely on ER for proliferation independent of E₂. Most tamoxifen and aromatase inhibitor-resistant breast cancers develop resistance by non-classical signaling as described above. SERDs such as Fulvestrant are steroidal anti-estrogens used in second-line therapy of ER positive breast cancers. Fulvestrant binds to ER, and is a pure competitive inhibitor with no agonist activity. It functions by binding to ER in the ligand binding domain and inhibits ER dimerization and signals proteolytic degradation with its long hydro-carbon side chain (110). Fulvestrant decreases cancer progression by 34% in patients resistant to first line therapies (111). Use of Fulvestrant is limited to second line treatment, primarily because of the global loss of ER, which is needed in normal healthy tissue.

1.4.4 Luminal Breast Cancer: Resistance to Endocrine Therapies. Resistance to endocrine therapy has been addressed by several theories of how hormone receptor positive breast cancer may behave over the course of disease progression. ER loss over time occurs in 20% in patients originally diagnosed with Luminal subtypes of breast cancer (112–114). These tumors are no longer reliant on estrogen and utilize pathways that are used in lieu of estrogen. In some cases, upregulation of HER2 occurs and, although it is rare (113,115), can actually drive down the expression of ER and PR, rendering cells less responsive to anti-estrogen therapy (116,117). Pre-

clinical work has suggested the possibility that tumors switch back and forth between ER and HER2 positivity by selective pressure from neo-adjuvant therapies (29,113,115,116,118,118). This may require continuous monitoring with use of multiple biopsies.

ER splice variants (ER α 36) and estrogen related receptors ERR, though not commonly seen, have been implicated in resistance to tamoxifen therapy. ER coregulators are thought to play a more important role in tamoxifen resistance. Overexpression of AIB1 has shown to be an important for tamoxifen resistance both in vitro and in the clinical setting (119,120). Furthermore, the silencing of NCoR is associated with lack of transrepression by Tamoxifen, resulting in Tamoxifen resistance (93). ER can localize outside of the nucleus where it can act as an activator of cytoplasmic and membrane signaling complexes (120–123). These pathways have been shown to be a part of a feed forward loop which increases ER cytoplasmic localization, enhancing ER's non-genomic signaling. Interestingly both tamoxifen and estrogen can activate this cascade, creating an “off target” effect that supports tamoxifen resistance (120,121,123). Lastly ER can remain active in the presence of estrogen antagonists via tethering by NF-kB and AP-1 to maintain its genotropic effects (121,124,125).

Loss of PR is common during hormone therapy and is associated with worse outcome. ER upregulates PR, and if a tumor is ER+/PR-, it indicates ER is functioning independent of ligand (117). This is in part to be due to ER splice variants, and gain of function mutations. PR loss is also associated with increased PI3K signaling, which is known to downregulate PR expression (126). In some instances when patients progress on antiestrogen therapies (Tamoxifen and aromatase inhibitors), high dose estrogen is given to stimulate a switch to estrogen dependence and upregulation of ER. Following estrogen treatment, patients are withdrawn from estrogen. This induced estrogen dependence and deprivation causes cells to become less proliferative. Though

this is not common practice, a single patient is reported to have metastatic bone disease controlled for 8 years by continuous sequences of estrogen therapy followed by withdrawal (119). Other resistant theories include the small population of tumor like stem cells, which may play a crucial role in shifting the balance of tumor cell populations between endocrine dependent and independent pathways.

Though there is no clinical evidence, pre-clinical studies have shown that upregulation of mitotic signaling pathways may play a role in endocrine therapy resistance. For example, upregulation of Myc, cyclin D and cyclin E cause resistance to anti-estrogens *in vitro*. Furthermore, loss of function mutations in P27 and P21, followed by inactivation of pRb is also indicative of resistance (127,128). In parallel, it is expected that growth factor receptor signaling from the tumor microenvironment plays an essential role in resistance. Tyrosine kinase families such as IGF1, FGF, and VEGF, as well as cellular Src, AKT, and stress-related kinases have been implicated (117,129–131). Despite knowledge of all of these possible pathways and mechanisms of resistance, the most reliable and clinically relevant mechanism established to date is the EGFR/HER2 pathways as therapies that target this signaling axis are effective.

1.5 ER+ breast cancer dormancy and the role of anti-estrogen therapy

Breast Cancer Dormancy and metastasis is the primary reason for mortality in ER+ breast cancer cases. Dormancy is defined as a period when tumors are undetectable and can remain in a quiescent state below the threshold for identification in the clinic. Roughly 20-40% of ER+ breast cancer metastasizes to distant sites, with half occurring after 5 years of dormancy (upwards to 20 years) before reappearing (132). ER- tumors recur much more quickly and reappear in less than 3 years (133). ER+ breast cancers rely upon E₂ for growth and proliferation and anti-estrogen therapies have powerful effects in decreasing recurrence (134). However, recurrence is simply

postponed with increased time of exposure to anti-estrogens. This suggests that limiting E_2 signaling through ER does not kill the cancer cells but keeps cells in a state of dormancy (132). E_2 is not required for basal growth and survival of ER+ cells. The ER apoprotein can maintain low state of basal growth through the upregulation of the RAR α apoprotein, directing cell survival and growth pathways (135). Though anti-estrogen therapy increases duration of survival in ER+ breast cancer cases, the issues of metastasis and dormancy remain as major problems throughout the remaining years of a patient's life.

1.6 Progesterone Biology

Progesterone is a steroid sex hormone that is often thought of as estrogen's opposing counterpart. It belongs to a group of hormones called progestogens and is the most functionally relevant and abundant progestogen in the human body (136). Progesterone acts as a signaling molecule by binding to its receptors, the progesterone receptors (PR). There are two major nuclear PR isoforms and several membrane PRs that act as strong intracellular signal transducers (as discussed below).

Progesterone is synthesized from its precursor pregnalone by the enzyme 3-beta-hydroxysteroid dehydrogenase (137). During pre-menopausal years the corpus luteum secreted progesterone disseminates through the entire body. Most of the systemic progesterone is bound to albumin and transcortin with only 10% being unbound (138). Progesterone is often called the hormone of pregnancy because of its important roles prior to blastocyst implantation and post-implantation (76). Progesterone is responsible for converting the endometrium into the secretory phase, a time when the endometrial epithelium is prepared for implantation. It however plays an anti-mitogenic role in opposing the trophic effects of E_2 on the endometrium. However, progesterone promotes a state of stasis that supports vascular composition following implantation

for fetal development and placental growth (139). If implantation does not occur, progesterone levels decrease due to loss circulating human chorionic gonadotropin (developed by the blastocyst) signaling to the corpus luteum. Loss of progesterone signaling results in atrophy and shedding of endometrial lining and marks the beginning of menses (140). Progesterone is also responsible for reducing the maternal adaptive immune system in order to protect the fetus from rejection (141). The presence of progesterone is required for pregnancy and inhibition of fetal partition throughout the gestational term. During this protective period, progesterone reduces smooth muscle contractility, inhibits lactation, and opposes onset of labor. Progesterone is essential for secondary sexual characteristics such as proper breast development. Progesterone is responsible for lobuloalveolar development in the mammary gland (described further below) by the upregulation of paracrine factors such as RANKL (142).

1.7 Nuclear Progesterone Receptor Isoforms and their functions

The progesterone receptor (PR) is encoded by the *PGR* gene located on chromosome 11q22. It has three isoforms which are all encoded by the same gene. The expression of each isoform is under the control of alternate promoter usage (143). The expression of the progesterone receptors is primarily regulated by the distinct estrogen response elements located upstream of the *PGR* locus. The three isoforms include the progesterone receptor A (PR-A), the progesterone receptor B (PR-B) and the progesterone receptor C (PR-C). PR-A and PR-B are the major isoforms expressed in human tissues and have a ligand dependent role. The long-term genotropic actions of progesterone are mediated through PR-A and PR-B and act in a similar fashion as other steroid receptors. In the absence of ligand, the PRs are sequestered by heat shock proteins Hsp-90,-70 and P59 (144–146). Upon progesterone binding, the receptor undergoes a conformational change resulting in a monomeric receptor absent of Hsp's (147). The receptors spontaneously dimerize

(both in hetero- and homo-dimers) and bind to specific DNA sequences called progesterone response elements (PREs) (147,148). PR/PRE occupied sites recruit co-activators and co-repressors to regulate gene expression. PR-B is the longer isoform with a length of 933 amino acids and includes an additional AF3 domain (149). PR-A is identical to PR-B except that it lacks the N-terminal AF-3 domain and is 769 amino acids in length (149) (Figure 1.1). Both isoforms have identical transcriptional activation domains (AFs) with AF1 located in the N-terminus and AF-2 in the ligand binding domain. AF1 and AF2 can function independently or they can synergize through an intra-molecular interaction between the N- and C-termini (143,150–153). Both homodimers and heterodimers can bind to an imperfect PRE palindrome (G•ACA•••TGT•C) (154). Each one of the three possible dimer pairs regulates a distinct set of genes (155,156). Both receptors have similar affinity for progesterone, but the transcriptional profile of each isoform has little overlap (157). In most cellular contexts, PR-A acts as a transcriptional repressor and PR-B acts as a transcriptional activator (158). PR-B has a higher affinity for transcriptional co-activators GRIP and SRC1, whereas these cofactors do not bind to PR-A. The first 140 amino acids of PR-A contain the inhibitory domain (ID). The ID is completely exposed due to the lack of the AF-3 domain (158). When deleterious point mutations are made in the ID, the transcriptional repressive function of PR-A is lost (158). The intact exposed ID is responsible for the high affinity between PR-A and the co-repressor SMRT (159). PR-A is considered a strong trans-dominant repressor of PR-B, glucocorticoid receptor (GR), androgen receptor (AR), mineralocorticoid receptor (MR), and estrogen receptor (ER) (160–162).




Figure 1.1. Progesterone receptor isoforms and functional domains

Unlike ER, PR is not inherently proliferative or anti-proliferative. Progesterone/PR activate the progression through one mitotic cycle followed by G1 arrest. The halt in cell cycle is caused by the induction of P27, P21 and reduction of cyclins D and E. During G1 arrest, progesterone upregulates growth factor receptors to promote paracrine stimulation of growth. Progesterone can be paradoxical and can act as an inhibitor of growth, or a necessary prerequisite for growth depending on the environmental context (163,164). The inhibitory effects of progestins on tumor growth were being pursued as a therapeutic in the early 1980s, and was observed to be as useful as anti-estrogens (165). However, it is important to note these early studies were using tumor growth as an endpoint and not tumor progression (invasion and metastasis) which will be discussed below.

Both PR-A and PR-B are normally expressed *in vivo*, however the ratio of expression is variable based upon tissue/cell type, physiological states, and disease. PR-A and PR-B are known to have unique tissue specific roles, and can have altered expression ratios depending on the anatomical and physiological context. Isoform levels change drastically in the endometrium depending on the stage of the menstrual cycle. In the CNS PR-A is the predominant form in the pituitary gland and PR-B is the predominant isoform in the hypothalamus (167). In the breast, overexpression of PR-A causes severe hyperplasia and disorganized basement membrane of the duct (168). In contrast, overexpression of PR-B causes growth arrest of the duct and inhibition of lobulo-alveolar differentiation (169). Furthermore, PR-A knockout in mice has no effect on normal breast development. Clinical evidence has shown different roles for each isoform expression in cancer as well. Overexpression of PR-A in human breast tumors is associated with more aggressive breast cancers and lower disease-free survival (170). In contrast, over-expression of PR-B is associated with more aggressive endometrial, cervical and ovarian cancers (171). Though the PR isoforms are similar in structure, the distinct role of each is quite different depending on the cell type and tissue.

1.8 Role of estrogen in invasion and metastasis

ER positive breast cancer accounts for the majority of breast cancers (75-80%) and strongly relies upon E_2 for growth. Growth is supported by activation of genes that support mitosis, cell cycle progression, and survival (172). Tamoxifen and aromatase inhibitors as described above have had significant impact in increasing survival. However, ER+ breast cancers can become growth adapted through multiple pathways (173) to grow independent of E_2 (135). In over 90% of cases with lymph node positive metastasis, cancer cells still retain ER even if growth is not reliant on E_2 (174).

The majority of studies of E₂ mediated effects on breast cancer have been devoted to the genotropic effects on growth (175). However, it is important to note that E₂/ER play multiple roles unrelated to proliferation. In the ductal epithelium, E₂ signaling through ER is required for terminal differentiation and morphogenesis of the duct. In ER expressing breast cancer cells, E₂ represses invasion both *in vitro* and *in vivo* (176–178). Furthermore, clinical evidence from *The Women's Health Initiative* has shown that women with prior hysterectomy receiving estrogen hormone replacement monotherapy have decreased risk for invasive ductal carcinoma when compared to non-users (60).

Transcriptional regulation by E₂ through ER can activate genes but a majority of E₂ regulated genes are repressed. Most studies of E₂-repressed genes have focused on a subset of genes thought to be negative regulators of growth and survival(179–181). However, E₂ also represses critical genes that are necessary for invasion *in vitro* (182). This repressive effect on invasion was clearly defined by the ability of ER to bind co-repressors and down regulate genes needed for invasiveness (182). Furthermore, the use of tamoxifen blocked the repressive role of ER increasing invasion (182). Ectopic overexpression of ER in the presence of estrogen reduced invasive capacity in hormone receptor-negative cells (183). Furthermore, ER's ability to repress invasion occurs even if cells do not rely on E₂ for growth (182). The hormone regulated repressive effects of ER rely upon the AF-2 domain, as mutations in this region (LBD) result in loss of regulation of invasiveness (184) (Figure 1.1). Clinical studies have shown that tamoxifen did reduce mitotic capabilities of ER+ breast cancer, but also increased the risk of contralateral ER- breast tumors 5 fold (134). E₂ and ER play an important dual role in supporting growth/survival but repressing invasiveness/metastasis in breast cancer cells.

1.9 Role of progesterone in breast cancer invasiveness and metastasis

Progesterone and other progestins increase invasiveness and metastasis. During normal post-pubertal development breast cells are required to proliferate, migrate, and invade during the luteal phase and pregnancy (185). Both of these events are marked by high levels of plasma progesterone. This led to the hypothesis that progesterone could take advantage of these pathways and utilize them for the progression of breast cancer. Women receiving hormone replacement therapy with both E₂ and progestin have a higher incidence of invasive breast cancer when compared to non-users and women receiving E₂ monotherapy (59). Progestins at high doses cause rapid cellular changes through non-genomic signaling. These rapid signaling cascades increase migratory capacity by increasing focal adhesion (FA) complexes needed for lamellopodia and filopodia (186). FAs are mediated by Focal Adhesion Kinases (FAKs), which activate the recruitment of the stress fiber mediators vinculin, talin and paxillin (187,188). High dose progesterone (>10nM) through PR increases FAK phosphorylation resulting in rapid increased cellular protrusions into the extracellular space. Furthermore, increased migratory ability is mediated by liganded nuclear PRs utilizing Src signaling (189). Interfering with each PR, Src, RHOA, ROCK2, MAPK and MEK1/2 independently resulted in the blocking of progestins' ability to promote FA complexes. In addition to FAK signaling, high doses of progestin (>20 nM) has been reported to reduce E-cadherin protein in MCF7 cells, resulting in a more mesenchymal phenotype. Non-genomic signaling clearly results in an increased metastatic phenotype, however, all studies were performed at doses well above post-menopausal plasma and correspond to HRT scenarios.

Malignant ER⁺ breast cancer tissues often have a dysregulated expression of the PR isoforms. Normal PR⁺ breast tissue cells express equal amounts of each PR isoform. However,

70% of metastatic tumors have an excess of PR-A or PR-B (170,190). Moreover, the overexpression of PR-A is associated with lower disease-free survival (170). Interestingly, tumors overexpressing PR-A often manifest in post-menopausal years (170), a time when circulating progesterone levels are in the sub-nanomolar ranges (191). Most studies of progesterone receptor-dependent invasiveness have relied upon the ectopic expression of PR-B with progestin doses well above physiological levels (192–196). Knock out models in mice show that PR-B expression alone allows for normal breast ductal morphogenesis (197). In contrast, the expression of PR-A alone leads to malignant transformation (198). Furthermore, overexpression of PR-A leads to ductal hyperplasia and dysplasia at normal endogenous progesterone levels (168,199). It was long thought that following menopause, progesterone was virtually absent (~1 nM) when compared to their normal physiological ranges during reproductive years (4 nM in the follicular phase and increases up to 50 nM in the luteal phase) (200). This led to the hypothesis that the mere expression of either progesterone receptor isoform in the absence of hormone could regulate a gene profile that supported invasiveness. It has been reported that apo-PR-A has a distinct regulatory profile that is sufficient to alter cell morphology into a more migratory phenotype (201). Historically all of the *in vitro* evidence supporting the role of progesterone on breast cancer cell invasiveness has relied upon the forced expression of the progesterone receptors in triple negative breast cancer, or with progesterone doses well above normal tissue concentrations throughout a woman's life. Furthermore, progesterone signaling has been primarily studied in the absence of E₂, and little is known about the cross talk between ER and PR and their combined role in breast cancer progression.

1.10 The Role of EMT in ER+ Breast Cancer Metastasis

The current understanding of the role of reproductive hormones on ER+ breast cancer progression and invasiveness has primarily focused upon the role of E₂ signaling through its receptor ER. ER has become a quintessential biomarker in predicting the use of antiestrogens and aromatase inhibitors in the clinic (202). E₂ is known to function through ER to activate the expression of growth and survival genes (203), and conversely recruit co-repressors to trans-repress genes required for invasiveness (182). Hormonal regulation of invasiveness in ER+/PR+ breast cancers has been well studied but little ground has been gained on the role of these receptors and ligands on the epithelial-to-mesenchymal transition (EMT) thought to occur during metastasis.

EMT is often regarded as an essential step in the progression of breast cancer to a more invasive phenotype (204). This transition is marked by loss of polarity, loss of cell-cell adhesion with gain in migratory and invasive capacities (204). This process occurs in the development of the mesoderm (205), neural tube formation (206), wound healing (207) and cancer metastasis (208). The mesenchymal like phenotype is marked by loss of E-cadherin, beta catenin, and claudin-1, along with a gain of expression of N-cadherin, vimentin, slug, and snail (209). EMT has become an important topic in the progression of breast cancer oncogenesis. However, the relationship between EMT and hormonal regulation in ER+ breast cancers has become less clear with many confounding interpretations (175,210–214).

The loss of E-cadherin is considered to be necessary for the EMT to begin (215). Some reports have shown that low dose E₂ decreases the expression of E-cadherin, resulting in increased migratory capacity. However, there was no investigation into its regulation on invasiveness (183,216–218). Initiation of metastasis requires cells to become more invasive, and EMT confers a more invasive phenotype. However, EMT has been reported to not be required for metastasis

(204,219,220). Moreover, pathological analysis of IDC tissues have shown that cells within a lesion retain tertiary structures such as acinars and luminal spaces (221). These structures maintain tight junctions, desmosomes, and cellular polarity (221,222). Most important, the epithelial characteristic in these patients (N=149) showed no correlation with metastatic disease (222). These finding have been partially reconciled by the concept of epithelial reversion from the mesenchymal phenotype (223,224). Until recently this has been the justification for the lack of mesenchymal-like cells seeded in meta-sites. Mechanistic fate mapping in both breast and pancreatic cancer have shown that EMT is unnecessary for invasion and metastasis to occur (219,220). It is important to note that EMT can lead to cellular dissemination but is not required (219,220). EMT is reported to actually play a crucial a role in chemo-resistance during metastasis (219,220). EMT in breast cancers has been widely attributed to loss of ER. The ER apoprotein is considered to be the master regulator of maintaining a epithelial-like phenotype and epithelial markers (211–213,225,226). This is at odds with the few reports stating E₂ signaling through ER is a primary component of advanced disease progression (227,228). Hormonal regulation of invasiveness has been clearly defined, but whether EMT plays a part has not been clearly elucidated.

1.11. Current status of treatments for advanced breast cancer and their limitations

1.11.1 Survival of patients with metastatic breast cancer

Patients with estrogen receptor (ER)-positive metastatic breast cancer often respond to endocrine therapy (ET), which can reduce tumor burden and symptoms with generally fewer side effects and toxicities when compared to chemotherapy. However, few if any patients with metastatic breast cancer will be cured, and the goal of therapy is principally for palliative purposes. Efforts are made to reduce the number of side effects and still stabilize or reduce the burden of

disease. Once a patient develops progressive breast cancer that is not responding to endocrine therapy, chemotherapy regimens are implemented in the same manner as hormone receptor negative breast cancer as discussed below.

Following surgery of breast cancer, disease can recur at both regional and distant sites. Local recurrence is defined as cancer that reappears on the ipsilateral chest wall. Furthermore, recurrence can also include a tumor that involves regional lymph nodes such as ipsilateral axillary, supraclavicular and less commonly the infraclavicular and/or internal mammary nodes. Roughly 5-10% of patients who have received surgery will have locoregional relapse within a 10 year time (229–235). Half of these patients will have recurrence isolated in the chest wall (236,237). Of these patients, 30-40% will have regional metastases in the supraclavicular, axillary, or internal mammary nodes. It is estimated that patients with locoregional metastasis have synchronous distant metastasis as well (234). The median time to locoregional recurrence after surgery is 3 years, and over 90% arise within five years (238–241). However, relapse can be delayed with the use of Tamoxifen in hormone receptor-positive disease (242). For women with locoregional metastasis, the most consistently accurate prognostic factor is the interval between initial diagnosis and recurrence. Disease-free survival of at least two years is associated with a significantly better outcome when compared to earlier recurrence regardless of breast cancer subtype (229,233,238). Furthermore, long-term control of disease is dependent upon the disease volume. Disease control rates are highest with either limited chest wall or axillary node involvement, and when supraclavicular nodes are not involved (238,241).

There are few prospective randomized trials, and most available data come from single institute studies (238). A post-mastectomy study in 145 women showed that survival depended on the location of metastasis, and was comprised of patients with diverse subtypes of breast cancer.

Though hormone positive breast cancers are less likely to relapse at meta-sites, if locoregional disease persists after initial treatment, survival rates are similar to other breast cancers (hormone receptor negative). Overall survival rates for breast cancer identified in the chest wall alone, or axilla alone is 50%. Survival rates for supraclavicular nodes alone and chest wall plus axilla is 28%. Lastly, survival rates for supraclavicular nodes plus chest wall/axilla are 7% (238).

1.11.2 Treatment of metastatic breast cancer

Surgical intervention: Whenever possible, guidelines suggest wide excision of all nodules that are amenable to resection (230,238,240,243). Resections have shown to reduce the required dose of radiotherapy (RT) and increase long-term disease control (as discussed below). Though conservative surgery is often considered, complete excision results in less frequent recurrence (21% vs. 60%) (241). However, extensive surgery for locally recurrent disease is only performed if other options are limited (244–246), and if surgery cannot be performed, systemic treatments are preferable (discussed below). Following wide local excisions, a second local recurrence occurs in 60-70% of cases (247,248). The likelihood of success is increased when a recurrence pattern in a patient has fewer lesions with a relapse period of greater than 2 years for all breast cancers (244,249–252).

Radiotherapy (RT) is an essential part of treatment for women with breast cancer recurrence. Optimal RT management generally involves treatment to the entire chest wall and draining lymph node areas. Conservative treatment of the chest wall increases the risk for future recurrences in the supraclavicular and axillary regions(238,241,243). For patients who have a non-resectable chest wall recurrence, radiation alone can be attempted. However, 60 to 70 percent will experience a second local recurrence (239,241,248,253). Because of the high risk of a second recurrence in these patients, systemic therapy (discussed below) is preferred.

Systemic therapy:

It is commonly agreed that higher response rates are seen with chemotherapy when compared to endocrine therapy in advanced hormone receptor positive cancer with poor prognosis (especially with visceral metastasis). A meta-analysis that included eight randomized trials, compared chemotherapy alone to endocrine therapy alone (254). Patient response was far superior for chemotherapy over endocrine therapy (relative risk 1.25, 95% CI 1.01-1.54). In general, endocrine therapy is beneficial but has to be timed correctly. Endocrine therapy has fewer side effects, but its benefits only occur after many months of treatment. Therefore, chemotherapy with anthracyclines, taxanes, platinums, and etoposide are first line in advanced metastatic disease. After (if) chemotherapy stabilizes disease progression, a switch to maintenance endocrine therapy can be used. Endocrine therapy is a preferable method when the option is available because of reduced treatment side effects without compromising overall survival (255–257). It is important to note no survival benefit was seen when chemotherapy and endocrine therapy were combined.

Treatment approach and success

As discussed above, breast cancer treatment options can vary among individuals, but systematic treatments of early stage breast cancers are quite distinct systematic. Most of the treatment regimens primarily depend upon hormone receptor and HER2 status. However once distal metastasis has occurred (Stage 4), almost all cancers are aggressively treated with chemotherapy with follow up advanced hormone therapy(ER+), or with experimental drugs (Table 1). Furthermore, success rates for 5-year survival are dependent upon stage and disease progression, and less dependent upon disease subtype, although this may change for more recently developed treatments when prospective studies with endpoints of up to 20-year survival are completed.

Breast Cancer Stage	Step 1	Step 2	Step 3	Step 4	Step 5	Overall 5 year Survival
Stage 1 (ER+)	Breast Conserving Surgery	Radiation (<70 YO)	Chemotherapy (tumor > 1cm)	hormone therapy (5 years)	NA	100%
Stage 1 (HER2+)	Trastuzumab /Pertuzumab	Breast Conserving Surgery	Local Radiation (<70 YO)	Chemotherapy (tumor > 1cm)	Trastuzumab /Pertuzumab	
Stage 1 TNBC	Breast Conserving Surgery	Chemotherapy	NA	NA	NA	93%
Stage 2 (ER+)	neo-adjuvant therapy	Breast non-conserving	Local Radiation (<70 YO)	Chemotherapy	hormone therapy (5 years)	
Stage 2 (HER2+)	Trastuzumab /Pertuzumab	Breast non-conserving	Chemotherapy (tumor > 1cm)	Trastuzumab /Pertuzumab	Hormone therapy (if ER+)	
Stage 2 TNBC	Chemotherapy	Surgery	Chemotherapy	Tamoxifen in some instances	NA	
Stage 3 ER+	Neo-adjuvant chemo	Advanced Surgery	Regional Radiation	Chemotherapy	hormone therapy (5 years)	72%
Stage 3 HER2+	Neo-adjuvant chemo	Advanced Surgery	Regional Radiation	Chemotherapy (tumor > 1cm)	Trastuzumab /Pertuzumab (1 year)	
Stage 3 TNBC	Aggressive chemotherapy	Regional Radiation	Aggressive chemotherapy	NA	NA	
Stage 4 ER+	Aggressive chemotherapy	Regional Radiation	bisphosphonates (indicated for bone Met)	Fulvestrant (if no stabilization)	Clinical trial	22%
Stage 4 HER2+	Aggressive chemotherapy	Regional Radiation	bisphosphonates (indicated for bone Met)	capectabine	Clinical trial	
Stage 4 TNBC	Aggressive chemotherapy	Regional Radiation	bisphosphonates (indicated for bone Met)	Aggressive chemotherapy	Clinical trial	

Table 1.1. Treatments steps for molecular subtypes of breast cancer and 5-year overall survival

1.11.3 Molecular subtype-site specific distal metastases and overall survival.

Though advances in breast cancer have been made in the past 20 years, roughly 30% of patients with early diagnosed breast cancer will experience relapse with distant metastatic disease. Triple negative cancers are often thought of as the more aggressive disease due to limited treatment options. However, even with lower relapse rates, ER+ positive tumors make up the majority of metastatic breast cancers. A study with a sample size of 3,726 patients found that of all breast cancers, 22% of breast cancers metastasized to distant organs and were ER+, whereas the other subtypes accounted for less than 5% of breast cancer patients (27). Furthermore, although women with ER+ breast cancers do have a higher 10-year overall survival rate (Table 1), 30% and 46% of the patients with luminal A and luminal B cancers respectively will not survive 10 years. This clearly demonstrates that ER+ breast cancers are not truly indolent, even though more treatment options are available for them.

Risk of recurrence is generally defined by tumor size, nodal involvement, and lymphovascular invasion (27). However, there has not been a large-scale analysis of spread and specific recurrence. Current EMSO and UpToDate guidelines focus on treatment strategies for specific subtypes of disease based upon the molecular subtype at initial diagnosis (i.e. hormone therapy vs chemotherapy). Characteristics of the primary tumor are generally retained at the meta-site. Yet as disease progresses with continuous relapse, a defined treatment scheme for each subtype fades. Though the total number of patients that succumb to breast cancer are similar between subtypes (Table 1), the disease progression in the final stages is quite different, with different specific sites of metastasis between subgroups (Table 2). Bone is the common site amongst all subtypes (except basal). A report using multivariate analysis (with luminal A as the control) showed luminal B tumors preferentially metastasizing to the brain and lungs when

compared to other tumor subtypes. However, all the other subtypes have more metastasis to the liver and bone when compared to Luminal B (27).

Total N = 3726	N	Percent of Patients	15 year Relapse Rate	10 Year Overall survival	Distant metastasis
Luminal A	1639	44%	28%	70%	12%
Luminal B	894	22%	43%	54%	10%
Luminal HER2+	242	7%	48%	46%	3%
HER2+ enriched	265	7%	51%	48%	4%
Basal like	365	10%	43%	53%	4%
TNBC Non Basal	317	9%	35%	63%	2%

Table 1.2 Patient relapse rate, overall survival and frequency of distant metastasis.

Subtype	No. Patients N	Brain		Liver		Lung		Bone		Distant Nodal		Pleural		Other	
		N	%	N	%	N	%	N	%	N	%	N	%	N	%
Luminal A	458	35	7.6	131	28.6	109	23.8	305	66.6	73	15.9	129	28.2	62	13.5
Luminal B	378	41	10.8	121	32	115	30.4	270	71.4	88	23.3	133	35.2	73	19.3
Luminal HER2+	117	18	15.4	52	44.4	43	36.8	76	65	26	22.2	40	34.2	16	13.7
HER2+ (ER-/PR-)	136	39	28.7	62	45.6	64	47.1	81	59.6	34	25	43	31.6	23	16.9
Basal	159	40	25.2	34	21.4	68	42.8	62	39	63	39.6	47	29.6	38	23.9
TN nonbasal	109	24	22	35	32.1	39	35.8	47	43.1	39	35.8	31	28.4	28	25.7

Table 1.3 Metastatic site based upon breast cancer molecular subtype

It is important to note that current treatment regimens for luminal breast cancer focus primarily on reducing tumor burden, rather than inhibiting metastasis. Currently there are no treatments that specifically target the process of metastasis, which is the cause of 95% of breast cancer deaths. It is therefore the goal of this study to first seek a better understanding of fundamental mechanisms that determine the metastatic potential of luminal breast cancer. A little explored area in this regard is micro RNA-mediated regulation of metastasis in luminal breast cancer despite the known importance of micro-RNAs in many aspects of hormone signaling in breast cancer. It is the premise of this thesis that discovery of micro RNA mediators of hormonal control of invasiveness and metastasis of luminal breast cancer will enable a better mechanistic understanding of metastasis of this major cancer sub-type.

1.12 microRNA biogenesis and Regulation of mRNAs

Micro RNA (miRNA) is a small non-coding RNA molecule that is roughly 22 nucleotides in length. miRNAs are conserved in plants, animals, and viruses (258). These short RNAs primarily act as endogenous silencers of mRNA transcripts (258). miRNAs function by base pairing with complementary sequences found within mRNA sequences resulting in silencing by three different modes of action: (I) recruitment of mediators that cleave the mRNA into two pieces; (II) destabilization of the mRNA by shortening the poly(A) tail; and (III) significantly decreasing efficiency of ribosomal translation machinery (259,260). The human genome codes for over 1000 miRNAs which are found in both introns and exons (261). miRNAs in animals are very promiscuous with a single miRNA targeting up to 500 unique mRNA transcripts. It is estimated that 60 percent of the human genome is regulated by miRNAs (262,263). miRNA genes are transcribed by RNA polymerase II and require a promoter sequence upstream (264,265). The initial RNA transcript is called the pri-miRNA. This precursor is capped at the 5' end and has a poly (A) tail at the 3' end. Pri-miRNA is 80 nucleotides long and folds back on itself to create a secondary stem and loop structure. The pri-miRNA is then processed by the enzymes Drosha, and Pasha, cleaving the 5'-Cap and Poly (A) tail. This shorter double stranded RNA structure is called pre-miRNA (264,266). It is important to note that each pri-miRNA can code for up to 7 miRNAs. However, expression patterns of miRNAs from the same pre-cursor can vary based on the flanking processing coding sequences (267). Pre-miRNAs are then exported from the nucleus by Exportin-5, which recognizes the enzyme Drosha and 3' overhang of the miRNA (268). Once in the cytoplasm, the loop joining the 3' and 5' segment is cleaved by the protein Dicer. This process creates an imperfect RNA duplex, and also unwinds the duplex (269,270). Only one strand is incorporated into the RNA induced silencing complex (RISC). This is in part decided by the

thermodynamic stability of base-pairing on the 5' end compared to the 3' end, and the location of the loop cleavage (271–274). The passenger strand is often rapidly degraded prior to RISC complex joining. Once the RISC has joined, the Argonaute protein (Ago) in the complex can cleave the mRNA target or sequester the mRNA to inhibit translation (275). There are 8 Ago proteins in humans, and all have unique co-factor binding abilities that result in various levels of mRNA translational repression (276). The functional guide miRNA is thought to be retained in the cleft of the Ago protein and can target multiple mRNAs. Thus, a single miRNA can be much more potent than the previously expected 1:1 miRNA/mRNA degradation (275,276). Degradation of mature miRNAs and miRNA duplexes outside of the scope of the RISC complex have been discovered in *C-elegans* and plants. However, human homologues are yet to be elucidated (277).

1.13 miRNA Mediators in Breast Cancer

miRNAs can be deemed oncogenes or tumor suppressors depending on the context of mRNA inhibition and pathway regulation. After the discovery of miRNAs, it was observed that various breast cancer subtypes exhibited unique miRNA profile signatures (278–281). Most studies on miRNAs are focused on associations to identify signatures for tumor subtype. However, functional studies have shown that most miRNAs act as tumor suppressors and play a strong role in opposing progression in various tumor types (282). For instance, miR-125b down regulates HER2 but is absent in most HER2+ tumors (283). miR-205 regulates HMGB3 and its ectopic expression significantly promotes apoptosis in breast cancer (284,285). Expression of the miR-17-92 cluster in breast cancer is associated with significantly reduced metastasis (286) and the miR-200 family is essential for maintaining epithelial phenotype (287,288). Furthermore reintroduction of miR-200 family members have decreased aggressiveness of various tumor subtypes (289–291).

It is very clear that tumor suppressor miRNAs in one cancer type can act as an oncogene

in another cancer cell type. The actions of many miRNAs are dependent upon cell, tissue, and environmental contexts. These miRNAs can have various different roles system-wide (281). This has been considered to be the result of inconsistent studies in the miRNA field, as high-throughput studies are highly flawed based on limitations in technology (281). Furthermore, low throughput studies using specific primer/probes for mature miRNAs have shown context specific regulation of miRNAs. For instance, miR-146 acts a tumor suppressor by targeting NF- κ B in gastric cancers, but also strongly down regulates BRCA1 in breast cancers (292–294). These studies truly underscore the importance of miRNA investigation in tissue specific contexts when attributing functional roles to each miRNA.

Most studies on miRNAs have relied on the basic observation of virtual complete loss, or gain of miRNA expression in disease tissues when compared to normal tissues. Very little is known about the modulation of expression of miRNAs by hormones and their respective receptors. A compilation of six studies has shown that E₂ was able to regulate 43 miRNAs (295), but little was done to explore the functionality of any of the miRNAs. It was identified that miRNAs that are present in triple negative breast cancers and absent in ER+ breast cancers were important for the identification of ER regulation. Inhibition of miRs-221/222 in MDA-MB-468 restored ER expression and increased tamoxifen sensitivity (296). Furthermore, estrogen signaling can self-regulate oneself by negative feedback loops utilizing miRNAs. E₂/ER signaling negatively regulates itself by upregulating miR-206 which targets ER mRNA(297). E₂ regulation of miRNAs has been well noted and is hypothesized to play a critical role in breast cancer development. In contrast, progesterone regulated miRNAs are understudied in the breast tissue with a majority of studies focusing on miRNA expression in endometrial tissue (298).

1.14 Current challenges of directly using miRNAs in cancer treatment

As described above many miRNAs are tumor suppressors and oncogenes (onco-miRs), and reintroducing miRNAs/inhibitors in the *in vitro* setting has been demonstrated to cause modulation of tumor growth and invasion to overcome chemoresistance. Re-introducing miRNAs is achieved by using synthetic RNA duplexes (mimics) that can be chemically modified to be more stable and amenable to different delivery methods. To inhibit a miRNA, antimiRs, and antigomirs are used. AntimiRs are single stranded RNAs that are complementary in sequence to the mature form of miRNA and often reduce the overall targeted miRNA. Furthermore, antigomirs are miRNA inhibitors with the 2'-O-methoxyethyl modification. This modification creates a much stronger bond to the miRNA, but also stabilizes the entire duplex.

The most common mode of delivery is the use of lipid nanoparticles, and is currently in use in a phase I clinical trial (NCT01829971). The tumor suppressor miR-34 has been successfully delivered to lung(299), prostate(300), and liver (300) in mouse models. Studies were performed with local injection and systemic delivery, which both resulted in decreased tumor growth. In other reports researchers have delivered miRNAs using 1,2 dioleoyl-*sn* glycerol-3 phosphatidylcholine (DOPC) liposomal carriers. In mouse tumor model studies, DOPC delivery of miR-200 family members increased radiosensitivity and decreased total tumor burden when compared to control mice (301).

In addition to the classical nanoparticle delivery systems, miRNAs can be linked to a peptide backbone that is sensitive to pH (pHLIP). When the miRNA-pHLIP encounters a low pH environment, a conformation change occurs. The peptide carboxyl terminal end is then inserted into the cell membrane and the miRNA is released. This creates a unique delivery system with the miRNA remaining stable during transport to the tumor microenvironment (302).

miRNAs are viewed as desirable therapeutics due to their low toxicity profile, and chemical stability. Given the current rapid advances in understanding each miRNA and its role in cancer, numerous drug targets within their regulatory pathways will eventually likely be identified. The current limitations of direct clinical applications of miRNAs in treating disease primarily relate to efficiency of delivery of their mimics and inhibitors, but it may only be a matter of time before successful delivery methods are developed. **As it pertains to this thesis, studies of miRNAs can provide fundamental insights into molecular mechanisms governing cancer progression. Novel regulatory pathways involving miRNA mediators of metastasis of luminal breast cancer could reveal protein targets for selective interventions to suppress metastasis of luminal breast cancer.**

CHAPTER 2- ROLE OF THE SHORT ISOFORM OF THE PROGESTERONE RECEPTOR IN BREAST CANCER CELL INVASIVENESS AT ESTROGEN AND PROGESTERONE LEVELS IN THE PRE- AND POST-MENOPAUSAL RANGES

2.1 Introduction

The process of breast oncogenesis is believed to span up to several decades. Most (> 78 percent) of newly diagnosed breast cancer cases occur in women who are older than 50 years (303) and the median age at diagnosis is 61 years (304). In most cases the tumors express the estrogen receptor (ER). ER+ tumors are exquisitely sensitive to anti-estrogen therapy. However, ER+ breast cancer is often metastatic at the time of diagnosis and metastatic ER+ tumors also frequently appear after many years of dormancy (132,305). In either case, the metastatic disease is generally incurable and even targeted therapies are generally only palliative. Therefore, it is necessary to understand more about deregulated molecular mechanisms that confer invasive properties on ER+ breast cancer cells. Clearly, both pre-menopausal and post-menopausal events that influence breast tumor invasiveness are clinically highly significant in breast tumor progression. Profound decreases in the levels of circulating estrogen and progesterone are a hallmark of post-menopausal physiology although, in post-menopausal women, breast, endometrial and adipose tissues contain much higher levels of estrogen and progesterone, compared to plasma levels of the hormones (73,74,306–308).

As the progesterone receptor (PR) gene is a target of estrogen, the PR expression status of ER+ breast tumors is believed to reflect the robustness of ER signaling and hence predict patient response to anti-estrogen therapy. Nevertheless, PR agonists do directly support invasiveness and metastatic potential in ER+/PR+ breast cancer cells, as demonstrated using *in vivo* experimental models (309,310). The physiological relevance of these model systems is supported by the observation that in postmenopausal women, hormone replacement therapy with the combination

of estrogen and progestin was associated with increased incidence of invasive breast cancer and breast cancer mortality compared with non-users (59) whereas, estrogen monotherapy in women with prior hysterectomy was associated with a persistent decrease in the onset of invasive breast cancer (60). However, in post-menopausal women who are not undergoing hormone replacement, the role of the endogenous hormones in the progression of ER+/PR+ breast tumors is unclear.

PR has two isoforms, A and B, that are expressed by alternative promoter usage from a single gene; PR-B is identical to PR-A except for the presence of an additional 164 amino acid amino-terminal segment that contains within it, an additional activation function, AF3 (311). PR-B and PR-A exhibit both distinctive and overlapping patterns of agonist-induced gene activation or gene repression, depending on the variable contexts of the target promoters and the nature of the associated chromatin sites of PR binding (156,311,312). In cells expressing equal amounts of PR-A and PR-B, a substantial proportion of the two proteins are sequestered by forming a heterodimer; the heterodimer regulates a smaller and unique set of genes compared to the homodimers (155,156). Clinical studies have shown that although in normal breast PR-A and PR-B are expressed at comparable levels, this balance is commonly altered during breast oncogenesis with a predominance of a high PR-A:PR-B ratio in early, as well as progressed lesions (190). An elevated PR-A:PR-B ratio, which is frequently due to overexpression of PR-A, is associated with a lower rate of disease-free survival (170).

In vitro molecular studies have shown that when hormone-depleted breast cancer cells are treated with PR agonists, they induce invasiveness through several non-genomic and genomic signaling pathways of progestin (192,313–318). Some of those studies have further reported that it is PR-B that mediates progestin-induced invasiveness *in vitro* (192,193). The progesterone doses that were used to demonstrate substantial PR-B dependent effects on invasiveness *in vitro* were

relatively high, corresponding to the plasma range of the hormone levels associated with only the luteal phase of the menstrual cycle or with pregnancy. Horwitz and co-workers have also elegantly demonstrated *in vitro* that the mere overexpression of PR-A confers an inherently more aggressive phenotype in breast cancer cells, including adhesion to extracellular matrix, migratory capacity and survival, due to hormone-independent gene regulation by PR-A (201).

Most breast tumors are ER+ (319) and continue to retain ER expression even as they progress to hormone-independence (320,321). Estrogen supports the growth of ER+ breast tumors but it suppresses invasiveness of the tumor cells whether or not their growth is hormone-sensitive and also suppresses breast tumor progression (321–327). However, *in vitro* studies of the role of PR in breast cancer cell invasiveness have generally been investigated mechanistically in the absence of estrogen signaling. The studies have either used ER+ cell line models in the absence of estrogen or they have relied on forced expression of PRs in ER-negative cells (192–196). The relative contributions of PR ligands to invasiveness through opposing the suppressive effect of estrogen and the underlying mechanisms are still unclear in the literature.

Further, although the gene regulatory profile of ER has been shown to be estrogen dose-dependent (328), it is less clear whether PR has distinct mechanisms of action that depend on progesterone dose. The plasma levels of estrogen in pre-menopausal women is 1.4 nM - 1.6 nM in the follicular phase and 3.6 nM - 4.2 nM in the luteal phase (64). Plasma levels of estrogen in post-menopausal women is 0.027 ± 0.01 nM whereas breast tissue levels of estrogen in post-menopausal women is 1.4 ± 0.7 nM (72–74). The plasma level of progesterone ranges from 0.6 nM to 4 nM in the follicular phase and increases up to > 50 nM in the luteal phase(200) whereas post-menopausal women have a wide range of 0.047nM to 0.318nM (median 0.127nM) (191). The breast tissue level of progesterone in post-menopausal women is above an order of magnitude greater than its

plasma levels (306). Therefore, further investigation of the role of the individual PR isoforms on ER+ breast cancer cell invasiveness in the context of estrogen signaling and in the physiological range of breast tissue hormone levels was needed to more fully understand early events in hormonal regulation of breast cancer progression.

The ER+ model cell lines used in this study included T47D (ER+/PR+), ZR-75-1 (ER+/PR+) and BT474 (ER+/PR+/HER2+) cells. All three cell lines express both PR-A and PR-B. To dissect the actions of the individual PR isoforms, we also used recombinant T47D cells generated by Dr. Kathryn Horwitz and co-workers that virtually exclusively expressed PR-A or PR-B in addition to ER (329).

2.2 Materials and methods

2.2.1 Chemicals and reagents.

Dulbecco's modified Eagles medium (DMEM) and phenol red-free DMEM, glutamine, penicillin, streptomycin, Fetal Bovine Serum (FBS), charcoal stripped FBS and TaqMan probes were purchased (Life Technologies, Carlsbad, CA). 17β -estradiol (E_2), R5020, RU486, progesterone and medroxyprogesterone acetate (MPA) were purchased from Sigma Aldrich (Saint Louis, MO). Growth factor reduced matrigel (Cat# 356231) and calcein AM fluorescent dye (Cat# 354216) were purchased from BD Biosciences (San Jose, CA). PR-B directed siRNAs (339,340) and control non-silencing siRNA (Cat# SIC001) were ordered from Sigma Aldrich (St. Louis, MO). siRNAs targeting TM4SF1 (Cat# S8367), HES1 (Cat# S6920), PRKCH (CAT#S1107), and ELF5 (CAT# S4629) were purchase from Life Technologies (Carlsbad, CA).

2.4.2 Cell culture and treatment.

BT474, T47D and ZR-75-1 breast cancer cells (American Type Culture Collection) were cultured in DMEM supplemented with FBS (10%) penicillin (100 unit/ml) streptomycin

(100ug/ml) and L-glutamine (2mM). T47D-A and T47D-B cells were a generous gift from Dr. Katherine Horowitz (University of Colorado, Denver, CO) and were cultured as previously described (312). The cell lines were all cultured at 37°C with 5% CO₂. Before hormone treatment, cells were plated in 6-well plates at 30% confluence in phenol red-free media supplemented with charcoal-stripped FBS and incubated at 37°C with 5% CO₂ for 48 h. Cells were then treated with vehicle, progesterone, MPA, R5020, RU486 and E₂ alone or in various combinations at concentrations as indicated for each individual experiment for a duration of 48 h. The cells were then harvested for mRNA analysis, western blot analysis or cell invasion assays.

2.2.3 Western blot analysis.

Cells were lysed using RIPA Buffer (150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 1% SDS, and 50mM Tris pH 8.0) containing protease inhibitor cocktail (Pierce Biotechnology, Rockford IL). The lysates were chilled on ice and agitated by vortex every ten minutes for one hour. Total protein concentration was measured by Bradford assay (Bio-Rad laboratories, Hercules, CA). A total amount of 10-40 µg protein per sample was resolved by electrophoresis on a 8% SDS-polyacrylamide gel and transferred to a PVDF membrane (Millipore Corporation, Bedford MA). Membranes were probed with primary polyclonal rabbit anti-PR antibody (sc-539, Santa Cruz biotechnologies, CA), polyclonal rabbit anti-ER α antibody (sc-543, Santa Cruz Biotechnologies, CA), mouse monoclonal anti-GAPDH antibody (sc-4472, Santa Cruz Biotechnologies, CA), rabbit polyclonal anti-HES1 (sc-25392, Santa Cruz Biotechnologies, CA) or mouse monoclonal anti-ELF-5(sc-376737, Santa Cruz Biotechnologies, CA). The blots were then probed with appropriate horseradish peroxidase conjugated secondary antibody (Vector Laboratories, MD). The protein bands were visualized using enhanced chemiluminescence reagent Hyglo Quick spray (Denville Scientific, South Plainfield, NJ) per the manufacturer's suggested

protocol. Relative protein expression was determined by ImageJ (National Institutes of Health, USA).

2.2.4 RNA isolation, reverse transcription PCR and real time PCR.

Total RNA was isolated using the RNeasy mini kit (Qiagen, MD). Reverse transcription PCR reactions were performed using high capacity complementary DNA archive kit (Life Technologies Corporation, Carlsbad, CA) according to manufacturer's protocol. cDNA was measured by quantitative real time PCR using the StepOne Plus Real time PCR system (Life technologies Corporation, Carlsbad, CA). All mRNA measurements were performed in biological triplicates, and all C_T values were normalized to intra-sample GAPDH. mRNA values were represented as fold difference, which is calculated using the formula $= 2^{-\Delta\Delta C_T}$, where $\Delta\Delta C_T = \Delta C_T$ sample $-\Delta C_T$ calibrator ($\Delta C_T = C_T$ of gene of interest- C_T of GAPDH).

2.2.5 Boyden chamber transwell invasion assay.

Cells (1×10^5) were re-suspended in the appropriate culture media devoid of serum and phenol red and added to the top chamber of the flouroblok inserts (Cat# 351152, 8 μ M pore membrane: BD biosciences, Bedford, MA) coated with growth factor reduced matrigel (0.2 mg/ml). The chemoattractant comprised phenol red-free media supplemented with FBS (20%). The appropriate hormone treatment was included in both the top and bottom chambers. Each treatment was replicated in three wells and the entire experiment was replicated at least three times. Cells were allowed to invade for 24 h at 37°C with 5% CO₂. Cells that invaded to the bottom surface were stained with calcein AM (4ug/ml) in serum free media in the dark for 1 h at 37°C with 5% CO₂. Images were captured in an identical manner from each well in 5 non-overlapping fields (the middle of the well and surrounding fields) using a 4x objective. Images were analyzed

using ImageJ software (National Institutes of Health, USA) and the number of cells invaded was quantified by brightness and pixel size.

2.2.6 Migration Assay.

Pre-treatment and preparation of cells and the experimental protocol were identical to those described above for the Boyden chamber transwell invasion assay with the exception that the transwells were devoid of matrigel.

2.2.7 Lentiviral transduction.

293FT cells were used to generate lentiviral particles by transfection using lipofectamine 2000 (Life Technologies Corporation, Carlsbad, CA). Packaging plasmids pMD2G, PMDLg/RRE, and pRSV/Rev were cotransfected with pCDH PR-A expression plasmid, or pCDH empty vector plasmid. Lentivirus containing supernatant was harvested at 48 h and 72 h after transfection. T47D cells were plated in phenol red-free DMEM supplemented with heat-inactivated charcoal-stripped FBS (10%) and 2mM L-Glutamine two days before infection. For infection, T47D cells were transduced with either pCDH empty vector lentivirus or pCDH PR-A lentivirus with polybrene (8 µg/ml) for 5 h. A second transduction was performed similarly for another 5 h. The cells were then incubated in phenol red-free DMEM supplemented with charcoal-stripped serum (10%) and L-Glutamine (2mM) for 48 h. Following infection, cells were harvested for western blots and cell invasion assays as described previously.

2.2.8 siRNA Transfection.

Cells were plated to 30% confluence without antibiotic in phenol-red free DMEM medium supplemented with 10% charcoal-stripped FBS. 24 hours later cells were transfected with siRNA directed against specific gene targets or non-silencing siRNA using lipofectamine (Life Technologies, Carlsbad, CA) according to the manufacturer's protocol.

2.2.9 mRNA expression profiling.

T47D-A and T47D-B cells were depleted of hormone for 48 h as described above. Cells were then either treated with vehicle, 1nM E₂, 1nM R5020, or 1nM E₂+ 1nM R5020 for 48 h. Total RNA was isolated using the RNeasy mini kit (Qiagen, MD). Sample identities were randomized for blinded analysis. The samples were analyzed at the Wayne State University School of Medicine Applied Genomics Center (AGTC) using the HumanHT-12 v4 Expression BeadChip with the Illumina HiScan System (Illumina, San Diego, CA). A total of 47,000 probes were used to analyze the transcriptome expression for each treatment group. Data was analyzed using Partek V6.6 software (St. Louis, MO), and processed using genome Studio (Illumina, San Diego, CA). Expression values were normalized using quantile-normalization, with background subtraction. Log transformation to the base of 2, followed by one way ANOVA was used to determine error. The differentially expressed genes were identified by comparing E₂ treatment with vehicle treatment, R5020 treatment with vehicle treatment and E₂ treatment with E₂+R5020 treatment (repressed or activated with a fold difference of 1.5 and a p value < 0.05). Genes that had activated expression in E₂+R5020 treatment but were repressed by E₂ treatment were identified. Genes that were activated in E₂ treatment but repressed by E₂+R5020 were also identified. Gene ontology analysis was performed by literature mining by searching the MEDLINE database (National institutes of Health, USA) with a query of “name of gene” followed by the term “AND Cancer” or “ AND Breast Cancer”. All articles under the specified query were examined to determine gene function in breast cancer. Validation of Microarray Data was performed by real-time RT-PCR as described above using TaqMan probes.

2.2.10 Statistical analysis.

Experimental values were presented as mean +/- standard deviation using triplicate treatment sets. The statistical difference between values was determined by using one way ANOVA followed by post hoc paired t-test. The significant *P* values are noted in the figures. Concordant results were obtained from at least three repetitions of the experiments conducted on different days.

2.2.11 Supplemental Tables 1-13. mRNA profiling of estrogen (1nM) and progesterone (1nM) regulated genes in cells expressing ER and either PR-A or PR-B .

Expression values from genome expression profiling in tables can be found:

<http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=508>

2.3 Results

2.3.1 Estrogen dose dependence for inhibition of invasiveness.

Estrogen (E_2) is known to inhibit breast cancer cell invasiveness (326,330–333). To relate the effect of E_2 on invasiveness to physiological E_2 levels, the E_2 dose response for inhibition of invasiveness was determined in BT474, T47D and ZR-75-1 cells. E_2 was able to inhibit invasiveness of the cells in the sub-nanomolar range with most of the inhibition occurring below 0.01 nM and virtually complete inhibition occurring at 0.1 nM in all three cell lines (Figure 2.1-A, B, C). Thus the E_2 dose that was required for substantial or virtually complete suppression of invasiveness in the three ER+ cell lines is at the low end of the literature consensus for both plasma and breast tissue levels of E_2 in pre-menopausal (1.4nM- 4.2nM) or post-menopausal (0.027 ± 0.01 nM in plasma; $1.4\text{nM} \pm 0.7$ in breast tissue) women (64,72–74). Invasiveness remained completely suppressed at higher concentrations of E_2 (10nM and 20nM) (Figure 2.2).

2.3.2 Dose-dependent dual regulation of invasiveness by natural and synthetic progestins.

Plasma levels of progesterone are known to change throughout a woman's menstrual cycle ranging from 0.6 nM to 4 nM in the follicular phase and upwards to greater than 50 nM in the luteal phase (200). Furthermore, the median plasma concentration of progesterone in postmenopausal women is 0.127 nM (191) with breast tissue concentrations an order of magnitude greater than in the plasma (306). To examine the effects on progesterone in the context of estrogen signaling, BT474, T47D and ZR-75-1 cells were treated at varying concentrations (0 nM-100 nM) of progesterone either alone or in the presence of a fixed concentration (1 nM) of E₂ (Figure 2.1D-F). In all the three cell lines E₂ alone inhibited invasiveness. However, progesterone at 0.5 nM at least partially rescued invasiveness from the effects of E₂ and showed virtually complete rescue in all cases at a concentration of 1 nM. It may be noted that progesterone alone (in the absence of E₂) did not influence invasion below a concentration of 2.5 nM - 5 nM but only rescued invasiveness from E₂ regulation in the low concentration range (Figure 2.1-D, 2.1E, 2.1F). At higher concentrations, progesterone progressively increased invasiveness of the cells independent of estrogen (Figure 2.1D-F).




Figure 2.1 Dose response of regulation of breast cancer cell invasiveness by estrogen and progesterone. In panels A-C, hormone depleted BT474 cells (*Panel A*), T47D cells (*Panel B*) and ZR-75-1 cells (*Panel C*) at 30% confluence were treated with vehicle or the indicated concentrations of E₂ for 48 h. Cells were trypsinized and subjected to the matrigel transwell invasion assay with vehicle or the appropriate concentration of hormone present in the top and bottom chambers, as described under Materials and Methods. In the negative control, serum free media (SFM) was used instead of the FBS chemoattractant. Data points in the plots in *Panels A-C* represent values for invasiveness represented as average number of cells invaded with the background (SFM) values subtracted. In panels D-F, Hormone depleted BT474 cells (*Panel D*), T47D cells (*Panel E*) and ZR-75-1 cells (*Panel F*) at 30% confluence were treated with vehicle or E₂ (1 nM) and the indicated concentrations of progesterone for 48 h. Cells were trypsinized and subjected to the matrigel transwell invasion assay.




Figure 2.2 Inhibition of invasiveness by estrogen at different concentrations. Hormone depleted BT474 cells (*Panel A*), T47D cells (*Panel B*) and ZR-75-1 cells (*Panel C*) at 30% confluence were treated with vehicle or the indicated concentrations of E₂ for 48 h. Cells were trypsinized and subjected to the matrigel transwell invasion assay with vehicle or the appropriate concentration of hormone present in the top and bottom chambers, as described under Materials and Methods. In the negative control, serum free media (SFM) was used instead of the FBS chemoattractant. Values are represented as average number of cells invaded from experimental triplicates and the error bars represent standard deviation. P Values are indicated.

The hormones regulated invasiveness of the cells without affecting their migratory capacity (i.e., in the absence of matrigel in the transwells) (Figure 2.3). Thus, the data in Figure 2.1 (D-F) reveals two components of progesterone's effect on invasiveness *in vitro* in the three cell line models studied: (i) at low concentrations, progesterone rescues invasiveness from suppression by E_2 ; and (ii) at higher concentrations, progesterone also induces invasiveness independent of E_2 .

As noted above, during the luteal phase of the menstrual cycle, the E_2 level is elevated to about 4 nM along with an increase in the progesterone levels from about 4 nM to about 50 nM. Therefore, we tested the effect of 4 nM and 50 nM R5020 (a more stable synthetic progestin), in the presence of 4 nM E_2 on invasiveness of T47D, ZR-75-1 and BT474 cells (Figure 2.4A-2.4C). In all the three cell lines, suppression of invasiveness by E_2 was completely prevented by both concentrations of R5020 and at 50 nM R5020, there was a further increase in invasiveness (Figure 2.4A-2.4C).

The dual effect of progesterone on invasiveness was recapitulated in all the three cell lines using the potent synthetic progestin medroxyprogesterone acetate (MPA). When MPA is used as a contraceptive (intramuscular route of administration) it has a mean plasma concentration of 2.58 nM (334) and has a 10-20 fold higher plasma concentration when administered orally during hormone replacement therapy (335). At a concentration of 1 nM, MPA only reversed suppression of invasion by E_2 , but at higher concentrations (10 nM and 100 nM) MPA induced an increase in invasiveness well above the basal level whether or not E_2 was present (Figure 2.4D-2.4F).




Figure 2.3 Absence of hormonal control of migration capacity of ER+/PR+ model cells. Hormone depleted T47D cells (*Panel A*), BT474 cells (*Panel B*) and ZR-75-1 cells (*Panel C*) at 30% confluence were treated with vehicle, E₂ (1 nM), R5020 (1 nM), or E₂ (1 nM) plus R5020 (1 nM) for 48 h. Cells were trypsinized and subjected to transwell migration assay (i.e., in the absence of matrigel) with vehicle or the appropriate concentration of hormone present in the top and bottom chambers, as described under Materials and Methods. In the negative control, serum free media (SFM) was used instead of the FBS chemoattractant. Values are represented as average numbers of cells migrated from experimental triplicates and the error bars represent standard deviation. One-way ANOVA was performed and there was no significant difference between the treatment groups.




Figure 2.4 Regulation of breast cancer cell invasiveness by pre-menopausal concentrations of estrogen and progestin and dose-dependent effects of medroxyprogesterone acetate. In panels A-C, hormone depleted ZR-75-1 cells (*Panel A*), T47D cells (*Panel B*), and BT474 cells (*Panel C*) at 30% confluence were treated with vehicle or E₂ (4 nM), alone or in combination with R5020 (5 nM or 50 nM) for 48 h. Cells were trypsinized and subjected to the matrigel transwell invasion assay with vehicle or the appropriate concentration of E₂ and/or R5020 present in the top and bottom chambers, as described under Materials and Methods. In the negative control, serum free media (SFM) was used instead of the FBS chemoattractant. In panels D-F, hormone-depleted ZR-75-1 cells (*Panel D*), T47D cells (*Panel E*), and BT474 cells (*Panel F*) cells at 30% confluence were treated with vehicle or the indicated concentrations of MPA either with or without 1nM E₂ for 48 h. Cells were trypsinized and subjected to the matrigel invasion assay as described under Materials and Methods. One-way ANOVA was performed on triplicate treatment sets and P values are indicated.

2.3.3 The distinctive role of each PR isoform in the regulation of invasiveness by progestins.

The above observations led to the question of which PR-isoform(s) could mediate each of the two components of the regulation of invasiveness by progestins. To address this question, the effect of progestin dose on breast cancer cell invasiveness was tested in the absence or presence of 1nM E₂ using recombinant T47D cells that exclusively express PR-A (T47D-A cells) or PR-B (T47D-B cells) (Figure 2.5A). The recombinant cells were a kind gift from Dr. Kathryn Horwitz who generated the cells as previously described (329). Due to possible variance in absolute values of the number of cells invaded across experiments for a given cell line, we compared the invasive capacity of the T47D-A and T47D-B cells plated together under the same conditions at the same time. There was no difference in the invasive capacity of the two isogenic cell lines (Figure 2.6). In T47D-A cells both, R5020 and MPA only rescued invasiveness from E₂ regulation at all concentrations tested (1nM, 10nM or 100 nM) but had no effect on invasiveness in the absence of E₂ (Figure 2.5B and 2.5C). In contrast, in T47D-B cells, 1 nM of either R5020 or MPA was unable to rescue invasiveness from E₂ regulation but at the higher concentrations (10 nM or 100 nM) they induced invasiveness well above the basal level and this was uninfluenced by the presence of E₂ (Figure 2.5D and 2.5E).




Figure 2.5 PR-A vs. PR-B mediated effects of progestins on invasiveness of breast cancer cells. Panel A shows a western blot of cell lysates from T47D-A and T47D-B. In panels A-E, hormone-depleted T47D-A cells (*Panels B and C*) and T47D-B cells (*Panels D and E*) at 30% confluence were treated with vehicle or 1 nM E₂ in combination with the indicated concentrations of R5020 (*Panels B and D*) or MPA (*Panels C and E*) for 48 h. Cells were trypsinized and subjected to the matrigel transwell invasion assay, as described under Materials and Methods. In panels F-J, hormone depleted cells were transfected with either siRNA directed against PR-B or non-targeted control siRNA and incubated for 48h. In Panel F cell lysates from the transfected cells were analyzed by western blot for PR or GAPDH (loading control). T47D cells transfected with control siRNA (*Panel G*) or PR-B targeted siRNA (*Panel H*) and also BT474 cells transfected with control siRNA (*Panel I*) or PR-B targeted siRNA (*Panel J*) were treated with hormones and subjected to the matrigel transwell invasion assay. In panels B-E and G-J, One-way ANOVA was performed and P values are indicated.

As a complementary approach, we utilized siRNA knockdown of PR-B in parental T47D cells and in BT474 cells that express equal amounts of PR-A and PR-B. Both cell lines were transfected with siRNA directed against a target site in the unique 5' segment of the PR-B mRNA or with control non-silencing siRNA using Lipofectamine. Knockdown of PR-B (western blots in Figure 2.5F) resulted in a loss of E₂-independent induction of invasiveness at the higher concentrations (10 nM and 100 nM) of R5020 in both T47D cells and BT474 cells (Figure 2.5H and 2.5J) in contrast to the control siRNA transfected cells (Figure 2.5G and 2.5I). However, the selective depletion of PR-B did not alter R5020's ability to rescue invasiveness in the presence of E₂, at all concentrations (1nM, 10nM, and 100nM) of R5020 (Figure 2.5G-2.5J). This result is consistent with those observed above using T47D-A cells. The above results demonstrate that PR-A exclusively mediates the role of low dose progestins in opposing suppression of invasiveness by E₂, whereas PR-B exclusively mediates E₂-independent induction of invasiveness at high doses of progestins.




Figure 2.6 Invasive capacity of the isogenic T47D-A vs. T47D-B cell lines. T47D-A and T47D-B cells at 30% confluence were incubated in hormone-depleted media for 96 hours. Cells were trypsinized and subjected to the matrigel transwell invasion assay as described under Materials and Methods. Values are represented as average number of cells invaded from experimental triplicates and the error bars represent standard deviation.

2.3.4 Effect of RU486 on PR-A mediated induction of invasiveness by progestins.

RU486 is a synthetic antagonist of progesterone that is PR isoform selective in specific target gene contexts. Therefore it was of interest to test the effect of RU486 on the PR-A dependent actions of progesterone on breast cancer cell invasiveness. The cell lines T47D-A, T47D-B and BT474 were treated with either E₂, the progestin R5020, or the anti-progestin RU486, each at a concentration of 1 nM in the various combinations indicated in Figure 2.7. In T47D-A cells, RU486 disrupted the ability of R5020 to rescue invasiveness from E₂ suppression but did not have any effect by itself on invasiveness, in either the presence or absence of E₂ (Figure 2.7A). On the other hand, in T47D-B cells, RU486 had no effect on invasiveness under any of the conditions tested when each of the ligands was used at a concentration of 1 nM (Figure 2.7B). In BT474 cells, which express equal amounts of both PR isoforms, the effect of RU486 was similar to that observed in the T47D-A cells, demonstrating that agonist or antagonist actions that modulate the effect of PR-A on invasiveness are functionally independent of PR-B expression (Figure 2.7C).

2.3.5 Hypersensitization of PR-A to progestin through overexpression of the receptor.

As noted above, PR-A is frequently overexpressed in invasive clinical breast tumors. It was therefore of interest to examine the possibility that overexpression of PR-A in the tumor cells may sensitize PR-A mediated regulation of invasiveness to post-menopausal breast tissue levels of progesterone.




Figure 2.7 Effect of RU486 on regulation of breast cancer cell invasiveness by R5020 in relation to estrogen, PR-A and PR-B. Hormone depleted T47D-A (*Panel A*), T47D-B (*Panel B*), and BT474 (*Panel C*) cells at 30% confluence were treated with vehicle or the indicated combinations of E₂, R5020 and RU486, each at a concentration of 1nM for 48 h. Cells were trypsinized and subjected to the matrigel transwell invasion assay with vehicle or the appropriate concentration of E₂, R5020 or RU486 present in the top and bottom chambers, as described under Materials and Methods. In the negative control, serum free media (SFM) was used instead of the FBS chemoattractant. Values are represented as average number of cells invaded from triplicate treatment sets and the error bars represent standard deviation. One-way ANOVA was performed on triplicate treatment sets and P values are indicated.




Figure 2.8 Effect of overexpressing of PR-A on the progestin dose response for rescue of invasiveness from estrogen regulation. PR-A was ectopically overexpressed in hormone-depleted T47D cells by lentiviral transduction, as described under Materials and Methods. Whole cell lysates from cells transduced with either the PR-A expression vector or the control empty vector were probed for PR and for GAPDH (*Panel A*). Cells transduced with the control empty vector (*Panel B*) or PR-A expression vector (*Panel C*) at 30% confluence were treated with vehicle or the indicated concentrations of R5020 in the absence or in the presence of E₂ (1 nM) for 48 h. Cells were then trypsinized and subjected to the matrigel transwell invasion assay. Values are represented as average number of cells invaded from triplicate treatment sets and the error bars represent standard deviation. One-way ANOVA was performed on triplicate treatment sets and P values are indicated.

T47D cells express comparable amounts of PR-A and PR-B protein as observed on a western blot probed with an antibody against a common carboxyl-terminal peptide of the two receptor isoforms (Figure 2.8A). Lentiviral transduction of a PR-A expression plasmid increased the level of PR-A by approximately 3.7-fold, without altering the expression of PR-B (Figure 2.8A). The R5020 dose-dependence for rescue of invasiveness from E₂ regulation was compared between the PR-A overexpressing cells and the control cells transduced with the empty vector. Overexpression of PR-A clearly conferred hypersensitivity to R5020 as the progestin partially rescued invasiveness even at a concentration of 0.05 nM and fully rescued invasiveness at a concentration of 0.2 nM in the PR-A overexpressing cells (Figure 2.8C); in comparison, in the control cells a concentration of 0.5 nM - 1.0 nM R5020 was required to observe similar effects (Figure 2.8B).

2.3.6 PR isoform A-dependent regulation of E₂ target genes by progestin and their functional role.

E₂ acts through its receptor ER to repress expression of genes known to be involved in breast tumor invasion, EMT, and metastasis (182,332,333,336,337). The ability of progestins to oppose E₂ regulation of invasiveness did not involve a decrease in ER expression as evident from a western blot of T47D-A cells treated with R5020 (Figure 2.9A).

Next, we undertook to examine PR isoform-specific effects on transcriptional signaling by E₂ using T47D-A or T47D-B cells. A concentration of 1 nM R5020 was chosen because at this concentration the progestin completely rescued invasiveness from E₂ regulation (through PR-A) but did not exert E₂-independent effects on invasiveness (through PR-B). The cells were treated with vehicle, 1 nM E₂, 1 nM R5020 or 1 nM R5020 + 1 nM E₂ for an extended duration of 48 hours to examine expression of both direct and indirect target genes of the hormones. mRNA

expression profiles were examined by DNA microarray analysis using the Illumina platform and an arbitrary cut off value of 1.5-fold was applied to identify patterns of changes in mRNA expression. In T47D-A cells, among 631 genes that were repressed by E₂ (Supplemental Table 1) (Figure 2.9B), R5020 opposed the repression of 108 genes (Supplemental Table 2) (Figure 2.9B) including 48 genes that were activated by R5020, independent of E₂ (Supplemental Table 3) (Figure 2.9B). In T47D-B cells, among 311 genes that were repressed by E₂ (Supplemental Table 4) (Figure 2.9C), R5020 opposed the repression of 47 genes (Supplemental Table 5) (Figure 2.9C) including 21 genes that were activated by R5020, independent of E₂ (Supplemental Table 6) (Figure 2.9C). Inspection of these gene lists revealed that of the 108 E₂ repressed genes whose expression was rescued by R5020 in T47D-A cells, only 9 genes were also rescued by R5020 in T47D-B cells. The E₂ repressed genes that were activated by progesterone alone were also cell-type specific, with only 8 exceptions. Thus, repression of 99 genes by E₂ was opposed by R5020 in an exclusively PR isoform A-dependent manner. We next searched the literature to identify all the genes in this group that had suggested or established roles in breast tumor biology. A total of 19 genes were clearly known to be associated with breast tumor biology and they predominantly supported breast tumor progression, including invasiveness and metastasis (Supplemental Table 7). The DNA microarray data is validated for 4 representative genes (HES1, PRKCH, ELF5 and TM4SF1) by quantitative real time RT-PCR in Figure 2.10A and 2.10B using T47D-A and T47D-B cells. We also confirmed that these four genes were regulated in T47D (parental), BT474, and ZR-75-1 cells in the same pattern as that observed in T47D-A cells (Figure 2.10C-2.10E).




Figure 2.9 Effect of low dose progestin on the gene repression profile of estrogen in relation to PR-A and PR-B. Hormone depleted T47D-A or T47D-B cells at 30% confluence were treated with vehicle, 1 nM E₂, 1 nM R5020 (P) or 1nM E₂ plus 1nM R5020 (E₂+P) for 48 h. In *Panel A*, whole cell lysates from the treated T47D-A cells were probed by western blot for ER α and for GAPDH. In parallel, total RNA was extracted from the treated T47D-A and T47D-B cells and subjected to mRNA expression profiling as described under Materials and Methods. The mRNA profiling data is represented in the Venn diagrams in *Panel B* (for T47DA cells) and in *Panel C* (for T47D-B cells). *Panels B* and *C* show comparisons among the gene set repressed by E₂ (E₂ repressed vs. Vehicle), the gene set activated by R5020 in the absence of E₂ (P activated vs. Vehicle) and the gene set activated by R5020 in the presence of E₂ (E₂+P activated vs. E₂). The data represents results from experimental triplicates.




Figure 2.10 Validation of gene expression profiling. The total RNA samples used for mRNA expression profiling in Figure 6 were used for validation of the mRNA profiling data for selected genes in T47D-A cells (*Panel A*) and T47D-B cells (*Panel B*). Validation of estrogen and progestin regulation of these genes in the PR-A+ cells was also extended to T47D (parental) cells (*Panel C*), BT474 cells (*Panel D*) and ZR-75-1 cells (*Panel E*). RNA purified from the treated cells was reverse transcribed and the cDNA was analyzed by real-time PCR using TaqMan Probes, as described under Materials and Methods. Relative mRNA levels were measured in the samples for HES1, PRKCH, ELF5, and TM4SF1 genes. All C_T Values were normalized to GAPDH and represented as fold change in comparison to vehicle treated controls.

The four genes (HES1, PRKCH, ELF5 and TM4SF1) validated above have all been associated with cancer progression. To directly test whether regulation of these genes by E₂ mediated the hormonal effects of E₂ on invasiveness in ER+ breast cancer cells, we used a loss-of-function approach. T47D and BT474 cells were transfected with siRNAs against the four genes either individually (Figure 2.11A and 2.11E) or together (Figure 2.11B and 2.11F); in all cases, the siRNAs effectively knocked down the genes, as observed by their mRNA levels compared to the cells transfected with control non-targeted siRNA (Figure 2.11A, 2.11B, 2.11E and 2.11F). Individually knocking down the genes decreased invasiveness of the cells to different degrees (Figure 2.11C and 2.11G) and the combined knockdown completely suppressed invasiveness (Figure 2.11D and 2.11H). The results indicate the functional relevance of genes whose regulation by E₂ was found in this study to be opposed by low dose progesterone acting through PR-A. Clearly the subset of E₂ repressed genes that are counter-regulated by progesterone/PR-A include genes that mediate hormonal regulation of invasiveness in breast cancer cells.

A similar analysis was then conducted for E₂ activated genes in T47D-A (Figure 2.12A and Supplemental Tables 8-10) and T47D-B (Figure 2.12B and Supplemental Tables 11-13) cells. We found that activation of 112 genes by E₂ was opposed by R5020 in an exclusively PR-A isoform dependent manner. Within this group, the small number of genes with better known functions in breast tumor biology tended to support growth and inhibit invasiveness.




Figure 2.11 Functional testing of selected tumor progression genes. Hormone-depleted T47D cells (Panels A-D) and BT474 (Panels E-H) were transfected with control siRNA, TM4SF1 siRNA, HES1 siRNA, ELF5 siRNA and PRKCH siRNA independently (Panel A, C, E, and G) or all four targeted siRNAs in combination (Panels B, D, F, H). After 72 hours cell were subjected to the transwell matrigel invasion assay (Panels C, D, G, and H) as described under Materials and Methods. In the negative controls, serum free medium (SFM) was used instead of the FBS chemoattractant. Values are represented as average number of cells invaded from triplicate treatment sets and the error bars represent standard deviation. One way ANOVA was performed on triplicate treatment sets and P values are indicated.




Figure 2.12 Effect of low dose progestin on the gene activation profile of estrogen in relation to PR-A and PR-B. Hormone depleted T47D-A or T47D-B cells at 30% confluence were treated with vehicle, 1 nM E₂, 1 nM R5020 (P) or 1nM E₂ plus 1nM R5020 (E₂+P) for 48 h. Total RNA was extracted from the treated T47D-A and T47D-B cells and subjected to mRNA expression profiling as described under Materials and Methods. The mRNA profiling data is represented in the Venn diagrams in *Panel A* (for T47DA cells) and in *Panel B* (for T47D-B cells). *Panels A* and *B* show comparisons among the gene set activated by E₂ (E₂ activated vs. Vehicle), the gene set repressed by R5020 in the absence of E₂ (P repressed vs. Vehicle) and the gene set repressed by R5020 in the presence of E₂ (E₂+P repressed vs. E₂). The data represents results from experimental triplicates.

2.4 Discussion

The results of this study reveal that the positive effect of progestins on invasiveness of ER+ breast cancer cells has two components: 1. rescue of invasiveness from estrogen repression at relatively low progestin concentrations that is mediated exclusively by PR isoform A; and 2. estrogen-independent induction of invasiveness at high progestin concentrations that is mediated exclusively by PR isoform B. Moreover, PR-A was sensitized to even lower levels of progestin when this receptor isoform was overexpressed relative to PR-B. Similar to the observations here on PR isoforms, other steroid receptors are also known to induce distinct genotropic and phenotypic effects at different hormone doses as well as hypersensitization to hormone by a few fold overexpression of the receptor (328,338).

The relevance of the above findings to the physiological hormone status prior to and after menopause is apparent. The estrogen dose that was required for substantial or virtually complete suppression of invasiveness in ER+ cells is well under the plasma levels of estrogen in pre-menopausal women. It is also within the range of plasma and breast tissue levels of estrogen in post-menopausal women. The full effect of PR-A on the invasiveness of the various breast cancer cell lines occurred at < 1 nM progesterone and the dose requirement was reduced to < 0.2 nM when the expression level of PR-A was elevated. Thus, dysregulated PR-A has the potential to rescue invasiveness of breast cancer cells from estrogen regulation in response to post-menopausal plasma/breast tissue progesterone levels. This is in contrast to PR-B, which only induced invasiveness progressively with progesterone dose in the range of 5 nM to 50 nM. Thus, isoform A of PR plays the predominant hormone-dependent role in increasing invasiveness of ER+ breast cancer cells at progesterone concentrations that include the entire range of follicular phase, luteal phase and post-menopausal hormone levels, particularly when the cells overexpress PR-A. The

findings on the role of PR isoforms also extend to plasma progestin levels associated with the use of MPA, either in contraception or in hormone replacement therapy. Therefore in luminal breast cancer, prior to diagnosis or after cessation of treatment, PR-A may have a greater mechanistic role in promoting invasiveness than PR-B.

The unique ability of only isoform A of PR to oppose regulation of invasiveness by estrogen at low progesterone concentrations is clearly reflected in the differential abilities of PR-A and PR-B to mediate cross-talk between progesterone and estrogen with respect to patterns of gene regulation. Gene expression analysis using isogenic recombinant (T47D) cells that exclusively expressed either the A or the B isoform of PR revealed that the cross-talk between estrogen and low dose progesterone affected the expression of estrogen target genes with diverse functions. However, among these genes, the subsets that were regulated by progesterone through PR-A vs. PR-B were largely non-overlapping. The genes whose regulation by estrogen was opposed by progesterone in an exclusively PR-A dependent manner included both estrogen-activated and estrogen-repressed genes. The estrogen-repressed genes were more noteworthy in the context of this study as they included genes with established roles in progression of breast cancer. Moreover, we demonstrated that selected genes from this subset (HES1, PRKCH, ELF5 and TM4SF1) did support invasiveness in ER+ breast cancer cells.

In response to the binding of progesterone, several mechanisms could conceivably enable PR-A to oppose estrogen's action on a subset of estrogen target genes. The ligand-dependent activity of PR-A did not result in any change in ER expression. Rather, the exact mechanism of PR-A isoform dependent cross-talk between progesterone and estrogen signaling could depend on the target gene context. For example, (i) PR-A could compete with ER to bind to tethering proteins at repressive sites in the chromatin, either simply blocking repression by estrogen/ER or activating

the target gene; (ii) PR-A could bind at chromatin sites that are different from the repressive sites of ER binding and compete with ER for interaction with the pre-initiation complex of the target genes; (iii) PR-A could indirectly oppose gene regulation by estrogen by regulating transcription of other regulatory proteins or microRNAs. The amino-terminal truncation in PR-A could expose protein binding motifs that are unexposed in PR-B enabling unique or higher affinity interactions of agonist bound PR-A with other regulatory proteins in the chromatin. Similar chromatin interactions of PR-B may therefore require higher doses of progestins. More extensive studies including ChIP-seq analyses should help to establish specific mechanisms by which PR-A may de-regulate estrogen target genes.

In mice, selective ablation of PR-B revealed that PR-B was not required for the normal physiology of the uterus or the ovary but was necessary for pregnancy-associated mammary gland morphogenesis (198). That study demonstrated that the ability of progesterone to suppress estrogen-induced endometrial proliferation was due to PR-A. In contrast, when PR-A was selectively ablated, progesterone not only failed to inhibit estrogen-induced cell proliferation in the endometrium but actually further increased proliferation of the uterine epithelium, an effect mediated by PR-B (197). Therefore, given the necessary role of PR-A in endometrial physiology, selectively disrupting its actions in breast cancer cells vs. endometrial tissue will require a better understanding of tissue-specific molecular pathways by which PR-A opposes estrogen signaling in breast cancer. Identifying and narrowly targeting a critical cross-talk pathway between PR-A and ER may enable suppression of tumor progression without disrupting the protective role of PR-A in the endometrium or the adverse effects of a broader PR antagonist. Such an intervention may also be useful in combination hormone replacement therapy. A molecular signature of hyperactive PR-A may also more effectively predict tumor progression.

CHAPTER 3. THE SHORT PROGESTERONE RECEPTOR ISOFORM SUPPORTS INVASIVENESS AND METASTASIS OF LUMINAL BREAST CANCER BY SUPPRESSING REGULATION OF CRITICAL MICRO RNAs BY ESTROGEN

3.1 Introduction

Breast oncogenesis may span up to several decades. Most (> 78 percent) of newly diagnosed breast cancer cases occur in women older than 50 years (303) with a median age at diagnosis of 61 years (304). Most breast tumors express the nuclear receptors for estrogen (ER) and progesterone (PR) (341) even through progression (174). Primary ER+ tumors are highly responsive to anti-estrogen therapy. However, ER+ breast cancer is often metastatic at the time of diagnosis and metastatic ER+ tumors also frequently appear after many years of dormancy (132,305). Indeed, over a fifth of breast cancer patients harbor distally metastasized ER+ tumors(27). Unfortunately, the metastatic disease is generally incurable and even targeted therapies are generally only palliative. Therefore, it is necessary to understand more about deregulated molecular mechanisms that confer invasive/metastatic properties on ER+ breast cancer cells. However, in contrast to more aggressive cancers, studies of metastasis of luminal breast cancer are rather sparse, due in part to the inherently slow metastatic spread of the tumors in animal models(342). This has likely limited studies of metastasis of ER+ breast tumors to models in which the tumor cells are directly injected into the circulation, bypassing events in the initiation of metastasis at the primary tumor site (342). Therefore, it is also desirable to design an experimental strategy that can functionally link novel physiological mechanisms governing invasiveness of ER+ breast cancer cells to their ability to leave the primary tumor site.

Estrogen supports the growth of ER+ breast tumors but it suppresses invasiveness of the tumor cells whether or not their growth is hormone-sensitive and also suppresses breast tumor progression (183). High dose and potent synthetic forms of progestins directly support

invasiveness and metastasis in ER+/PR+ breast cancer cells, demonstrated using *in vivo* experimental models (309,310). These models may be physiologically relevant in postmenopausal women on high dose hormone replacement therapy, where the combination of estrogen and progestin was associated with increased incidence of invasive breast cancer and breast cancer mortality compared with non-users (59), in contrast estrogen monotherapy in women with prior hysterectomy was associated with a persistent decrease in the onset of invasive breast cancer (60). However, in post-menopausal women who are not undergoing hormone replacement, the role of the endogenous hormones in the progression of ER+/PR+ breast tumors have not been adequately studied. Compared to the knowledge on the influence of estrogen on breast tumor physiology, much less is known about the mechanisms of progesterone action, particularly in the presence of active estrogen signaling. Moreover, although the levels of estrogen and progesterone change throughout the menstrual cycle and decrease after menopause very little is known about the hormone actions on tumor invasiveness/progression in the context of this changing hormone status during a woman's lifetime. Our recent findings in chapter 2 have addressed these questions by identifying a fundamental role for cross-talk between ER and PR in governing invasiveness of a variety of model luminal breast cancer cell lines in the entire range (pre- and post-menopausal) of physiological levels of estrogen and progesterone (157).

PR has two isoforms, A and B, expressed by alternative promoter usage from a single gene; PR-B is identical to PR-A except for the presence of an additional 164 amino acid amino-terminal segment that contains within it, an additional activation function, AF3 (157). PR-B and PR-A induce both distinctive and overlapping patterns of agonist-induced gene activation or gene repression, depending on the variable contexts of the target promoters and the nature of the associated chromatin sites of PR binding (156,157,312). The heterodimer of PR-A and PR-B

regulates a smaller and unique set of genes compared to the homodimers (156). Clinical studies have shown that although in normal breast PR-A and PR-B are expressed at comparable levels, this balance is commonly altered during breast oncogenesis with an increase in PR-A in early as well as progressed lesions (190). Overexpression of PR-A is associated with increased invasiveness of clinical tumor lesions and a lower rate of disease free survival (170).

In vitro studies in the literature originally suggested that PR-B is the principal mediator of progesterone-induced invasiveness of breast cancer cells (192,193), at odds with the clinical observations noted above that implicate PR-A in tumor progression. However, the *in vitro* studies of PR-B were performed at high (luteal stage and pregnancy-associated) concentrations of progesterone and also were conducted in the absence of estrogen signaling (192–195,343). The plasma estrogen range in pre-menopausal women is 1.4 nM -1.6 nM during the follicular phase, and 3.6 nM - 4.2 nM during the luteal phase (64). Plasma progesterone ranges from below 4 nM during follicular phase, up to > 50 nM during the luteal phase (344). Post-menopause, there is a marked decrease in circulating hormone levels with median values of 0.14 nM for estrogen and 0.13 nM for progesterone, yet the breast tissue may retain up to about 1nM of each hormone (191,306). We have recently reported studies that were performed in the entire range of estrogen and progesterone concentrations corresponding to pre- and post-menopausal hormone status and in the presence of both estrogen and progesterone signaling (Chapter 2) (157). As the previous *in vitro* studies of high dose progesterone effects on metastasis were conducted in the absence of estrogen signaling, we considered the possibility that modulation of estrogen action may comprise a distinct aspect of the regulation of invasiveness by progestins in the range of its physiological levels (157) . Estrogen strongly suppressed invasiveness of ER+ breast cancer cells at concentrations below 0.01 nM. At low (< 1 nM) concentrations, progesterone/progestins

completely abrogated the inhibition of invasiveness by estrogen. It was only in a higher (5 nM - 50 nM) concentration range that progestins progressively induced invasiveness in the absence of estrogen. The ability of progestins to rescue invasiveness from estrogen regulation was exclusively mediated by PR-A and was uninfluenced by PR-B. On the other hand, PR-B mediated the estrogen-independent component of progestin-induced invasiveness at either pharmacological (used in hormone replacement) progestin levels or progesterone levels associated with pregnancy. Overexpression of PR-A in PR-A+/PR-B+ cells lowered the progestin concentration needed to completely rescue invasiveness (to < 0.2 nM). The studies demonstrate that progesterone influences breast cancer cell invasiveness by rescuing it from estrogen regulation, exclusively via PR-A, in the entire pre- and post-menopausal range of estrogen and progesterone concentrations (157). These findings reconcile *in vitro* actions of PR isoforms with the clinically observed association between PR-A and progression of luminal breast cancer.

Although progesterone, acting through PR-A, appears to be the major culprit in promoting invasiveness of luminal breast cancer cells by counteracting estrogen, directly testing the effect of this mechanism on metastasis *in vivo* by manipulating hormone levels is not possible because estrogen depletion would prevent tumor formation. Instead, if a critical pathway of hormonal cross-talk between PR-A and ER that regulates *in vitro* invasiveness could be identified, it should be possible to test the effect of disrupting this pathway on metastasis using an appropriate *in vivo* model. Additionally, such a cross-talk pathway(s) may reveal better therapeutic targets as clinical interventions that broadly or systemically obstruct progesterone/PR signaling are precluded by the need for progesterone for endometrial homeostasis (145,345) and off-target effects of progesterone antagonists (346). In luminal breast cancer cells, ER strongly regulates tumor cell characteristics by regulating micro-RNAs (miRNAs) (347–350) and is itself also regulated by miRNAs

(347,350,351). There is less information on the regulation of PR by miRNAs or on regulation of miRNAs by progesterone/PR. Indeed, miRNAs regulate up to a third of the human genome and have diverse roles in normal physiology as well as profound roles as tumor suppressors and oncogenes (352). This study was undertaken to explore the possibility that regulation of certain miRNAs could be critical for cross-talk between progesterone/PR-A and estrogen/ER in the specific context of hormonal control of invasion *in vitro* and to manipulate such a cross-talk pathway(s) as a means of establishing the role of hormonal cross-talk of PR-A with ER in metastasis of luminal breast cancer.

3.2 Materials and Methods

3.2.1 Cell Line Models and Breast Tumor Specimens

BT474, T47D and ZR-75-1 breast cancer cells were purchased from American Type Culture Collection (ATCC). T47D-A (ER+/PR-A+/PR-B-null) and T47D-B (ER+/PR-B+/PR-A-null) recombinant cells isogenic with parental T47D cells were a generous gift from Dr. Katherine Horowitz (University of Colorado, Denver, CO) and were cultured as previously described (329). T47D-PR-A++ cells were previously generated in our laboratory (157). Recombinant BT474 cell lines with stable expression of PR shRNA (PR-shRNA cells), miR-92a-3p (miR-92a-3p-On cells) or miR-26b-5p inhibitor (miR-26b-5p-Off cells) and control cells harboring Lenti-miR-Blank plasmid were generated using PR shRNA lentiviral plasmid (Cat# 0000436004, Sigma-Aldrich, St. Louis MO) hsa-miR-92a-3p miRNA Lentivector (Cat# mh11076, ABM, Vancouver, BC) or Lenti-miR-Off-hsa-miR-26b-5p vector (Cat# mh30381, ABM, Vancouver, BC) or control Lenti-miR-blank vector (Cat# m007, ABM, Vancouver, BC) by lentiviral transduction methods described below. All human tumor samples, classified as ER+/PR+ ductal carcinoma, were obtained from Cooperative Human Tissue Network (CHTN).

3.2.2 Cell Culture and Hormone Depletion

Cell line models were cultured in DMEM supplemented with FBS (10%) penicillin (100 unit/ml) streptomycin (100ug/ml) and L-glutamine (2 mM) at 37°C in 5% CO₂. To maintain selection pressure, the media for the recombinant BT474 cells contained 0.5µg/ml puromycin and the media for T47D-A and T47D-B cells contained 200ug/ml geneticin. For hormone depletion, cells were plated at 30% confluence in phenol red-free media supplemented with charcoal-stripped FBS and incubated at 37°C in 5% CO₂ for 48 h.

3.2.3 Western Blot of Cells and Breast Tumor Tissues

Cell lysates were prepared as described (157). To prepare tumor tissue lysates, tissue (100mg) suspended in 500 ul of RIPA buffer was homogenized using the BioGen-PRO200 tissue homogenizer (Cat# 01-01200, Cambridge, MA) for 15 seconds on ice and centrifuged at 15,000x G and supernatant was used. Western blot was performed as previously described (157). The antibody probes include monoclonal rabbit anti-PR antibody (Cat# 8757, Cell Signaling, Danvers, MA), EMT sampler kit antibodies (Cat# 9782, Cell Signaling, Danvers, MA) or mouse monoclonal anti-GAPDH antibody (sc-4472, Santa Cruz Biotechnologies, CA) and appropriate horseradish peroxidase conjugated secondary antibodies (Vector Laboratories, MD). Relative protein expression was determined by semi-quantitative densitometry of auto-radiographic film using ImageJ software (National Institutes of Health, USA).

3.2.4 Boyden Chamber Transwell Invasion Assay

Cell invasion assays were performed as previously described (Chapter 2).

3.2.5 Isolation and Measurement of Micro RNA and mRNA

Total RNA was isolated from cells or tissues using the Exiqon miRCURY total RNA isolation kit (Vedebaek, Denmark). Breast tumor tissue lysates were prepared by suspending 50

mg tissue in 500ul of the lysis buffer and homogenized using the BioGen-PRO200 tissue homogenizer (Cat# 01-01200, Cambridge, MA) for 15 seconds on ice. Homogenized solution was centrifuged at high 15,000x G and supernatant was used for RNA extraction. Reverse transcription PCR reactions were performed using high capacity complementary DNA archive kit, or miRNA reverse transcription kit (Life Technologies Corporation, Carlsbad, CA). cDNA was measured by quantitative real time RT-PCR using TaqMan probes and the StepOne Plus Real time PCR system (Life technologies Corporation, Carlsbad, CA). All RNA measurements were performed in biological triplicates, and all CT values were normalized to intra-sample GAPDH (mRNA) or U6snRNA (miRNA). RNA values were represented as fold difference, which is calculated using the formula = $2^{-\Delta\Delta CT}$, where $\Delta\Delta CT = \Delta CT \text{ sample} - \Delta CT \text{ calibrator}$.

3.2.6 Affymetrix Profiling of Micro RNAs Regulated by PR-A

Hormone depleted T47D-A and T47D-B cells were treated with vehicle, or R5020 (1nM). Total RNA samples, isolated using the Exiqon miRCURY isolation kit (Denmark), were analyzed at the University of Michigan Microarray Core using the Affymetrix miRNA microarray generation IV (Affymetrix, Santa Clara, CA). Expression values were normalized using quantile-normalization, with background subtraction. Log transformation to the base of 2, followed by one-way ANOVA was used to determine error. The differentially expressed genes were identified by comparing R5020 treatment with vehicle treatment (repressed or activated with a cutoff fold difference of 1.5 and a p value < 0.05). Real-time RT-PCR was performed as described above to validate miRNAs that were exclusively regulated by PR-A.

3.2.7 Lentiviral Transduction

Packaging of lentiviral particles with pCDH empty vector plasmid, pCDH-PR shRNA, hsa-miR-92a-3p miRNA Lentivector or LentimiRa-Off-hsa-miR-26b-5p vector and transduction of

cells were performed as described (157). The pool of recombinant cells was selected by culturing in puromycin containing media for 6 weeks.

3.2.8 Transfection of siRNA or miRNA Inhibitor

Cells were plated to 30% confluence without antibiotic in phenol-red free DMEM medium supplemented with 10% charcoal-stripped FBS. 24 hours later cells were transfected with siRNA directed against specific gene targets, miRNA inhibitors (miRVana, Life Technologies, Carlsbad, CA) directed against specific miRNA targets or with appropriate non-silencing controls using lipofectamine (Life Technologies, Carlsbad, CA).

3.2.9 Metastasis Pathway Gene Array Expression Analysis

Human Tumor Metastasis Fast TaqMan Real-Time PCR array (Life Technologies, Carlsbad, CA) was performed on StepOne Realtime (Applied Biosystems). cDNA samples from BT474 (control transduced cells), BT474 92a-3p-On cells and BT474 miR-26b-5p-Off cells were analyzed. The $\Delta\Delta C_t$ method was used as described above to quantify gene expression.

3.2.10 Mouse Metastasis Model

Female athymic nude mice (Envigo, Indianapolis, IN) were implanted with 0.72 mg slow-release estradiol pellets (Innovative research of America, Sarasota, FL) on Day 0. On Day 3, 1×10^7 - 2×10^7 cells were suspended in 300 μ l of equal parts DMEM and Matrigel and implanted subcutaneously in the right flank just below the right shoulder. Mice were sacrificed on day 17. Tumors, ipsilateral and contralateral axillary and inguinal Lymph-nodes and livers were harvested from the mice. All tissues were homogenized and total RNA extracted as described above for human tissues. The degree of tissue infiltration by the human tumor cells (metastasis) was measured in terms of the amount of mRNA present for human GAPDH by quantitative real time

RT-PCR using human and mouse species-specific high efficiency Taqman Probes. The mRNA values for human GAPDH was normalized to the mRNA for mouse GAPDH.

3.3 Results

3.3.1 Identification of micro RNAs that are uniquely regulated by low dose progesterone through PR-A.

Progesterone bound to PR-A could impinge on regulation of invasiveness by E_2/ER in a manner that is mediated by one or more miRNAs in the following ways (depicted as schematics in Figure 3.1A and 3.1B). First, Progesterone/PR-A could either activate or repress miRNA(s) (independent of estrogen) and this would then result in rescue of invasiveness from estrogen repression (Figure 3.1A). On the other hand, E_2/ER could either activate or repress miRNA(s) resulting in inhibition of invasiveness; in this case, progesterone/PR-A could suppress regulation of the miRNAs by E_2 , resulting in rescue of invasiveness from estrogen repression (Figure 3.1B). To identify these putative miRNAs we used the following cell line models: T47D-A (ER+/PR-A+/PR-B-null), T47D-B (ER+/PR-A-null/PR-B+), parental T47D (ER+/PR-A+/PR-B+), BT474 (ER+/PR-A+/PR-B+) and ZR-75-1(ER+/PR-A+/PR-B+).

To identify candidate miRNAs in the putative pathways illustrated in Figure 3.1A, we first undertook Affymetrix miRNA profiling to screen for miRNAs activated or repressed by PR-A but not PR-B at a low dose (1 nM) of R5020. This was accomplished by using Affymetrix miRNA profiling of miRNA changes in hormone-depleted T47D-A vs. T47D-B cells treated with R5020 followed by data validation by quantitative RT-PCR. We found 5 miRNAs, that were activated by low dose progestin and PR-A (i.e., in T47D-A cells) but not by PR-B (i.e., in T47D-B cells). They are miR-6805-5p, miR-584-5p, miR-1228-5p, miR-501-5p and miR-668-5p. These 5 miRNAs were also strongly up-regulated in other PR-A-positive cell lines including

parental T47D cells, BT474 cells and ZR-75-1 cells (**Figure 3.1C**; values in *Table 3.1*). The same Affymetrix miRNA analysis did not reveal any miRNAs that were repressed via PR-A alone.

In contrast to progestin regulated miRNAs there is considerable literature data on miRNAs regulated by E_2 acting through ER (*not shown*). All of these miRNAs, that were either activated or repressed by E_2 , were tested by real time RT-PCR analysis to identify miRNAs whose regulation by E_2 was prevented by R5020 in T47D-A cells (i.e., via PR-A) but not in T47D-B cells (i.e., via PR-B). In this manner, ten miRNAs were identified; five among them (miR-17-5p, miR-20a-5p, miR-92a-3p, miR-106a-5p and miR-106b-5p) were activated by E_2 and five (miR-26b-5p, miR-27a-5p, miR-27b-5p, miR-200c-5p and Let7a-5p) were repressed by E_2 in the absence of progestin/PR-A. The counter-regulation of these E_2 -regulated miRNAs by progestin/PR-A was also confirmed in the other PR-A-positive cell lines including parental T47D cells, BT474 cells and ZR-75-1 cells (Figure 3.1D and 3.1E; values in *tables 3.2 and 3.3*). Finally, to ensure that higher doses of progestin did not enable PR-B to mimic regulation of the 15 miRNAs by PR-A, T47D-B cells were treated with vehicle, 1 nM E_2 , and 1nM E_2 plus R5020 (1nM-50nM). There was no progestin dose-dependent miRNA activation or opposition to E_2 regulation by PR-B (Figure 3.2).




Figure 3.1: Possible pathways and candidate miRNAs that could be involved in the hormone-dependent cross talk of PR-A with ER that regulates invasiveness in breast cancer cells. Panel A and Panel B are schematic representations of possible pathways by which miRNAs could mediate the cross-talk of progestin (P)-bound PR-A with E₂-bound ER to influence invasiveness and metastasis of luminal breast cancer cells. In **Panels C-E**, hormone depleted T47D-A, T47D-B, T47D, BT474, and ZR-75-1 cells at 30% confluence were treated with vehicle, 1 nM E₂, 1 nM R5020 (P) or 1nM E₂ plus 1nM R5020 (E₂ + P) for 48 h. Total RNA was then extracted and the relative levels of each miRNA indicated were quantified in all the samples. The miRNA profiling data is represented in the heat map in **Panel C** for miRNAs activated by progestin plus PR-A (even in the absence of E₂), in **Panel D** for E₂ activated miRNAs that were counter-regulated by progestin plus PR-A and in **Panel E** for E₂ repressed miRNAs that were counter-regulated by Progestin plus PR-A. The data represents results from experimental triplicates.

miRNA	Cell Line	Vehicle	Vehicle (STDV)	E2	E2 (STDV)	R5020	R5020 (STDV)	E2+R5020	E2+R5020 (STDV)
miR-668-5p	T47DA	1	0.137	0.759	0.179	12.787	0.456	8.995	0.888
miR-668-5p	T47DB	1	0.044	0.623	0.077	1.120	0.071	0.817	0.027
miR-668-5p	T47D	1	0.101	0.689	0.108	11.109	0.086	14.911	1.534
miR-668-5p	BT474	1	0.059	0.507	0.068	7.430	0.212	6.966	0.580
miR-668-5p	ZR-75-1	1	0.109	0.326	0.038	5.531	0.248	7.757	0.370
miR-501-5p	T47DA	1	0.115	0.570	0.011	2.665	0.014	2.131	0.195
miR-501-5p	T47DB	1	0.043	0.452	0.008	1.183	0.022	0.410	0.040
miR-501-5p	T47D	1	0.130	0.886	0.002	2.553	0.087	3.650	0.378
miR-501-5p	BT474	1	0.009	0.854	0.015	3.056	0.069	3.269	0.427
miR-501-5p	ZR-75-1	1	0.058	0.483	0.013	2.684	0.064	2.591	0.162
miR-1228-5p	T47DA	1	0.235	0.333	0.168	8.806	1.515	11.414	2.080
miR-1228-5p	T47DB	1	0.183	0.454	0.158	0.814	0.040	0.434	0.156
miR-1228-5p	T47D	1	0.731	0.671	0.100	3.463	0.047	8.467	2.631
miR-1228-5p	BT474	1	0.261	0.607	0.153	5.550	0.799	6.340	0.880
miR-1228-5p	ZR-75-1	1	0.643	0.676	0.249	14.028	1.160	13.336	2.044
miR-584-5p	T47DA	1	0.015	0.413	0.008	10.488	0.307	9.007	0.455
miR-584-5p	T47DB	1	0.023	0.454	0.012	0.884	0.019	0.634	0.026
miR-584-5p	T47D	1	0.066	0.650	0.039	9.094	0.292	7.867	0.520
miR-584-5p	BT474	1	0.058	0.527	0.006	6.498	0.077	7.806	0.787
miR-584-5p	ZR-75-1	1	0.036	0.463	0.011	11.993	0.010	11.784	0.809
miR-6805-5p	T47DA	1	0.300	1.248	0.014	3.662	0.025	5.516	0.374
miR-6805-5p	T47DB	1	0.372	0.401	0.263	0.759	0.138	0.279	0.245
miR-6805-5p	T47D	1	0.338	0.520	0.359	2.766	1.261	7.552	2.352
miR-6805-5p	BT474	1	0.794	0.365	0.364	3.895	1.628	2.909	0.458
miR-6805-5p	ZR-75-1	1	0.516	0.657	0.211	7.338	2.672	7.158	2.117

Table 3.1 Data corresponding to heat map in Figure 3.1C

miRNA	Cell Line	Vehicle	Vehicle (STDV)	E2	E2 (STDV)	R5020	R5020 (STDV)	E2+R5020	E2+R5020 (STDV)
miR-17-5p	T47DA	1	0.062	2.507	0.035	1.327	0.018	0.961	0.008
miR-17-5p	T47DB	1	0.203	3.709	0.182	1.040	0.019	3.031	0.354
miR-17-5p	T47D	1	0.009	4.162	0.178	2.035	0.050	1.098	0.056
miR-17-5p	BT474	1	0.013	6.276	0.336	0.705	0.018	0.741	0.008
miR-17-5p	ZR-75-1	1	0.023	5.567	0.051	1.066	0.040	0.858	0.039
miR-20a-5p	T47DA	1	0.013	1.703	0.014	0.353	0.003	0.262	0.006
miR-20a-5p	T47DB	1	0.195	4.368	0.286	1.253	0.086	3.572	0.222
miR-20a-5p	T47D	1	0.075	4.048	0.056	1.009	0.034	0.795	0.012
miR-20a-5p	BT474	1	0.038	7.425	0.413	0.835	0.016	0.870	0.010
miR-20a-5p	ZR-75-1	1	0.034	5.527	0.102	1.102	0.008	0.839	0.015
miR-92A-3p	T47DA	1	0.020	2.541	0.024	0.786	0.006	0.955	0.014
miR-92A-3p	T47DB	1	0.141	3.217	1.325	1.259	0.472	2.921	3.323
miR-92A-3p	T47D	1	0.046	4.651	0.123	1.445	0.072	1.168	0.022
miR-92A-3p	BT474	1	0.029	6.591	0.043	1.062	0.037	1.253	0.011
miR-92A-3p	ZR-75-1	1	0.021	5.882	0.046	1.129	0.011	0.713	0.009
miR-106A-5p	T47DA	1	0.049	3.737	0.051	2.012	0.060	1.768	0.046
miR-106A-5p	T47DB	1	0.090	4.436	0.204	1.161	0.111	3.779	0.344
miR-106A-5p	T47D	1	0.019	4.966	0.070	1.137	0.015	0.773	0.053
miR-106A-5p	BT474	1	0.038	7.581	0.291	1.075	0.015	1.026	0.020
miR-106A-5p	ZR-75-1	1	0.062	8.964	0.116	1.335	0.052	1.120	0.021
miR-106b-5p	T47DA	1	0.045	4.024	0.084	1.162	0.008	0.970	0.019
miR-106b-5p	T47DB	1	0.048	3.217	0.515	1.259	0.086	2.921	0.202
miR-106b-5p	T47D	1	0.064	1.362	0.023	0.420	0.003	0.311	0.003
miR-106b-5p	BT474	1	0.013	3.095	0.018	0.414	0.024	0.377	0.006
miR-106b-5p	ZR-75-1	1	0.022	2.404	0.010	0.470	0.013	0.408	0.002

Table 3.2 Data corresponding to the heat map Figure 3.1D

miRNA	Cell Line	Vehicle	Vehicle (STDV)	E2	E2 (STDV)	R5020	R5020 (STDV)	E2+R5020	E2+R5020 (STDV)
miR-26b-5p	T47DA	1	0.074	0.204	0.004	0.820	0.067	0.973	0.021
miR-26b-5p	T47DB	1	0.033	0.545	0.007	1.403	0.030	0.665	0.022
miR-26b-5p	T47D	1	0.056	0.501	0.018	0.978	0.469	1.031	0.067
miR-26b-5p	BT474	1	0.067	0.694	0.049	1.240	0.017	1.168	0.101
miR-26b-5p	ZR-75-1	1	0.087	0.350	0.046	1.201	0.027	1.795	0.127
miR-27a-5p	T47DA	1	0.305	0.212	0.044	3.399	0.252	2.362	0.253
miR-27a-5p	T47DB	1	0.102	0.603	0.144	0.997	0.149	0.544	0.070
miR-27a-5p	T47D	1	0.096	0.508	0.097	2.280	0.602	5.320	1.091
miR-27a-5p	BT474	1	0.258	0.267	0.238	1.004	0.284	1.440	0.336
miR-27a-5p	ZR-75-1	1	0.261	0.233	0.017	0.824	0.131	0.793	0.088
miR-27b-5p	T47DA	1	0.086	0.167	0.059	0.828	0.197	0.874	0.129
miR-27b-5p	T47DB	1	0.033	0.516	0.010	0.928	0.147	0.600	0.031
miR-27b-5p	T47D	1	0.032	0.487	0.010	1.289	0.067	1.033	0.036
miR-27b-5p	BT474	1	0.150	0.376	0.125	1.177	0.303	1.130	0.145
miR-27b-5p	ZR-75-1	1	0.073	0.046	0.012	0.714	0.015	0.683	0.034
miR-200c-5p	T47DA	1	0.265	0.343	0.069	1.495	0.087	1.188	0.070
miR-200c-5p	T47DB	1	0.085	0.600	0.084	1.583	0.153	0.756	0.023
miR-200c-5p	T47D	1	0.138	0.504	0.039	2.533	0.038	1.514	0.985
miR-200c-5p	BT474	1	0.023	0.272	0.034	0.925	0.078	1.123	0.313
miR-200c-5p	ZR-75-1	1	0.139	0.282	0.029	1.260	0.024	1.790	0.069
Let7a-5p	T47DA	1	0.055	0.216	0.002	1.519	0.012	1.258	0.056
Let7a-5p	T47DB	1	0.065	0.527	0.004	1.830	0.120	0.782	0.026
Let7a-5p	T47D	1	0.026	0.642	0.011	1.392	0.035	1.177	0.034
Let7a-5p	BT474	1	0.065	0.577	0.016	1.207	0.079	0.888	0.005
Let7a-5p	ZR-75-1	1	0.026	0.562	0.008	1.898	0.047	1.812	0.052

Table 3.3 Data corresponding to the heat map in Figure 3.1E




Figure 3.2. Higher doses of progesterin do not enable PR-B to mimic the actions of PR-A on 15 miRNAs. Hormone depleted T47D-B cells at 30% confluence were treated with vehicle, 1 nM E₂, 1 nM R5020 (P) and 1nM E₂ plus 1 nM, 10 nM or 50 nM R5020 for 48 h. Total RNA was then extracted and the relative levels of each miRNA indicated were quantified. The miRNA profiling data is represented in the heat map.

3.3.2 Regulation of micro RNAs by PR-A is sensitized to lower doses of progestin by overexpression of PR-A to a level observed in tumors.

We have previously reported that compared to T47D cells, in the isogenic recombinant T47D-PR-A⁺⁺ cells that express a 3.6-fold higher level of PR-A (Figure 3.3E), lower doses of progesterone can rescue invasiveness from estrogen repression (Chapter 2). Among 53 primary tumor specimens examined by western blot, 13 specimens (~ 25 percent) showed levels of PR-A expression that were comparable to or higher than that in T47D-PR-A⁺⁺ cells (Figure 3.3A), confirming the clinical relevance of this isogenic model. In T47DA⁺⁺ cells, every one of the above 15 miRNAs was optimally regulated at or below 0.2 nM R5020 whereas the parental T47D cells required 0.5 – 1 nM R5020 for the same level of regulation (increase or decrease in the absence or presence of 1nM E₂) (Figure 3.3B-D; values in *Table 3.4*). This level of hyper-sensitization to progestin of miRNA regulation in T47D-PR-A⁺⁺ cells corresponds to the previously reported progestin dose dependence of invasiveness of T47D-PR-A⁺⁺ cells vs. parental T47D cells (157).

3.3.3 miR-92a-3p and miR-26b-5p are functionally linked to hormonal control of invasiveness.

We tested the ability of E₂ to repress invasiveness or for R5020 to rescue invasiveness following inhibition of each of the above 15 miRNAs in T47D and BT474 cells. Inhibition was confirmed by reduction in target miRNA 72h post-transfection, although residual miRNA-inhibitor duplexes may also be detected.




Figure 3.3: PR overexpression in primary luminal breast tumor specimens and the effect of PR-A overexpression on hormone sensitivity of miRNA regulation. Whole cell lysates from primary luminal breast tumors from 53 patients together with whole cell lysates from T47D PR-A++ cells were analyzed on western blots that were probed for PR and GAPDH (**Panel A**). Hormone-depleted T47D parental cells and T47D PR-A++ cells at 30% confluence were treated with vehicle, 1nM E₂ or 1nM E₂ plus a range (0.05nM – 1nM) of concentrations of R5020 (P) for 48h. Total RNA was then extracted and the relative levels of each miRNA indicated were quantified in all the samples. The miRNA profiling data is represented in the heat map in **Panel B** for miRNAs activated by progestin plus PR-A (even in the absence of E₂), in **Panel C** for E₂ activated miRNAs that were counter-regulated by progestin plus PR-A and in **Panel D** for E₂ repressed miRNAs that were counter-regulated by progestin plus PR-A. The data represents results from experimental triplicates. In **Panel E**, whole cell lysates from T47D cells and T47D PR-A++ cells were probed by western blot for PR and GAPDH.

Progesterin Activated miRNAs Realive Expression										
Cell Line	T47D PR-A ++					T47D				
	miR-1228-5P	miR-584-5P	miR-668-5P	miR-501-5P	miR-6823-5P	miR-1228-5P	miR-584-5P	miR-668-5P	miR-501-5P	miR-6823-5P
V	1	1	1	1	1	1	1	1	1	1
1nME	1.0377	0.6988	1.2414	1.3504	1.6888	1.1959	0.9914	1.2280	1.1559	1.3404
1nM E+0.05nM P	1.6626	0.7308	3.1849	3.8049	1.6862	1.1345	1.1206	1.3647	1.5847	1.3384
1nM E+0.2nM P	5.1131	3.0360	4.4787	6.1258	3.6560	1.1678	1.2877	1.6620	1.5874	1.8280
1nM E+0.5nM P	4.5812	3.8757	5.3508	7.7104	7.2341	2.0791	1.6298	1.8000	2.4149	2.1418
1nM E+1nM P	5.5846	3.9295	10.6955	11.2391	7.3695	5.4435	4.1027	3.2645	4.2015	5.5063
Progesterin Activated miRNAs Standard Deviation										
Cell Line	T47D PR-A ++					T47D				
	miR-1228-5P	miR-584-5P	miR-668-5P	miR-501-5P	miR-6823-5P	miR-1228-5P	miR-584-5P	miR-668-5P	miR-501-5P	miR-6823-5P
V	0.2821	0.2511	0.2605	0.0327	0.2895	0.1909	0.3371	0.0768	0.0472	0.1406
1nME	0.0240	0.2530	1.3226	0.4523	0.3514	0.0262	0.2002	0.1574	0.0405	0.8399
1nM E+0.05nM P	1.5487	0.2511	1.0117	1.4731	0.2774	0.0200	0.1436	0.3878	0.6602	0.5661
1nM E+0.2nM P	0.7863	0.8540	1.2262	0.4526	0.1742	0.0156	0.3212	0.7843	0.5650	0.6601
1nM E+0.5nM P	1.4848	1.1721	0.7908	0.8417	1.0526	0.7158	0.7465	0.7117	0.0576	1.1079
1nM E+1nM P	0.2519	0.6110	2.4907	0.1754	1.0388	1.8445	0.8914	1.1964	0.4397	0.7762
E2 Repressed miRNAs Realive Expression										
Cell Line	T47D PR-A ++					T47D				
	miR-200c-5p	miR-27a-5p	miR-27b-5p	LET7a	miR-26b-5p	miR-200c-5p	miR-27a-5p	miR-27b-5p	LET7a-5p	miR-26b-5p
V	1	1	1	1	1	1	1	1	1	1
1nME	0.2120	0.4680	0.2290	0.4142	0.3212	0.2368	0.2891	0.1382	0.1937	0.1394
1nM E+0.05nM P	0.2213	0.3612	0.2089	0.3256	0.3197	0.5974	0.6471	0.2833	0.1142	0.1767
1nM E+0.2nM P	1.3835	1.0420	1.1593	1.7439	1.0006	0.4183	0.3477	0.3214	0.2216	0.1692
1nM E+0.5nM P	1.0297	1.5235	0.7375	1.2017	0.7361	1.3036	0.5882	1.2017	0.8695	0.3253
1nM E+1nM P	0.9201	2.0322	1.0644	1.2943	0.7032	0.9459	1.5867	0.8708	0.8190	0.6338
E2 Repressed miRNAs Standard Deviation										
Cell Line	T47D PR-A ++					T47D				
	miR-200c-5p	miR-27a-5p	miR-27b-5p	LET7a	miR-26b-5p	miR-200c-5p	miR-27a-5p	miR-27b-5p	LET7a-5p	miR-26b-5p
V	0.0500	0.0329	0.1349	0.0659	0.0566	0.0789	0.1228	0.1277	0.0258	0.0516
1nME	0.0344	0.0634	0.0475	0.0102	0.0054	0.0148	0.0295	0.0379	0.0095	0.0042
1nM E+0.05nM P	0.0104	0.1058	0.0166	0.0014	0.0101	0.0652	0.0524	0.0264	0.0418	0.0409
1nM E+0.2nM P	0.0473	0.0961	0.0626	0.0255	0.0540	0.0171	0.0346	0.3291	0.0092	0.0291
1nM E+0.5nM P	0.0391	0.0789	0.1241	0.0303	0.0396	0.0562	0.0335	0.1603	0.0117	0.0212
1nM E+1nM P	0.0437	0.0866	0.1258	0.0121	0.0039	0.0446	0.0789	0.0583	0.0286	0.0557
E2 Activated miRNAs Realive Expression										
Cell Line	T47D PR-A ++					T47D				
	miR-17-5p	miR-20a-5p	miR-92a-3p	miR-106a-5p	miR-106b-5p	miR-17-5p	miR-20a-5p	miR-92a-3p	miR-106a-5p	miR-106b-5p
V	1	1	1	1	1	1	1	1	1	1
1nME	7.823	4.965	4.436	4.261	5.504	6.306	4.054	3.786	3.116	2.516
1nM E+0.05nM P	7.544	4.582	3.952	3.670	5.007	5.190	3.508	2.639	2.897	2.970
1nM E+0.2nM P	1.514	1.247	1.284	1.147	1.410	4.090	2.038	2.036	2.095	2.794
1nM E+0.5nM P	1.206	0.911	0.921	0.656	1.274	1.800	1.116	0.728	1.013	0.916
1nM E+1nM P	1.413	0.917	0.921	0.454	1.180	1.633	0.887	0.718	0.653	0.703
E2 Activated miRNAs Standard Deviation										
Cell Line	T47D PR-A ++					T47D				
	miR-17-5p	miR-20a-5p	miR-92a-3p	miR-106a-5p	miR-106b-5p	miR-17-5p	miR-20a-5p	miR-92a-3p	miR-106a-5p	miR-106b-5p
V	0.1333	0.2080	0.2075	0.0180	0.0665	0.0790	0.2086	0.4110	0.0202	0.0616
1nME	0.1146	0.1938	0.5273	0.0674	0.1015	0.1690	0.3245	0.9685	0.1023	0.1320
1nM E+0.05nM P	0.0829	0.2934	0.0738	0.0692	0.1176	0.4861	0.0736	0.0759	0.1628	0.0178
1nM E+0.2nM P	0.1163	0.0626	0.1987	0.0140	0.0627	0.0697	0.3214	0.0539	0.0592	0.2230
1nM E+0.5nM P	0.0810	0.1299	0.1858	0.0136	0.0506	0.1451	0.1580	0.0087	0.0510	0.0634
1nM E+1nM P	0.1902	0.2831	0.0502	0.0136	0.0342	1.4383	0.1822	0.0112	0.0330	0.0265

Table 3.4 Data corresponding to heat maps in Figure 3.2B -D




Figure 3.4: Effect of inhibiting miRNAs hormonally regulated by PR-A and ER on invasiveness of luminal breast cancer cells. Hormone-depleted T47D and BT474 cells were transfected with either control Inhibitor (I-Ctrl) or the indicated miRNA specific inhibitor. The inhibitors are indicated in the Figure by using the prefix 'I' for the corresponding target miRNA. Twenty-four hours later, cells were treated for 48 h with vehicle, E₂ (1nM), or E₂ (1nM) + R5020 (1nM) as indicated. Total RNA was then extracted and the relative levels of each miRNA indicated were quantified in all the samples. Histograms show the miRNA expression data for progestin activated miRNAs (**Panel A**), E₂ activated miRNAs (**Panel D**) and E₂ repressed miRNAs (**Panel G**). In parallel, the treated cells were subjected to the trans-well matrigel invasion assay (**Panels B, C, E, F, H and I**). One-way ANOVA with Post-hoc unpaired t-test was performed on triplicate treatment sets and *P*-values are indicated.

We first inhibited each of the progestin/PR-A activated (but not E₂-regulated) miRNAs, miR-6805-5p, miR-584-5p, miR-1228-5p, miR-501-5p and miR-668-5p (Figure 3.4A). Invasiveness was unaffected in all cases in the presence of E₂ and R5020 (Figure 3.4B and 3.4C), indicating that these miRNAs do not have a role in hormonal cross-talk between progestin/PR-A and E₂/ER that influences invasiveness.

Next, we inhibited the five miRNAs whose activation by E₂ was blocked by progestin (miR-17-5p, miR-20a-5p, miR-92a-3p, miR-106a-5p and miR-106b-5p) (Figure 3.4D). Inhibition of miR-92a-3p alone abrogated the ability of E₂ to repress invasiveness in both T47D and BT474 cells (Figure 3.4E and 3.4F). Therefore, the ability of progestin/PR-A to block activation of miR-92a-3p by E₂ must be critical for the functional cross-talk of progesterone via PR-A.

Finally, we inhibited the five miRNAs whose repression by E₂ was blocked by progestin (miR-26b-5p, miR-27a-5p, miR-27b-5p, miR-200c-5p and Let7a-5p) (Figure 3.4G). Inhibition of miR-26b-5p alone abrogated the ability of progestin to rescue invasiveness from E₂ repression in both T47D and BT474 cells (Figure 3.4H and 3.4I). Therefore, the ability of progestin/PR-A to block repression of miR-26b-5p by E₂ must also be a critical mechanism of cross-talk of progesterone via PR-A in the rescue of invasiveness.

3.3.4 miR-92a-3p and miR-26b-5p regulate genes associated with invasiveness and metastasis in luminal breast cancer cells

To further study the roles of miR-92a-3p and miR-26b-5p in relation to gene expression and metastasis, we generated two types of pooled (to avoid clonal bias) stable recombinant BT474 cells. In one case, miR-92a-3p (E₂ activated miRNA) was constitutively expressed ('miR-92a-3p-On' cells in Figure 3.5A). In the other case, miR-26b-5p (E₂ repressed miRNA) was constitutively

inhibited due to expression of a miR-26b-5p inhibitor ('miR-26b-5p-Off' cells in Figure 3.5B). Hormonal regulation of miR-26b-5p and miR-92a-3p was unaffected in miR-92a-3p-On cells and miR-26b-5p-Off cells, respectively, indicating these two miRNAs are regulated independently (Figure 3.5A and 3.5B). Both the miR-92a-3p-On cells (Figure 3.5C) and the miR-26b-5p-Off cells (Figure 3.5D) showed repressed invasiveness even in the absence of hormones, similar to the E₂ treated control cells (harboring Lenti-miR-blank plasmid). Moreover, the ability of R5020 to rescue invasiveness was lost in both the miR-92a-3p-On cells (Figure 3.5C) and in the miR-26b-5p-Off cells (Figure 3.5D), in contrast to the control cells. Next, the miR-92a-3p-On and miR-26b-5p-Off cells, treated with both E₂ and R5020, were examined for quantitative changes in the metastasis/invasion transcriptome, using a commercial pathway cDNA TaqMan PCR array. When compared to the control cells, both the recombinant cells showed broad and partially overlapping increases in the expression of cellular adhesion molecules and inhibitors of metastasis but not a remarkable effect on the expression of genes known to promote metastasis (Figure 3.5E; values in *Table 3.5*). Therefore, miR-92a-3p and miR-26b-5p are part of independently regulated but convergent pathways through which E₂ controls genes that have functional roles in metastasis. It follows that the ability of PR-A to oppose regulation of these miRNAs by E₂ enables progesterone to induce a gene regulatory pattern that supports metastasis.




Figure 3.5: Roles of miR-92a-3p and miR-26b-5p in regulation of invasiveness and metastasis genes. Control BT474 cells (harboring Lenti-miR-Blank plasmid) and isogenic recombinant cells constitutively expressing miR-92a-3p mimic (BT474 miR-92a-3p-On cells) or stably expressing miR-26b-5p inhibitor (BT474 miR-26b-5p-Off cells) were hormone depleted and treated with vehicle or 1 nM E₂, 1 nM R5020 or the combination of E₂ and R5020 for 48 h. Total RNA was then isolated and miR-92a-3p (**Panel A**) and miR-26b-5p (**Panel B**) were quantified. In parallel, the trans-well invasion assay was performed on the treated BT474 miR-92a-On cells (**Panel C**) and BT474 miR-26b-Off cells (**Panel D**) together with the parental control cells. In **Panel E**, total RNA was isolated from BT474 control, miR-92a-On and miR-26b-Off cells treated with 1 nM E₂ in combination with 1nM R5020 for 48 h and analyzed using the Taqman metastasis transcriptome array. The transcriptome expression profile is shown in the heat map.

GENE	Fold Ctrl	Fold BT474-92a-ON	Fold BT474 26B-Off
CD44	1	2.316416999	2.574727833
CDH1	1	2.025666086	2.384783942
CEACAM1	1	4.845103232	5.42203053
CTNNA1	1	7.106474336	8.400452225
DCC	1	4.958002985	44.31955593
FAT1	1	9.395387515	16.2554325
FN1	1	1.578332857	5.461599989
ITGB3	1	21.29900314	15.36544899
LAMB1	1	6.696123735	3.480976036
MCAM	1	14.83712831	7.093445645
NCAM1	1	2.723552889	7.633145435
NF2	1	3.432347888	8.139986046
PECAM1	1	1.950441098	2.064285982
PNN	1	4.776060885	3.502094472
EPCAM	1	12.85159964	8.040079562
TPBG	1	8.611349358	2.909127387
BRMS1	1	2.298133076	2.404106858
CD82	1	2.262846516	2.365688268
DAPK1	1	15.38801379	18.52161213
EGFR4	1	2.171072951	4.718021745
HTATIP2	1	5.600129858	11.83932987
KISS1	1	3.663169991	1.108748001
KISS1R	1	3.500650202	0.864848727
MTSS1	1	2.708765346	5.514740787
NME1	1	3.39929129	7.445899935
SERPINB5	1	2.196839365	2.576055727
SMAD2	1	5.694093453	3.994134299
SMAD4	1	6.143653096	3.756083873
TIMP1	1	5.899718246	1.913834685
TIMP2	1	2.966268703	0.984000086
TIMP4	1	5.502287445	10.74901235
TNFSF10	1	10.75559405	3.654028186
CTSK	1	0.621476427	0.293877228
CXCL12	1	1.01222664	1.448997555
CXCR4	1	11.3978419	13.94306207
FXRD5	1	3.52564289	2.506085504
HPSE	1	1.218603449	0.958312208
MET	1	0.916107629	1.171739803
MGAT5	1	1.2646	1.259167763
MMP1	1	1.01222664	0.975231364
MMP14	1	1.047621586	1.550015227
MMP9	1	1.170272731	6.45689996
MTA1	1	1.186129555	0.942979457
MTA2	1	1.218603449	1.799029205
RHOC	1	1.482436467	18.48372069
S100A4	1	1.488414392	1.05132146
SNCG	1	1.578332857	0.892392677
TIAM1	1	1.636131835	1.331492053
TMPRSS4	1	1.680661473	1.523832323

Table 3.5 Data corresponding to heat map in Figure 4E.

An additional relevant question was whether estrogen and/or progesterone could at least partially regulate epithelial vs mesenchymal characteristics of luminal breast cancer cells, although it has been well established that ER expression confers the epithelial phenotype. Using a commercial EMT panel antibody kit and BT474, T47D, and ZR-75-1 cell lines, we observed no change in established epithelial/mesenchymal markers when cells were treated individually or in combination with E₂ and R5020 (Figure 3.6A and 3.6B) in contrast to depletion of the ER apo-protein (Figure 3.6C). Therefore, it was irrelevant to explore EMT in the context of hormonal regulation of miR-92a-3p or miR-26b-5p.

3.3.5 miR-92a-3p and miR-26b-5p profoundly impact metastasis *in vivo*

Studies of hormonal regulation of metastasis of model luminal breast tumor xenografts in mice is technically challenging for the following reasons. First, estrogen needs to always be present for the tumors to grow, optimally administered to the mice through implanted slow release, low dose E₂ pellets; therefore, the hormone levels cannot be modulated. Second, the constant exposure to even the low dose of E₂ needed to support tumor growth causes urinary retention and cystitis in the mice, limiting the duration of the experiments to about 2-3 weeks. Finally, luminal breast tumors are inherently less aggressive and metastasize relatively slowly, so that it is not possible to histologically detect micro-metastases within the 2-3-week duration of the experiments. We overcame these problems in the current study design that investigated whether modulation of miRNAs 92a-3p and 26b-5p could govern metastasis in mice bearing luminal breast tumor xenografts.




Figure 3.6. Hormonal regulation of invasiveness is not mediated by epithelial to mesenchymal transition (EMT). BT474, T47D and ZR-75-1 cells were treated with vehicle (V), E₂ (1nM), R5020 (P) (1nM), E₂+R5020 (E+P) (each at 1nM) for 48 h and total protein was analyzed by western blot for epithelial and mesenchymal markers (Panel A). A similar analysis was performed on T47D cells using hormone concentrations representing the follicular phase (4 nM E₂, 4 nM P) and luteal phase (4 nM E₂, 50 nM P) of the menstrual cycle (Panel B). In no case did hormones induce EMT. BT474, T47D, and ZR-75-1 cells were hormone-depleted, transfected with either Control siRNA or ER siRNA and cell lysates were analyzed by western blot for epithelial and mesenchymal markers 72 h post-transfection (Panel C); loss of the ER apo-protein induced EMT.




Figure 3.7 In BT474 PR-shRNA cells, progestin cannot rescue invasiveness from estrogen repression. BT474 PR-shRNA cells show depletion of PR mRNA (Panel A, left) and loss of PR protein (western blot in Panel A, right) compared with the control BT474 cells. In the trans-well invasion assay, E₂ (1 nM) suppresses invasiveness even in the presence of R5020 (1 nM) in BT474 PR-shRNA cells (Panel B, right). In contrast, in the control BT474 cells, R5020 rescues invasiveness from E₂ repression (Panel B, left).

We used as xenograft models, the recombinant BT474 cells in which cross-talk between E₂/ER and progesterin/PR-A affecting invasiveness was disrupted by constitutive expression of miR-92a-3p (miR-92a-3p-On cells discussed above) or constitutive inhibition of miR-26b-5p (miR-26b-5p-Off cells discussed above) for comparison with the control cells. As a metastasis assay validation tool, we also generated and used as xenografts, pooled (to avoid clonal bias) stable recombinant BT474 cells in which PR was knocked down (BT474 PR-shRNA cells); in these cells, we confirmed that the PR knockdown resulted in loss of the ability of R5020 to rescue *in vitro* invasiveness from E₂ regulation (Figure 3.7). The previously established range of plasma estrogen in mice implanted the slow release E₂ pellets is 1.8 - 4.8 nM (353,354). The established range of plasma progesterone in mice on commercial diet is 3.2 - 5.6 nM (354). To measure metastasis of subcutaneous implantation of the xenografts in the right flank, we measured tumor cell infiltration in the ipsilateral axillary lymph nodes by the sensitive assay of measuring mRNA for human GAPDH present in the lymph nodes, 14 days after implanting the xenografts. The control BT474 cells consistently infiltrated the lymph node whereas depletion of PR in these cells showed virtually complete suppression of lymph node infiltration, validating the metastasis assay (Figure 3.8A and 3.8B). In mice bearing xenografts of miR-92a-3p-On cells (Figure 3.8C and 3.8D) or miR-26b-5p-Off cells (Figure 3.8E and 3.8F), metastasis was similarly dramatically suppressed, demonstrating that the profound effects of changing the levels of these two miRNAs on cellular invasiveness observed above extend to their effects on metastasis *in vivo*.




Figure 3.8: Roles of miR-92a-3p and miR-26b-5p in regulating metastasis in an *in vivo* lymph node infiltration model. BT474 control cells (**Panels A-F**), BT474 PR-shRNA cells (**Panels A and B**), BT474 miR-92a-3p-On cells (**Panels C and D**) and BT474-miR-26b-5p-Off (**Panels E and F**) were implanted subcutaneously in the right flank to form tumor xenografts in athymic female nude mice (8 mice per group) that had been implanted with slow release, low dose estradiol pellets. Mice were sacrificed at 2 weeks, and the proximal ipsilateral lymph node (right axillary) was harvested. Total RNA was extracted from lymph nodes, and high efficiency species specific Taqman probes for human and mouse GAPDH were used to measure relative degrees of lymph node infiltration by the human tumor cells. Using the Ct values for human GAPDH as Target and mouse GAPDH as endogenous reference, the human cell infiltration into mouse lymph node was calculated by the $\Delta\Delta Ct$ method with a calibrator ΔCt of 10.79 in all cases (**Panels A, C and E**). Tumor mass was measured on the day of sacrifice (**Panels B, D, and F**). Statistical analysis using Student's unpaired t-test was used for two group comparisons and *P*-values are indicated.

The foregoing results strongly support the premise that positive (for miR-92a-3p) or negative (for miR-26b-5p) regulation of these two miRNAs by E₂ causes suppression of not only invasiveness but also metastasis of luminal breast cancer cells and that by extension of this reasoning, the restoration of these miRNAs to their original levels (as in the control tumors) by progesterone via PR-A must support metastasis.

3.3.6 In primary human luminal breast tumors PR-A expression correlates negatively with miR-92a-3p and positively with miR-26b-5p

Using total RNA samples extracted from 53 ER+/PR+ primary luminal breast tumor specimens, the expression profile of PR-A mRNA was obtained and compared with the expression profiles of miR-92a-3p and miR-26b-5p obtained from the same RNA preparations. Despite the inherent and variable heterogeneity among the tumor specimens due to a variable ratio of tumor cells to stroma, miR-92a-3p correlated negatively with PR-A mRNA with an $r = -0.272$ ($p=0.004$) (Figure 3.9) and miRNA-26b-5p correlated positively with PR-A mRNA with $r = 0.342$ ($p=0.001$) (Figure 6B). Moreover, as shown in the heat map in Figure 3.9C, the inverse expression trends of the two miRNAs generally occurred within the same samples. Finally, relative PR-A protein levels among the tumors generally corresponded to the relative PR-A mRNA levels (Figure 3.9D) with the caveat that the protein was measured only semi-quantitatively by non-linear densitometry from western blots (Figure 2A) and was also necessarily extracted from a different part of each tumor specimen than RNA.




Figure 3.9. Correlation analysis of PR-A, miR-92a-3p and miR-26b-5p in primary luminal breast tumor specimens. Total RNA was extracted from tumor specimens from 53 breast cancer patients. Real time RT-PCR was used to quantify PR-A mRNA, miR-92a-3p and miR-26b-5p. The measurements were repeated 3 times to generate biological replicates, resulting in 159 Ct values for each RNA. The efficiency of each primer pair ($E = 2$) was used to normalize the real time RT-PCR data and a relative gene expression

3.4 Discussion

In aggressive cancers including hormone receptor-negative breast cancers, at least the early stages of metastasis have likely already occurred at the time of detection of the primary tumor. In contrast, luminal breast tumors are better differentiated and relatively indolent, metastasize much slower and offer a wider window of time for prediction of metastatic potential and for effective intervention to suppress metastasis. This study has elucidated a critical role for two miRNAs in enabling progesterone to oppose specific actions of estrogen, thus promoting invasiveness and metastasis of luminal breast cancer cells. The mechanism entails a central role for the short PR isoform A in mediating this effect of progesterone. We have previously shown that PR-A induces invasiveness in the entire range of circulating hormone levels covering pre- and post-menopausal years and that overexpression of PR-A further sensitizes the cells to progesterone levels in the low end of its post-menopausal plasma range, an observation that also held true for the response of the two miRNAs to progesterone. In this study, the discovery of miRNAs that mediate the cross-talk between PR-A and ER that results in invasiveness was crucial in developing a study design that demonstrated the profound role of this cross-talk in supporting metastasis *in vivo*.

None of the five miRNAs identified in this study as being regulated by progesterone in a PR-A isoform-specific, but estrogen-independent, manner affected the ability of estrogen to suppress invasiveness. However, two of ten miRNAs that were regulated by estrogen in a manner that was opposed by progesterone, exclusively via isoform A of PR, had profound roles in invasiveness and metastasis. They are miR-92a-3p (activated by estrogen) and miR-26b-5p (repressed by estrogen). We demonstrated that regulation of these two miRNAs enabled estrogen to suppress invasiveness and blocking of this regulation by progesterone via PR-A restored invasiveness. Further, up-regulation of miR-92a-3p and down-regulation of miR-26b-5p induced

changes in invasion and metastasis pathway genes that were similar in part but both trending toward a non-metastatic phenotype and also resulted in suppression of metastasis *in vivo*. Notably miR-92a-3p and miR-26b-5p mediate independent but convergent pathways of hormonal control of invasion and metastasis. The ability of estrogen to effectively suppress invasiveness even at very low concentrations (~ 0.01 nM)(157) may therefore be explained by the combined effects of sub-optimal regulation of these two miRNAs by estrogen.

We observed relative overexpression of PR-A in about 25 percent of primary luminal breast tumors obtained from patients. When, in an isogenic cell line model, PR-A was overexpressed to such a level, the reduced progestin concentration required for optimal induction of invasiveness also optimally suppressed regulation of miR-92a-3p and miR-26b-5p by estrogen. The clinical relevance of this functional effect of PR-A overexpression is further supported by the negative correlation of miR-92a-3p expression and positive correlation of miR-26b-5p expression with PR-A expression in clinical tumors, notwithstanding the inherent heterogeneity in tumor vs. stromal content in the specimens.

Consistent with our findings, miR-92a expression is inversely correlated to tumor grade, positive lymph node status and recurrence-free survival in breast cancer (355,356). Curiously, miR-92a is part of the miR-17~92 cluster that supports oncogenesis and cancer progression in many other cell types (356,357) demonstrating cell type-specific differences in the actions of miR-92a. miR-26a and miR-26b are both repressed by estrogen via stimulation of c-MYC expression resulting in the proliferative effect of estrogen in breast cancer cells (358). However, it is only miR-26b that is of interest in our study as the repression of miR-26a was opposed by progestin through PR-B as well as PR-A. Relatively little is known about the role of miR-26b in invasiveness and metastasis of breast cancer. In mesenchymal stem cells, miR-26b induces migration by

activating focal adhesion kinase (359) whereas, in bladder cancer, miR-26b inhibits migration and invasion (360). In the case of luminal breast cancer, our studies show that the ability of progesterone plus PR-A to prevent suppression of miR-26b-5p by estrogen leads to increased invasion and metastasis, again underscoring cell type specific differences in the actions of miR-26b-5p.

In conclusion, our model systems have established narrow miRNA-mediated pathways of cross-talk in hormone-dependent signaling between ER and PR-A which may account for the variable invasive and metastatic potential of primary luminal breast tumors. The relative expression/activity of PR-A may be a particularly significant determinant of the extent of this cross-talk, especially in the context of post-menopausal plasma hormone levels. Therefore, this study may have established a fundamental physiological mechanism governing metastatic spread of luminal breast cancer. Additionally, miRNA signatures of hyperactive PR-A have the potential to serve as predictors of clinical progression of luminal breast cancer. Moreover, miRNAs identified in this study that mediate functionally relevant cross-talk between PR-A and ER may reveal target pathways for interventions to suppress progression of luminal breast cancer that would avoid disruption of hormone signaling in normal tissues.

CHAPTER 4- CONCLUSION

Our studies have been described in this thesis in two parts entitled “Role of the short isoform of the progesterone receptor in breast cancer cell invasiveness at estrogen and progesterone levels in the pre- and post-menopausal ranges” and “The Short Progesterone Receptor Isoform Supports Invasiveness and Metastasis of Luminal Breast Cancer by Suppressing Regulation of Critical Micro RNAs by Estrogen”. The results of these two studies are summarized below.

Role of the short isoform of the progesterone receptor in breast cancer cell invasiveness at estrogen and progesterone levels in the pre- and post-menopausal ranges.

Overexpression of PR-A is a negative prognosticator for ER+ breast cancer but *in vitro* studies have implicated PR-B in progestin-induced invasiveness. As E₂ is known to suppress invasiveness and tumor progression and as the *in vitro* studies were conducted in models that either lacked ER or excluded estrogen, we examined the role of PR isoforms in the context of estrogen signaling. E₂ (< 0.01nM) strongly suppressed invasiveness in various ER+ model cell lines. At low (< 1nM) concentrations, progestins completely abrogated inhibition of invasiveness by estrogen. It was only in a higher (5nM - 50 nM) concentration range that progestins induced invasiveness in the absence of estrogen. The ability of low dose progestins to rescue invasiveness from estrogen regulation was exclusively mediated by PR-A, whereas PR-B mediated the estrogen-independent component of progestin-induced invasiveness. Overexpression of PR-A lowered the progestin concentration needed to completely rescue invasiveness. Among estrogen-regulated genes, progestin/PR-A counter-regulated a distinctive subset, including breast tumor progression genes (e.g., HES1, PRKCH, ELF5, TM4SF1), leading to invasiveness. In this manner, at relatively low hormone concentrations (corresponding to follicular stage and post-menopausal breast tissue or plasma

levels), progesterone influences breast cancer cell invasiveness by rescuing it from E₂ regulation via PR-A, whereas at higher concentrations the hormone also induces invasiveness independent of estrogen signaling, through PR-B. The findings point to a direct functional link between PR-A and progression of luminal breast cancer in the context of the entire range of pre- and post-menopausal plasma and breast tissue hormone levels.

The Short Progesterone Receptor Isoform Supports Invasiveness and Metastasis of Luminal Breast Cancer by Suppressing Regulation of Critical Micro RNAs by Estrogen.

Distal metastasis of luminal breast cancer is frequent and incurable, yet the underlying mechanisms leading to it are poorly understood. E₂ suppresses invasiveness of luminal breast cancer cells even at post-menopausal concentrations through ER. Invasive tumors overexpress PR-A. Even at low (post-menopausal) concentrations, progesterone activates PR-A, inducing invasiveness by counteracting estrogen, particularly when cells are hyper-sensitized to progesterone by PR-A overexpression. As a means to interrogating the role of this cross-talk in determining metastatic potential, we explored micro RNA mediators of selective cross-talk of PR-A with ER. We also developed a quantitative PCR-based lymph node infiltration assay in mouse xenograft models to address the slowness of tumor spread that limits studies of metastasis of luminal breast cancer. Fifteen miRNAs were regulated by progesterone via PR-A, but not PR-B, with increased progesterone sensitivity when PR-A was overexpressed. Two among them, whose induction (miR-92a-3p) or repression (miR-26b-5p) by estrogen was suppressed by progesterone plus PR-A, were critical for the cross-talk of PR-A with ER that caused a gene regulatory pattern of invasiveness and metastasis and complete rescue of invasiveness *in vitro*. The effect of expression changes of these miRNAs on *in vitro* invasiveness also manifested as metastatic potential *in vivo*. Finally, in primary breast tumors, PR-A expression correlated negatively with expression of miR-92a-3p and

positively with expression of miR-26b-5p. The studies establish hormonal cross-talk between PR-A and ER as likely a fundamental physiological mechanism that enables metastasis of luminal breast cancer. Additionally, micro RNAs, as biomarkers of hyperactive PR-A, may aid in predicting metastatic potential of luminal breast tumors. Further, miR-92a-3p and miR-26b-5p may reveal target pathways for selective intervention to suppress hormone-regulated metastasis, both pre- and post-menopause.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin.* 2016 Jan;66(1):7–30.
2. Geddes DT. Inside the lactating breast: the latest anatomy research. *J Midwifery Women's Health.* 2007;52(6):556–63.
3. Love SM, Barsky SH. Anatomy of the nipple and breast ducts revisited. *Cancer.* 2004;101(9):1947–57.
4. Understanding a Breast Cancer Diagnosis [Internet]. American Cancer Society; 2017 [cited 2017 Jul 2]. Available from: <https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis.html>
5. Patani N, Cutuli B, Mokbel K. Current management of DCIS: a review. *Breast Cancer Res Treat.* 2008;111(1):1–10.
6. Borst MJ, Ingold JA. Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. *Surgery.* 1993;114(4):637–42.
7. Lambert K, Patani N, Mokbel K. Ductal carcinoma in situ: recent advances and future prospects. *Int J Surg Oncol.* 2012;2012.
8. Lamovec J, Bračkko M. Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study. *J Surg Oncol.* 1991;48(1):28–33.
9. Sastre-Garau X, Jouve M, Asselain B, Vincent-Salomon A, Beuzeboc P, Dorval T, et al. Infiltrating lobular carcinoma of the breast: clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. *Cancer.* 1996;77(1):113–20.

10. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. *Breast Cancer Res.* 2004;6(3):R149.
11. Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. *The Lancet.* 1896;148(3803):162–5.
12. Allen E, Doisy EA. An ovarian hormone: Preliminary report on its localization, extraction and partial purification, and action in test animals. *J Am Med Assoc.* 1923;81(10):819–21.
13. Jensen E, Suzuki T, Kawashima T, Stumpf W, Jungblut PW, DeSombre E. A two-step mechanism for the interaction of estradiol with rat uterus. *Proc Natl Acad Sci.* 1968;59(2):632–8.
14. Jensen EV, Block GE, Smith S, Kyser K, DeSombre ER. Estrogen receptors and breast cancer response to adrenalectomy. *Natl Cancer Inst Monogr* 34 55-70 1971. 1971;
15. Clark GM, Osborne CK, McGuire WL. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. *J Clin Oncol.* 1984;2(10):1102–9.
16. Coussens L. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. *Science.* 1985;23:1132–40.
17. Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W. Human breast cancer: correlation of relapse and. *Science.* 1987;3798106(177):235.
18. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science.* 1989;244(4905):707–12.
19. Ross JS, Fletcher JA. The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. *Stem Cells.* 1998;16(6):413–28.

20. Schnitt SJ. Breast cancer in the 21st century: new opportunities and new challenges. *Mod Pathol.* 2001;14(3):213–8.
21. Nahta R, Hung M-C, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. *Cancer Res.* 2004;64(7):2343–6.
22. Hudis CA. Trastuzumab—mechanism of action and use in clinical practice. *N Engl J Med.* 2007;357(1):39–51.
23. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, et al. Concordance among gene-expression–based predictors for breast cancer. *N Engl J Med.* 2006;355(6):560–9.
24. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. *J Clin Oncol.* 2010;28(10):1684–91.
25. Carey LA. Through a glass darkly: advances in understanding breast cancer biology, 2000–2010. *Clin Breast Cancer.* 2010 Jun;10(3):188–95.
26. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. *Jama.* 2006;295(21):2492–502.
27. Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. *J Clin Oncol.* 2010;28(20):3271–7.
28. Uchida N, Suda T, Ishiguro K. Effect of chemotherapy for luminal a breast cancer. *Yonago Acta Med.* 2013;56(2):51.
29. Creighton CJ. The molecular profile of luminal B breast cancer. *Biol Targets Ther.* 2012;6:289.

30. Ellis MJ, Tao Y, Luo J, A'hern R, Evans DB, Bhatnagar AS, et al. Outcome prediction for estrogen receptor–positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. *J Natl Cancer Inst.* 2008;100(19):1380–8.
31. Loi S, Sotiriou C, Haibe-Kains B, Lallemand F, Conus NM, Piccart MJ, et al. Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer. *BMC Med Genomics.* 2009;2(1):37.
32. Reis-Filho JS, Weigelt B, Fumagalli D, Sotiriou C. Molecular profiling: moving away from tumor philately. *Sci Transl Med.* 2010;2(47):47ps43-47ps43.
33. Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. *Exp Ther Med.* 2010;1(5):747–54.
34. Hu Z, Fan C, Oh DS, Marron J, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. *BMC Genomics.* 2006;7(1):96.
35. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *N Engl J Med.* 2004;351(27):2817–26.
36. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. *Clin Cancer Res.* 2005;11(16):5678–85.
37. Bhargava R, Beriwal S, Dabbs DJ, Ozbek U, Soran A, Johnson RR, et al. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy. *Cancer.* 2010;116(6):1431–9.

38. Esserman L, Perou C, Cheang M, DeMichele A, Carey L, Van't Veer L, et al. Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657). *J Clin Oncol.* 2009;27(18S):LBA515-LBA515.
39. Parker JS, Prat A, Cheang M, Lenburg ME, Paik S, Perou C. Breast cancer molecular subtypes predict response to anthracycline/taxane-based chemotherapy. *Cancer Res.* 2009;69(24 Suppl 3).
40. Ignatiadis M, Bedard P, Haibe-Kains B, Singhal S, Loi S, Criscitiello C, et al. A Meta-Analysis of Gene Expression Profiling Studies Identifies Clinically Relevant Oncogenic Pathways in Basal-Like Breast Cancer. 2009;
41. Alba E, Calvo L, Albanell J, De la Haba J, Arcusa Lanza A, Chacon J, et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. *Ann Oncol.* 2012;23(12):3069–74.
42. Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios C, et al. 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). *Ann Oncol.* 2017;28(1):16–33.
43. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. *Clin Cancer Res.* 2009;15(7):2302–10.
44. Heitz F, Harter P, Lueck H-J, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, et al. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. *Eur J Cancer.* 2009;45(16):2792–8.

45. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. *Breast Cancer Res.* 2007;9(5):R65.
46. Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. *Clin Breast Cancer.* 2009;9:S73–81.
47. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. *Genome Biol.* 2007;8(5):R76.
48. Foulkes WD, Brunet J-S, Stefansson IM, Straume O, Chappuis PO, Bégin LR, et al. The prognostic implication of the basal-like (cyclin Ehigh/p27low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. *Cancer Res.* 2004;64(3):830–5.
49. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. *N Engl J Med.* 2009;361(2):123–34.
50. Rodler E, Korde L, Gralow J. Current treatment options in triple negative breast cancer. *Breast Dis.* 2011;32(1–2):99–122.
51. Nazarali SA, Narod SA. Tamoxifen for women at high risk of breast cancer. *Breast Cancer Targets Ther.* 2014;6:29.
52. Manna S, Holz MK. Tamoxifen Action in ER-Negative Breast Cancer. *Signal Transduct Insights.* 2016;5:1.
53. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. *The Lancet.* 1994;343(8899):692–5.

54. Ford D, Easton D, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. *Am J Hum Genet.* 1998;62(3):676–89.
55. Easton D, Steele L, Fields P, Ormiston W, Averill D, Daly P, et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. *Am J Hum Genet.* 1997;61(1):120.
56. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis—effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. *N Engl J Med.* 1997;336(20):1465–71.
57. Russo IH, Russo J. Role of hormones in mammary cancer initiation and progression. *J Mammary Gland Biol Neoplasia.* 1998;3(1):49–61.
58. DeBruin LS, Joseph PD. Perspectives on the chemical etiology of breast cancer. *Environ Health Perspect.* 2002;110(Suppl 1):119.
59. Chlebowski RT, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML, et al. Estrogen plus progestin and breast cancer incidence and mortality in the Women’s Health Initiative Observational Study. *J Natl Cancer Inst.* 2013;105(8):526–35.
60. LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. *Jama.* 2011;305(13):1305–14.
61. Siiteri PK, Schwarz BE, MacDonald PC. Estrogen receptors and the estrone hypothesis in relation to endometrial and breast cancer. *Gynecol Oncol.* 1974;2(2–3):228–38.
62. Files JA, Ko MG, Pruthi S. Bioidentical hormone therapy. In Elsevier; 2011. p. 673–80.

63. Overlie I, Moen M, Morkrid L, Skjæraasen J, Holte A. The endocrine transition around menopause-a five years prospective study with profiles of gonadotropines, estrogens, androgens and SHBG among healthy women. *Acta Obstet Gynecol Scand.* 1999;78(7):642–7.
64. Barnett JB, Woods MN, Lamon-Fava S, Schaefer EJ, McNamara JR, Spiegelman D, et al. Plasma lipid and lipoprotein levels during the follicular and luteal phases of the menstrual cycle. *J Clin Endocrinol Metab.* 2004;89(2):776–82.
65. Ryan KJ. Conversion of Δ^5 -androstene- 3β , 16α , 17β -triol to estriol by human placenta. *Endocrinology.* 1958;63(3):392–4.
66. Bliss SP, Navratil AM, Xie J, Roberson MS. GnRH signaling, the gonadotrope and endocrine control of fertility. *Front Neuroendocrinol.* 2010;31(3):322–40.
67. Dorrington JH, Moon YS, Armstrong DT. ESTRADIOL- 17β BIOSYNTHESIS IN CULTURED GRANULOSA CELLS FROM HYPOPHYSECTOMIZED IMMATURE RATS; STIMULATION BY FOLLICLE-STIMULATING HORMONE¹. *Endocrinology.* 1975;97(5):1328–31.
68. Strauss III JF, Martinez F, Kiriakidou M. Placental steroid hormone synthesis: unique features and unanswered questions. *Biol Reprod.* 1996;54(2):303–11.
69. Siiteri PK. Review of studies on estrogen biosynthesis in the human. *Cancer Res.* 1982;42(8 Supplement):3269s–3273s.
70. SIITERI PK, MacDonald PC. Placental estrogen biosynthesis during human pregnancy. 1966;
71. Simpson E. Sources of estrogen and their importance. *J Steroid Biochem Mol Biol.* 2003;86(3):225–30.

72. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C, Speizer FE. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. *Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol*. 1995 Sep;4(6):649–54.
73. Geisler J. Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. *J Steroid Biochem Mol Biol*. 2003;86(3):245–53.
74. Pasqualini J, Chetrite G, Blacker C, Feinstein M, Delalonde L, Talbi M, et al. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre-and postmenopausal breast cancer patients. *J Clin Endocrinol Metab*. 1996;81(4):1460–4.
75. Pike MC, Spicer DV, Dahmouch L, Press MF. Estrogens progestogens normal breast cell proliferation and breast cancer risk. *Epidemiol Rev*. 1993;15(1):17–35.
76. Levy C, Robel P, Gautray J, De Brux J, Verma U, Descomps B, et al. Estradiol and progesterone receptors in human endometrium: normal and abnormal menstrual cycles and early pregnancy. *Am J Obstet Gynecol*. 1980;136(5):646–51.
77. Riggs BL, Khosla S, Melton III LJ. Sex steroids and the construction and conservation of the adult skeleton. *Endocr Rev*. 2002;23(3):279–302.
78. Lindsay R, Aitken J, Anderson L, Hart D, MacDonald E, Clarke A. Long-term prevention of postmenopausal osteoporosis by oestrogen: evidence for an increased bone mass after delayed onset of oestrogen treatment. *The Lancet*. 1976;307(7968):1038–41.
79. Women's Health Initiative Steering Committee. Effects of Conjugated Equine Estrogen in Postmenopausal Women Having Undergone Hysterectomy: The Women's Health Initiative Randomized, Controlled Trials. *Obstet Gynecol Surv*. 2004;59(8):599–600.

80. Dennerstein L, Randolph J, Taffe J, Dudley E, Burger H. Hormones, mood, sexuality, and the menopausal transition. *Fertil Steril*. 2002;77:42–8.
81. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. *Psychoneuroendocrinology*. 1992;17(5):485–95.
82. Weiss M, Baerg E, Wisebord S, Temple J. The influence of gonadal hormones on periodicity of obsessive-compulsive disorder. 1995;
83. Ponglikitmongkol M, Green S, Chambon P. Genomic organization of the human oestrogen receptor gene. *EMBO J*. 1988;7(11):3385.
84. Zhao C, Dahlman-Wright K, Gustafsson J-Å. Estrogen receptor β : an overview and update. *Nucl Recept Signal*. 2008;6.
85. Hewitt SC, Korach KS. Estrogen receptors: structure, mechanisms and function. *Rev Endocr Metab Disord*. 2002 Sep;3(3):193–200.
86. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engström O, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. *Nature*. 1997;389(6652):753–8.
87. Koš M, Reid G, Denger S, Gannon F. Minireview: genomic organization of the human ER α gene promoter region. *Mol Endocrinol*. 2001;15(12):2057–63.
88. Pfaffl M, Lange I, Daxenberger A, Meyer H. Tissue-specific expression pattern of estrogen receptors (ER): Quantification of ER α and ER β mRNA with real-time RT-PCR. *Apmis*. 2001;109(S103).
89. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. *Nat Rev Cancer*. 2002;2(2):101–12.
90. Georgopoulos CM, Tissières RI. The biology of heat shock proteins and molecular chaperones. 1994.

91. Schwabe JW, Chapman L, Finch JT, Rhodes D. The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: how receptors discriminate between their response elements. *Cell*. 1993;75(3):567–78.
92. Webb P, Nguyen P, Shinsako J, Anderson C, Feng W, Nguyen MP, et al. Estrogen receptor activation function 1 works by binding p160 coactivator proteins. *Mol Endocrinol*. 1998;12(10):1605–18.
93. Lavinsky RM, Jepsen K, Heinzl T, Torchia J, Mullen T-M, Schiff R, et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. *Proc Natl Acad Sci*. 1998;95(6):2920–5.
94. Babu R, Kumar MN, Patil RH, Devaraju K, Ramesh GT, Sharma SC. Effect of estrogen and tamoxifen on the expression pattern of AP-1 factors in MCF-7 cells: role of c-Jun, c-Fos, and Fra-1 in cell cycle regulation. *Mol Cell Biochem*. 2013;380(1–2):143–51.
95. Lannigan DA. Estrogen receptor phosphorylation. *Steroids*. 2003 Jan;68(1):1–9.
96. Cole M, Jones C, Todd I. A new anti-oestrogenic agent in late breast cancer: an early clinical appraisal of ICI46474. *Br J Cancer*. 1971;25(2):270.
97. Harvell DM, Richer JK, Singh M, Spoelstra N, Finlayson C, Borges VF, et al. Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor. *Breast Cancer Res Treat*. 2008;112(3):489–501.
98. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J-Å, Nilsson S. Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists. *Mol Pharmacol*. 1998;54(1):105–12.

99. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. *J Natl Cancer Inst.* 1999;91(21):1829–46.
100. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. *JNCI J Natl Cancer Inst.* 1994;86(7):527–37.
101. Hernandez RK, Sørensen HT, Pedersen L, Jacobsen J, Lash TL. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism. *Cancer.* 2009;115(19):4442–9.
102. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. *Jama.* 2006;295(23):2727–41.
103. Simpson E. Role of aromatase in sex steroid action. *J Mol Endocrinol.* 2000;25(2):149–56.
104. Brodie A, Lu Q, Long B. Aromatase and its inhibitors. *J Steroid Biochem Mol Biol.* 1999;69(1):205–10.
105. Murphy MJ. Molecular action and clinical relevance of aromatase inhibitors. *The oncologist.* 1998;3(2):129–30.
106. Geisler J, Ekse D, Helle H, Duong NK, Lønning PE. An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples. *J Steroid Biochem Mol Biol.* 2008 Mar;109(1–2):90–5.

107. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor–positive breast cancer: status report 2004. *J Clin Oncol.* 2005;23(3):619–29.
108. Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor–positive breast cancer: status report 2002. *J Clin Oncol.* 2002;20(15):3317–27.
109. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. *Lancet Lond Engl.* 2005 Aug 6;366(9484):455–62.
110. Osborne C, Pippen J, Jones S, Parker L, Ellis M, Come S, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. *J Clin Oncol.* 2002;20(16):3386–95.
111. Robertson JFR, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. *J Clin Oncol Off J Am Soc Clin Oncol.* 2009 Sep 20;27(27):4530–5.
112. Encarnación CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SA, Osborne CK. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. *Breast Cancer Res Treat.* 1993;26(3):237–46.

113. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. *J Clin Oncol.* 2005;23(11):2469–76.
114. Hull DF, Clark GM, Osborne CK, Chamness GC, Knight WA, McGuire WL. Multiple estrogen receptor assays in human breast cancer. *Cancer Res.* 1983;43(1):413–6.
115. Lipton A, Leitzel K, Ali SM, Demers L, Harvey HA, Chaudri-Ross HA, et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. *Cancer.* 2005;104(2):257–63.
116. Lopez-Tarruella S, Schiff R. The dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm. *Clin Cancer Res.* 2007;13(23):6921–5.
117. Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. *Endocr Rev.* 2008;29(2):217–33.
118. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. *Cancer Res.* 2008;68(3):826–33.
119. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. *Annu Rev Med.* 2011;62:233–47.
120. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2–positive breast cancer. *J Natl Cancer Inst.* 2004;96(12):926–35.

121. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. *Clin Cancer Res.* 2004;10(1):331s–336s.
122. Levin ER, Pietras RJ. Estrogen receptors outside the nucleus in breast cancer. *Breast Cancer Res Treat.* 2008;108(3):351–61.
123. Santen RJ, Fan P, Zhang Z, Bao Y, Song RX-D, Yue W. Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and-resistant breast cancer cells. *Steroids.* 2009;74(7):586–94.
124. Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, Moore DH, et al. Enhanced NF κ B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. *BMC Cancer.* 2007;7(1):59.
125. Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M, et al. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. *Clin Cancer Res.* 1999;5(2):251–6.
126. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. *J Clin Oncol.* 2005;23(30):7721–35.
127. Span PN, Tjan-Heijnen VC, Manders P, Beex LV, Sweep CF. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. *Oncogene.* 2003;22(31):4898.
128. Butt AJ, McNeil CM, Musgrove EA, Sutherland RL. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. *Endocr Relat Cancer.* 2005;12(Supplement 1):S47–59.

129. Chakraborty AK, Welsh A, DiGiovanna MP. Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines. *Breast Cancer Res Treat.* 2010;120(2):327–35.
130. Kern F, McLeskey S, Zhang L, Kurebayashi J, Liu Y, Ding I, et al. Transfected MCF-7 cells as a model for breast cancer progression. *Breast Cancer Res Treat.* 1994;31(2):153–65.
131. Morgan L, Gee J, Pumford S, Farrow L, Finlay P, Robertson J, et al. Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically. *Cancer Biol Ther.* 2009;8(16):1550–8.
132. Zhang XH-F, Giuliano M, Trivedi MV, Schiff R, Osborne CK. Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer. *Clin Cancer Res.* 2013 Dec 1;19(23):6389–97.
133. Blows FM, Driver KE, Schmidt MK, Broeks A, Van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. *PLoS Med.* 2010;7(5):e1000279.
134. Li CI, Malone KE, Weiss NS, Daling JR. Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer. *J Natl Cancer Inst.* 2001;93(13):1008–13.
135. Salazar MD, Ratnam M, Patki M, Kisovic I, Trumbly R, Iman M, et al. During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor $\alpha 1$ apoprotein. *Breast Cancer Res.* 2011;13(1):1.
136. King TL, Brucker MC. *Pharmacology for Women’s Health* [Internet]. Jones & Bartlett Learning; 2010. Available from: <https://books.google.com/books?id=E9qVyrNPsBkC>

137. Sweat ML, Berliner DL, Bryson MJ, Nabors C, Haskell J, Holmstrom EG. The synthesis and metabolism of progesterone in the human and bovine ovary. *Biochim Biophys Acta*. 1960;40:289–96.
138. Rosenthal HE, SLAUNWHITE JR WR, SANDBERG AA. Transcortin: a corticosteroid-binding protein of plasma. X. Cortisol and progesterone interplay and unbound levels of these steroids in pregnancy. *J Clin Endocrinol Metab*. 1969;29(3):352–67.
139. Patel B, Elguero S, Thakore S, Dahoud W, Bedaiwy M, Mesiano S. Role of nuclear progesterone receptor isoforms in uterine pathophysiology. *Hum Reprod Update*. 2014;21(2):155–73.
140. Jabbour HN, Kelly RW, Fraser HM, Critchley HO. Endocrine regulation of menstruation. *Endocr Rev*. 2005;27(1):17–46.
141. Siiteri PK, Febres F, Clemens L, Chang RJ, Gondos B, Stites D. Progesterone and maintenance of pregnancy: is progesterone nature's immunosuppressant? *Ann N Y Acad Sci*. 1977;286(1):384–97.
142. Tanos T, Sflomos G, Echeverria PC, Ayyanan A, Gutierrez M, Delaloye J-F, et al. Progesterone/RANKL is a major regulatory axis in the human breast. *Sci Transl Med*. 2013;5(182):182ra55-182ra55.
143. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. *EMBO J*. 1990;9(5):1603.
144. Smith D, Faber L, Toft D. Purification of unactivated progesterone receptor and identification of novel receptor-associated proteins. *J Biol Chem*. 1990;265(7):3996–4003.

145. Li Q, Kannan A, DeMayo FJ, Lydon JP, Cooke PS, Yamagishi H, et al. The antiproliferative action of progesterone in uterine epithelium is mediated by Hand2. *Science*. 2011 Feb 18;331(6019):912–6.
146. Pratt WB, Hutchison KA, Scherrer LC. Steroid receptor folding by heat-shock proteins and composition of the receptor heterocomplex. *Trends Endocrinol Metab*. 1992;3(9):326–33.
147. DeMarzo A, Beck C, Onate S, Edwards D. Dimerization of mammalian progesterone receptors occurs in the absence of DNA and is related to the release of the 90-kDa heat shock protein. *Proc Natl Acad Sci*. 1991;88(1):72–6.
148. Bagchi MK, Elliston JF, Tsai SY, Edwards DP, Tsai M-J, O'Malley BW. Steroid hormone-dependent interaction of human progesterone receptor with its target enhancer element. *Mol Endocrinol*. 1988;2(12):1221–9.
149. Sartorius CA, Melville MY, Hovland AR, Tung L, Takimoto GS, Horwitz KB. A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. *Mol Endocrinol Baltim Md*. 1994;8(10):1347–60.
150. Dong X, Challis JRG, Lye SJ. Intramolecular interactions between the AF3 domain and the C-terminus of the human progesterone receptor are mediated through two LXXLL motifs. *J Mol Endocrinol*. 2004 Jun;32(3):843–57.
151. Takimoto GS, Tung L, Abdel-Hafiz H, Abel MG, Sartorius CA, Richer JK, et al. Functional properties of the N-terminal region of progesterone receptors and their mechanistic relationship to structure. *J Steroid Biochem Mol Biol*. 2003 Jun;85(2–5):209–19.
152. Tetel MJ, Giangrande PH, Leonhardt SA, McDonnell DP, Edwards DP. Hormone-dependent interaction between the amino- and carboxyl-terminal domains of progesterone receptor in vitro and in vivo. *Mol Endocrinol Baltim Md*. 1999 Jun;13(6):910–24.

153. Tung L, Abdel-Hafiz H, Shen T, Harvell DME, Nitao LK, Richer JK, et al. Progesterone receptors (PR)-B and -A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B. *Mol Endocrinol Baltim Md.* 2006 Nov;20(11):2656–70.
154. Yin P, Roqueiro D, Huang L, Owen JK, Xie A, Navarro A, et al. Genome-Wide Progesterone Receptor Binding: Cell Type-Specific and Shared Mechanisms in T47D Breast Cancer Cells and Primary Leiomyoma Cells. *PLOS ONE.* 2012 Jan 17;7(1):e29021.
155. Graham JD, Yager ML, Hill HD, Byth K, O'Neill GM, Clarke CL. Altered progesterone receptor isoform expression remodels progestin responsiveness of breast cancer cells. *Mol Endocrinol Baltim Md.* 2005 Nov;19(11):2713–35.
156. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. *J Biol Chem.* 2002;277(7):5209–18.
157. McFall T, Patki M, Rosati R, Ratnam M. Role of the short isoform of the progesterone receptor in breast cancer cell invasiveness at estrogen and progesterone levels in the pre- and post-menopausal ranges. *Oncotarget.* 2015;6(32):33146.
158. Giangrande PH, Pollio G, McDonnell DP. Mapping and characterization of the functional domains responsible for the differential activity of the A and B isoforms of the human progesterone receptor. *J Biol Chem.* 1997;272(52):32889–900.
159. Giangrande PH, Kimbrel EA, Edwards DP, McDonnell DP. The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. *Mol Cell Biol.* 2000 May;20(9):3102–15.

160. Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW, McDonnell DP. Human progesterone receptor A form is a cell-and promoter-specific repressor of human progesterone receptor B function. *Mol Endocrinol.* 1993;7(10):1244–55.
161. McDonnell DP, Clemm DL, Imhof MO. Definition of the cellular mechanisms which distinguish between hormone and antihormone activated steroid receptors. In 1994. p. 327–36.
162. McDonnell DP, Goldman ME. RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism. *J Biol Chem.* 1994;269(16):11945–9.
163. Groshong SD, Owen GI, Grimison B, Schauer IE, Todd MC, Langan TA, et al. Biphasic Regulation of Breast Cancer Cell Growth by Progesterone: Role of the Cyclin-Dependent Kinase Inhibitors, p21 and p27Kip1. *Mol Endocrinol.* 1997 Oct 1;11(11):1593–607.
164. Lange CA, Richer JK, Horwitz KB. Hypothesis: progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. *Mol Endocrinol.* 1999;13(6):829–36.
165. Greep RO. Recent Progress in Hormone Research: Proceedings of the 1984 Laurentian Hormone Conference [Internet]. Elsevier Science; 2013. (Recent progress in hormone research). Available from: <https://books.google.com/books?id=DyzIAgAAQBAJ>
166. Spelsberg TC, Halberg F. Circannual rhythms in steroid receptor concentration and nuclear binding in the chick oviduct. *Endocrinology.* 1980;107(4):1234–44.
167. Bethea CL, Widmann AA. Differential expression of progestin receptor isoforms in the hypothalamus, pituitary, and endometrium of rhesus macaques. *Endocrinology.* 1998;139(2):677–87.

168. Shyamala G, Yang X, Silberstein G, Barcellos-Hoff M, Dale E. Transgenic mice carrying an imbalance in the native ratio of A to B forms of progesterone receptor exhibit developmental abnormalities in mammary glands. *Proc Natl Acad Sci.* 1998;95(2):696–701.
169. Shyamala G, Yang X, Cardiff R, Dale E. Impact of progesterone receptor on cell-fate decisions during mammary gland development. *Proc Natl Acad Sci.* 2000;97(7):3044–9.
170. Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB, et al. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. *Clin Cancer Res.* 2004;10(8):2751–60.
171. Fujimoto J, Ichigo S, Hirose R, Sakaguchi H, Tamaya T. Clinical implication of expression of progesterone receptor form A and B mRNAs in secondary spreading of gynecologic cancers. *J Steroid Biochem Mol Biol.* 1997;62(5):449–54.
172. Feigelson HS, Henderson BE. Estrogens and breast cancer. *Carcinogenesis.* 1996;17(11):2279–84.
173. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. *Endocr Relat Cancer.* 2004;11(4):643–58.
174. Gomez-Fernandez C, Daneshbod Y, Nassiri M, Milikowski C, Alvarez C, Nadji M. Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer. *Am J Clin Pathol.* 2008;130(6):879–82.
175. Clemons M, Goss P. Estrogen and the risk of breast cancer. *N Engl J Med.* 2001 Jan 25;344(4):276–85.
176. Garcia M, Derocq D, FREiss G, Rochefort H. Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. *Proc Natl Acad Sci.* 1992;89(23):11538–42.

177. Garcia M, Derocq D, Platet N, Bonnet S, Brouillet J-P, Touitou I, et al. Both estradiol and tamoxifen decrease proliferation and invasiveness of cancer cells transfected with a mutated estrogen receptor. *J Steroid Biochem Mol Biol.* 1997;61(1):11–7.
178. Long BJ, Rose DP. Invasive capacity and regulation of urokinase-type plasminogen activator in estrogen receptor (ER)-negative MDA-MB-231 human breast cancer cells, and a transfectant (S30) stably expressing ER. *Cancer Lett.* 1996;99(2):209–15.
179. Varshochi R, Halim F, Sunters A, Alao JP, Madureira PA, Hart SM, et al. ICI182, 780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor α from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line. *J Biol Chem.* 2005;280(5):3185–96.
180. Stossi F, Likhite VS, Katzenellenbogen JA, Katzenellenbogen BS. Estrogen-occupied estrogen receptor represses cyclin G2 gene expression and recruits a repressor complex at the cyclin G2 promoter. *J Biol Chem.* 2006;281(24):16272–8.
181. Karmakar S, Foster EA, Smith CL. Estradiol downregulation of the tumor suppressor gene BTG2 requires estrogen receptor- α and the REA corepressor. *Int J Cancer.* 2009;124(8):1841–51.
182. Patki M, Trumbly R, Ratnam M. Differential effects of estrogen-dependent transactivation vs. transrepression by the estrogen receptor on invasiveness of HER2 overexpressing breast cancer cells. *Biochem Biophys Res Commun.* 2015;
183. Platet N, Cathiard AM, Gleizes M, Garcia M. Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. *Crit Rev Oncol Hematol.* 2004;51(1):55–67.

184. Platet N, Cunat S, Chalbos D, Rochefort H, Garcia M. Unliganded and liganded estrogen receptors protect against cancer invasion via different mechanisms. *Mol Endocrinol.* 2000;14(7):999–1009.
185. Spencer T, Bazer F. Biology of progesterone action during pregnancy recognition and maintenance of pregnancy. *Front Biosci J Virtual Libr.* 2002;7:d1879-98.
186. Abreu MTH, Hughes WE, Mele K, Lyons RJ, Rickwood D, Browne BC, et al. Gab2 regulates cytoskeletal organization and migration of mammary epithelial cells by modulating RhoA activation. *Mol Biol Cell.* 2011;22(1):105–16.
187. Burridge K, Chrzanowska-Wodnicka M. Focal adhesions, contractility, and signaling. *Annu Rev Cell Dev Biol.* 1996;12(1):463–519.
188. Critchley DR. Focal adhesions—the cytoskeletal connection. *Curr Opin Cell Biol.* 2000;12(1):133–9.
189. Fu X-D, Goglia L, Sanchez AM, Flamini M, Giretti MS, Tosi V, et al. Progesterone receptor enhances breast cancer cell motility and invasion via extranuclear activation of focal adhesion kinase. *Endocr Relat Cancer.* 2010;17(2):431–43.
190. Mote P, Bartow S, Tran N, Clarke C. Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. *Breast Cancer Res Treat.* 2002;72(2):163–72.
191. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. *J Natl Cancer Inst.* 2004 Dec 15;96(24):1856–65.

192. Ibrahim YH, Byron SA, Cui X, Lee AV, Yee D. Progesterone Receptor-B Regulation of Insulin-Like Growth Factor–Stimulated Cell Migration in Breast Cancer Cells via Insulin Receptor Substrate-2. *Mol Cancer Res.* 2008;6(9):1491–8.
193. Kariagina A, Xie J, Langohr IM, Opreanu RC, Basson MD, Haslam SZ. Progesterone Decreases Levels of the Adhesion Protein E-Cadherin and Promotes Invasiveness of Steroid Receptor Positive Breast Cancers. *Horm Cancer.* 2013;4(6):371–80.
194. Lin VC, Ng EH, Aw SE, Tan MG, Ng EH, Chan VS, et al. Progestins inhibit the growth of MDA-MB-231 cells transfected with progesterone receptor complementary DNA. *Clin Cancer Res.* 1999;5(2):395–403.
195. Lin VC, Eng AS, Hen NE, Ng EH, Chowdhury SH. Effect of progesterone on the invasive properties and tumor growth of progesterone receptor-transfected breast cancer cells MDA-MB-231. *Clin Cancer Res.* 2001;7(9):2880–6.
196. Sumida T, Itahana Y, Hamakawa H, Desprez P-Y. Reduction of human metastatic breast cancer cell aggressiveness on introduction of either form A or B of the progesterone receptor and then treatment with progestins. *Cancer Res.* 2004;64(21):7886–92.
197. Mulac-Jericevic B, Mullinax RA, DeMayo FJ, Lydon JP, Conneely OM. Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. *Science.* 2000;289(5485):1751–4.
198. Mulac-Jericevic B, Lydon JP, DeMayo FJ, Conneely OM. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. *Proc Natl Acad Sci.* 2003;100(17):9744–9.

199. Chou Y-C, Uehara N, Lowry JR, Shyamala G. Mammary epithelial cells of PR-A transgenic mice exhibit distinct alterations in gene expression and growth potential associated with transformation. *Carcinogenesis*. 2003;24(3):403–9.
200. Test Guide Historical Reference Ranges: Progesterone [Internet]. NIH Clinical Center <http://cclnprod.cc.nih.gov/dlm/testguide.nsf/Index/CB26894E1EB28DEF85256BA5005B000E?OpenDocument>; 2014. Available from: <http://cclnprod.cc.nih.gov/dlm/testguide.nsf/Index/CB26894E1EB28DEF85256BA5005B000E?OpenDocument>
201. Jacobsen BM, Schittone SA, Richer JK, Horwitz KB. Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. *Mol Endocrinol*. 2005;19(3):574–87.
202. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. *J Clin Oncol*. 1999;17(5):1474–1474.
203. Frasor J, Danes JM, Komm B, Chang KCN, Lyttle CR, Katzenellenbogen BS. Profiling of Estrogen Up- and Down-Regulated Gene Expression in Human Breast Cancer Cells: Insights into Gene Networks and Pathways Underlying Estrogenic Control of Proliferation and Cell Phenotype. *Endocrinology*. 2003 Oct 1;144(10):4562–74.
204. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. *Cancer Res*. 2006;66(17):8319–26.
205. Pérez-Pomares JM, Muñoz-Chápuli R. Epithelial–mesenchymal transitions: a mesodermal cell strategy for evolutive innovation in metazoans. *Anat Rec*. 2002;268(3):343–51.

206. Tucker RP. Neural crest cells: a model for invasive behavior. *Int J Biochem Cell Biol.* 2004;36(2):173–7.
207. Yan C, Grimm WA, Garner WL, Qin L, Travis T, Tan N, et al. Epithelial to mesenchymal transition in human skin wound healing is induced by tumor necrosis factor- α through bone morphogenic protein-2. *Am J Pathol.* 2010;176(5):2247–58.
208. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. *Oncogene.* 2010;29(34):4741–51.
209. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. *J Clin Invest.* 2009;119(6):1429–37.
210. Bracke ME, Charlier C, Bruyneel EA, Labit C, Mareel MM, Castronovo V. Tamoxifen restores the E-cadherin function in human breast cancer MCF-7/6 cells and suppresses their invasive phenotype. *Cancer Res.* 1994;54(17):4607–9.
211. Al Saleh S, Al Mulla F, Luqmani YA. Estrogen receptor silencing induces epithelial to mesenchymal transition in human breast cancer cells. *PLoS One.* 2011;6(6):e20610.
212. Bouris P, Skandalis SS, Piperigkou Z, Afratis N, Karamanou K, Aletras AJ, et al. Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells. *Matrix Biol.* 2015;43:42–60.
213. Cardamone MD, Bardella C, Gutierrez A, Di Croce L, Rosenfeld MG, Di Renzo MF, et al. ER α as ligand-independent activator of CDH-1 regulates determination and maintenance of epithelial morphology in breast cancer cells. *Proc Natl Acad Sci.* 2009;106(18):7420–5.
214. Fearon ER. Connecting estrogen receptor function, transcriptional repression, and E-cadherin expression in breast cancer. *Cancer Cell.* 2003;3(4):307–10.

215. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. *Cancer Res.* 2008;68(10):3645–54.
216. Oesterreich S, Deng W, Jiang S, Cui X, Ivanova M, Schiff R, et al. Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. *Cancer Res.* 2003;63(17):5203–8.
217. Park S-H, Cheung LW, Wong AS, Leung PC. Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor α . *Mol Endocrinol.* 2008;22(9):2085–98.
218. Ye Y, Xiao Y, Wang W, Yearsley K, Gao J, Shetuni B, et al. ER α signaling through slug regulates E-cadherin and EMT. *Oncogene.* 2010;29(10):1451–62.
219. Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. *Nature.* 2015;
220. Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. *Nature.* 2015;527(7579):472–6.
221. Ng W. Fine-needle aspiration cytology findings of an uncommon micropapillary variant of pure mucinous carcinoma of the breast. *Cancer Cytopathol.* 2002;96(5):280–8.
222. Tan D, Potts H, Leong A, Gillett C, Skilton D, Harris WH, et al. The biological and prognostic significance of cell polarity and E-cadherin in grade I infiltrating ductal carcinoma of the breast. *J Pathol.* 1999;189(1):20–7.

223. Bukholm I, Nesland J, Børresen-Dale A. Re-expression of E-cadherin, α -catenin and β -catenin, but not of γ -catenin, in metastatic tissue from breast cancer patients. *J Pathol.* 2000;190(1):15–9.
224. Das S, Becker BN, Hoffmann FM, Mertz JE. Complete reversal of epithelial to mesenchymal transition requires inhibition of both ZEB expression and the Rho pathway. *BMC Cell Biol.* 2009;10(1):94.
225. Wei X-L, Dou X-W, Bai J-W, Luo X-R, Qiu S-Q, Xi D-D, et al. ER α inhibits epithelial-mesenchymal transition by suppressing Bmi1 in breast cancer. *Oncotarget.* 2015;6(25):21704–17.
226. Scherbakov AM, Andreeva OE, Shatskaya VA, Krasil'nikov MA. The relationships between snail1 and estrogen receptor signaling in breast cancer cells. *J Cell Biochem.* 2012;113(6):2147–55.
227. Sun Y, Wang Y, Fan C, Gao P, Wang X, Wei G, et al. Estrogen promotes stemness and invasiveness of ER-positive breast cancer cells through Gli1 activation. *Mol Cancer.* 2014;13(1):1.
228. Planas-Silva MD, Waltz PK. Estrogen promotes reversible epithelial-to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells. *J Steroid Biochem Mol Biol.* 2007;104(1):11–21.
229. van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. *J Natl Cancer Inst.* 2000 Jul 19;92(14):1143–50.

230. Jacobson JA, Danforth DN, Cowan KH, d'Angelo T, Steinberg SM, Pierce L, et al. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. *N Engl J Med*. 1995 Apr 6;332(14):907–11.
231. Arriagada R, Lê MG, Rochard F, Contesso G. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. *J Clin Oncol Off J Am Soc Clin Oncol*. 1996 May;14(5):1558–64.
232. Stefanik D, Goldberg R, Byrne P, Smith F, Ueno W, Smith L, et al. Local-regional failure in patients treated with adjuvant chemotherapy for breast cancer. *J Clin Oncol Off J Am Soc Clin Oncol*. 1985 May;3(5):660–5.
233. Schmoor C, Sauerbrei W, Bastert G, Schumacher M. Role of isolated locoregional recurrence of breast cancer: results of four prospective studies. *J Clin Oncol Off J Am Soc Clin Oncol*. 2000 Apr;18(8):1696–708.
234. Buchanan CL, Dorn PL, Fey J, Giron G, Naik A, Mendez J, et al. Locoregional recurrence after mastectomy: incidence and outcomes. *J Am Coll Surg*. 2006 Oct;203(4):469–74.
235. Jatoi I, Tsimelzon A, Weiss H, Clark GM, Hilsenbeck SG. Hazard rates of recurrence following diagnosis of primary breast cancer. *Breast Cancer Res Treat*. 2005 Jan;89(2):173–8.
236. Katz A, Strom EA, Buchholz TA, Thames HD, Smith CD, Jhingran A, et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. *J Clin Oncol Off J Am Soc Clin Oncol*. 2000 Aug;18(15):2817–27.

237. Danish Breast Cancer Cooperative Group, Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. *J Clin Oncol Off J Am Soc Clin Oncol*. 2006 May 20;24(15):2268–75.
238. Willner J, Kiricuta IC, Kölbl O. Locoregional recurrence of breast cancer following mastectomy: always a fatal event? Results of univariate and multivariate analysis. *Int J Radiat Oncol Biol Phys*. 1997 Mar 1;37(4):853–63.
239. Ballo MT, Strom EA, Prost H, Singletary SE, Theriault RL, Buchholz TA, et al. Local-regional control of recurrent breast carcinoma after mastectomy: does hyperfractionated accelerated radiotherapy improve local control? *Int J Radiat Oncol Biol Phys*. 1999 Apr 1;44(1):105–12.
240. Haylock BJ, Coppin CM, Jackson J, Basco VE, Wilson KS. Locoregional first recurrence after mastectomy: prospective cohort studies with and without immediate chemotherapy. *Int J Radiat Oncol Biol Phys*. 2000 Jan 15;46(2):355–62.
241. Schwaibold F, Fowble BL, Solin LJ, Schultz DJ, Goodman RL. The results of radiation therapy for isolated local regional recurrence after mastectomy. *Int J Radiat Oncol Biol Phys*. 1991 Jul;21(2):299–310.
242. Pisansky TM, Ingle JN, Schaid DJ, Hass AC, Krook JE, Donohue JH, et al. Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Impact of clinical, histopathologic, and flow cytometric factors. *Cancer*. 1993 Aug 15;72(4):1247–60.

243. Halverson KJ, Perez CA, Kuske RR, Garcia DM, Simpson JR, Fineberg B. Isolated local-regional recurrence of breast cancer following mastectomy: radiotherapeutic management. *Int J Radiat Oncol Biol Phys.* 1990 Oct;19(4):851–8.
244. Faneyte IF, Rutgers EJ, Zoetmulder FA. Chest wall resection in the treatment of locally recurrent breast carcinoma: indications and outcome for 44 patients. *Cancer.* 1997 Sep 1;80(5):886–91.
245. Pfannschmidt J, Geisbüsch P, Muley T, Hoffmann H, Dienemann H. Surgical resection of secondary chest wall tumors. *Thorac Cardiovasc Surg.* 2005 Aug;53(4):234–9.
246. Kroll SS, Schusterman MA, Larson DL, Fender A. Long-term survival after chest-wall reconstruction with musculocutaneous flaps. *Plast Reconstr Surg.* 1990 Oct;86(4):697–701.
247. Andry G, Suciú S, Vico P, Faverly D, Andry-t’Hooft M, Verhest A, et al. Locoregional recurrences after 649 modified radical mastectomies: incidence and significance. *Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol.* 1989 Dec;15(6):476–85.
248. Beck TM, Hart NE, Woodard DA, Smith CE. Local or regionally recurrent carcinoma of the breast: results of therapy in 121 patients. *J Clin Oncol Off J Am Soc Clin Oncol.* 1983 Jun;1(6):400–5.
249. Flook D, Webster DJ, Hughes LE, Mansel RW. Salvage surgery for advanced local recurrence of breast cancer. *Br J Surg.* 1989 May;76(5):512–4.
250. Dahlstrøm KK, Andersson AP, Andersen M, Krag C. Wide local excision of recurrent breast cancer in the thoracic wall. *Cancer.* 1993 Aug 1;72(3):774–7.
251. Miyauchi K, Koyama H, Noguchi S, Inaji H, Yamamoto H, Kodama K, et al. Surgical treatment for chest wall recurrence of breast cancer. *Eur J Cancer Oxf Engl.* 1990. 1992;28A(6–7):1059–62.

252. Friedel G, Kuipers T, Dippon J, Al-Kammash F, Walles T, Kyriass T, et al. Full-thickness resection with myocutaneous flap reconstruction for locally recurrent breast cancer. *Ann Thorac Surg.* 2008 Jun;85(6):1894–900.
253. Aberizk WJ, Silver B, Henderson IC, Cady B, Harris JR. The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy. *Cancer.* 1986 Sep 15;58(6):1214–8.
254. Wilcken N, Hornbuckle J, Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. *Cochrane Database Syst Rev.* 2003;(2):CD002747.
255. Stockler M, Wilcken NR, Ghersi D, Simes RJ. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. *Cancer Treat Rev.* 2000 Jun;26(3):151–68.
256. Coates A, Gebiski V, Bishop JF, Jeal PN, Woods RL, Snyder R, et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. *N Engl J Med.* 1987 Dec 10;317(24):1490–5.
257. Muss HB, Case LD, Richards F, White DR, Cooper MR, Cruz JM, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. *N Engl J Med.* 1991 Nov 7;325(19):1342–8.
258. Ambros V. The functions of animal microRNAs. *Nature.* 2004;431(7006):350–5.
259. Bartel DP. MicroRNAs: target recognition and regulatory functions. *Cell.* 2009 Jan 23;136(2):215–33.
260. Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. *Annu Rev Biochem.* 2010;79:351–79.

261. Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, et al. Identification of hundreds of conserved and nonconserved human microRNAs. *Nat Genet.* 2005 Jul;37(7):766–70.
262. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell.* 2005 Jan 14;120(1):15–20.
263. Friedman RC, Farh KK-H, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. *Genome Res.* 2009 Jan;19(1):92–105.
264. Lee Y, Kim M, Han J, Yeom K-H, Lee S, Baek SH, et al. MicroRNA genes are transcribed by RNA polymerase II. *EMBO J.* 2004 Oct 13;23(20):4051–60.
265. Zhou X, Ruan J, Wang G, Zhang W. Characterization and identification of microRNA core promoters in four model species. *PLoS Comput Biol.* 2007 Mar 9;3(3):e37.
266. Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. *RNA N Y N.* 2004 Dec;10(12):1957–66.
267. Zhang W, Gao S, Zhou X, Xia J, Chellappan P, Zhou X, et al. Multiple distinct small RNAs originate from the same microRNA precursors. *Genome Biol.* 2010;11(8):R81.
268. Murchison EP, Hannon GJ. miRNAs on the move: miRNA biogenesis and the RNAi machinery. *Curr Opin Cell Biol.* 2004 Jun;16(3):223–9.
269. Park J-E, Heo I, Tian Y, Simanshu DK, Chang H, Jee D, et al. Dicer recognizes the 5' end of RNA for efficient and accurate processing. *Nature.* 2011 Jul 13;475(7355):201–5.
270. Ji X. The mechanism of RNase III action: how dicer dices. *Curr Top Microbiol Immunol.* 2008;320:99–116.

271. Krol J, Sobczak K, Wilczynska U, Drath M, Jasinska A, Kaczynska D, et al. Structural features of microRNA (miRNA) precursors and their relevance to miRNA biogenesis and small interfering RNA/short hairpin RNA design. *J Biol Chem*. 2004 Oct 1;279(40):42230–9.
272. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. *Cell*. 2003 Oct 17;115(2):209–16.
273. Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. *Cell*. 2003 Oct 17;115(2):199–208.
274. Lin S-L, Chang D, Ying S-Y. Asymmetry of intronic pre-miRNA structures in functional RISC assembly. *Gene*. 2005 Aug 15;356:32–8.
275. Pratt AJ, MacRae IJ. The RNA-induced silencing complex: a versatile gene-silencing machine. *J Biol Chem*. 2009 Jul 3;284(27):17897–901.
276. Schwarz DS, Zamore PD. Why do miRNAs live in the miRNP? *Genes Dev*. 2002 May 1;16(9):1025–31.
277. Kai ZS, Pasquinelli AE. MicroRNA assassins: factors that regulate the disappearance of miRNAs. *Nat Struct Mol Biol*. 2010 Jan;17(1):5–10.
278. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin S-F, Dunning MJ, et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. *Genome Biol*. 2007;8(10):R214.
279. Serpico D, Molino L, Di Cosimo S. microRNAs in breast cancer development and treatment. *Cancer Treat Rev*. 2014;40(5):595–604.
280. van Schooneveld E, Wouters MC, Van der Auwera I, Peeters DJ, Wildiers H, Van Dam PA, et al. Expression profiling of cancerous and normal breast tissues identifies microRNAs that

- are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. *Breast Cancer Res.* 2012;14(1):R34.
281. van Schooneveld E, Wildiers H, Vergote I, Vermeulen PB, Dirix LY, Van Laere SJ. Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. *Breast Cancer Res.* 2015;17(1):21.
282. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. *Dev Biol.* 2007;302(1):1–12.
283. Ferracin M, Bassi C, Pedriali M, Pagotto S, D'Abundo L, Zagatti B, et al. miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression. *Mol Cancer.* 2013;12(1):130.
284. Liu J, Mao Q, Liu Y, Hao X, Zhang S, Zhang J. Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. *Chin J Cancer Res.* 2013;25(1):46.
285. Elgamal OA, Park J-K, Gusev Y, Azevedo-Pouly ACP, Jiang J, Roopra A, et al. Tumor suppressive function of mir-205 in breast cancer is linked to HMGB3 regulation. *PloS One.* 2013;8(10):e76402.
286. Fan M, Sethuraman A, Brown M, Sun W, Pfeffer LM. Systematic analysis of metastasis-associated genes identifies miR-17-5p as a metastatic suppressor of basal-like breast cancer. *Breast Cancer Res Treat.* 2014;146(3):487–502.
287. Choi PS, Zakhary L, Choi W-Y, Caron S, Alvarez-Saavedra E, Miska EA, et al. Members of the miRNA-200 family regulate olfactory neurogenesis. *Neuron.* 2008;57(1):41–55.
288. Yi R, O'Carroll D, Pasolli HA, Zhang Z, Dietrich FS, Tarakhovsky A, et al. Morphogenesis in skin is governed by discrete sets of differentially expressed microRNAs. *Nat Genet.* 2006;38(3):356.

289. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. *Nat Cell Biol.* 2008;10(5):593.
290. Korpala M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. *J Biol Chem.* 2008;283(22):14910–4.
291. Park S-M, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. *Genes Dev.* 2008;22(7):894–907.
292. Xiang M, Birkbak NJ, Vafaizadeh V, Walker SR, Yeh JE, Liu S, et al. STAT3 induction of miR-146b forms a feedback loop to inhibit the NF- κ B to IL-6 signaling axis and STAT3-driven cancer phenotypes. *Sci Signal.* 2014;7(310):ra11.
293. Zhou L, Zhao X, Han Y, Lu Y, Shang Y, Liu C, et al. Regulation of UHRF1 by miR-146a/b modulates gastric cancer invasion and metastasis. *FASEB J.* 2013;27(12):4929–39.
294. Garcia AI, Buisson M, Bertrand P, Rimokh R, Rouleau E, Lopez BS, et al. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. *EMBO Mol Med.* 2011;3(5):279–90.
295. Klinge CM. miRNAs and estrogen action. *Trends Endocrinol Metab.* 2012 May;23(5):223–33.
296. Zhao J-J, Lin J, Yang H, Kong W, He L, Ma X, et al. MicroRNA-221/222 negatively regulates estrogen receptor α and is associated with tamoxifen resistance in breast cancer. *J Biol Chem.* 2008;283(45):31079–86.

297. Kondo N, Toyama T, Sugiura H, Fujii Y, Yamashita H. MiR-206 expression is down-regulated in estrogen receptor α -positive human breast cancer. *Cancer Res.* 2008;68(13):5004–8.
298. Cochrane DR, Spoelstra NS, Richer JK. The role of miRNAs in progesterone action. *Mol Cell Endocrinol.* 2012;357(1):50–9.
299. Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. *Mol Ther.* 2011;19(6):1116–22.
300. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. *Cancer Res.* 2010;70(14):5923–30.
301. Cortez MA, Valdecanas D, Zhang X, Zhan Y, Bhardwaj V, Calin GA, et al. Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. *Mol Ther.* 2014;22(8):1494–503.
302. Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, et al. MicroRNA silencing for cancer therapy targeted to the tumor microenvironment. *Nature.* 2015;518(7537):107.
303. American Cancer Society. *Cancer facts & figures.* The Society; 2008.
304. Ries L, Eisner M, Kosary C, Hankey B, Miller B, Clegg L, et al. *SEER Cancer Statistics Review, 1975-2004.* National Cancer Institute; Bethesda, MD: 2007. Available Seer Cancer Govcsr1975-2001. 2007;
305. Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E, on behalf of the ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO Clinical

- Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2012 Oct 1;23(suppl 7):vii11-vii19.
306. Newton CJ, Samuel DL, James VH. Aromatase activity and concentrations of cortisol, progesterone and testosterone in breast and abdominal adipose tissue. *J Steroid Biochem*. 1986 May;24(5):1033–9.
307. Åkerlund M, Batra S, Helm G. Comparison of plasma and myometrial tissue concentrations of estradiol-17 β and progesterone in nonpregnant women. *Contraception*. 1981;23(4):447–55.
308. Kinoshita T, Honma S, Shibata Y, Yamashita K, Watanabe Y, Maekubo H, et al. An innovative LC-MS/MS-based method for determining CYP 17 and CYP 19 activity in the adipose tissue of pre- and postmenopausal and ovariectomized women using ¹³C-labeled steroid substrates. *J Clin Endocrinol Metab*. 2014 Apr;99(4):1339–47.
309. Liang Y, Besch-Williford C, Brekken RA, Hyder SM. Progesterin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. *Cancer Res*. 2007 Oct 15;67(20):9929–36.
310. Liang Y, Benakanakere I, Besch-Williford C, Hyder RS, Ellersieck MR, Hyder SM. Synthetic progestins induce growth and metastasis of BT-474 human breast cancer xenografts in nude mice. *Menopause N Y N*. 2010 Oct;17(5):1040–7.
311. Jacobsen BM, Horwitz KB. Progesterone receptors, their isoforms and progesterone regulated transcription. *Mol Cell Endocrinol*. 2012;357(1):18–29.
312. Shatnawi A, Tran T, Ratnam M. R5020 and RU486 act as progesterone receptor agonists to enhance Sp1/Sp4-dependent gene transcription by an indirect mechanism. *Mol Endocrinol*. 2007;21(3):635–50.

313. Diaz J, Aranda E, Henriquez S, Quezada M, Espinoza E, Bravo ML, et al. Progesterone promotes focal adhesion formation and migration in breast cancer cells through induction of protease-activated receptor-1. *J Endocrinol.* 2012;214(2):165–75.
314. Fu X-D, Giretti MS, Baldacci C, Garibaldi S, Flamini M, Sanchez AM, et al. Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton. *PLoS One.* 2008;3(7):e2790.
315. Fu X-D, Goglia L, Sanchez AM, Flamini M, Giretti MS, Tosi V, et al. Progesterone receptor enhances breast cancer cell motility and invasion via extranuclear activation of focal adhesion kinase. *Endocr Relat Cancer.* 2010 Jun;17(2):431–43.
316. Holley AK, Kiningham KK, Spitz DR, Edwards DP, Jenkins JT, Moore MR. Progestin stimulation of manganese superoxide dismutase and invasive properties in T47D human breast cancer cells. *J Steroid Biochem Mol Biol.* 2009;117(1):23–30.
317. Henriquez S, Calderon C, Quezada M, Oliva B, Bravo ML, Aranda E, et al. Progesterone utilizes distinct membrane pools of tissue factor to increase coagulation and invasion and these effects are inhibited by TFPI. *J Cell Physiol.* 2011;226(12):3278–85.
318. Carnevale RP, Proietti CJ, Salatino M, Urtreger A, Peluffo G, Edwards DP, et al. Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways. *Mol Endocrinol.* 2007;21(6):1335–58.
319. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. *Breast Cancer Res.* 2007;9(1):R6.

320. Gomez-Fernandez C, Daneshbod Y, Nassiri M, Milikowski C, Alvarez C, Nadji M. Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer. *Am J Clin Pathol.* 2008;130(6):879–82.
321. Clemons M, Goss P. Estrogen and the risk of breast cancer. *N Engl J Med.* 2001;344(4):276–85.
322. Lin K-H, Wang W-J, Wu Y-H, Cheng S-Y. Activation of antimetastatic Nm23-H1 gene expression by estrogen and its α -receptor. *Endocrinology.* 2002;143(2):467–75.
323. Platet N, Cathiard AM, Gleizes M, Garcia M. Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. *Crit Rev Oncol Hematol.* 2004;51(1):55–67.
324. Beauchemin D, Lacombe C, Van Themsche C. PAX2 is activated by estradiol in breast cancer cells of the luminal subgroup selectively, to confer a low invasive phenotype. *Mol Cancer.* 2011;10:148.
325. Rochefort H, Platet N, Hayashido Y, Derocq D, Lucas A, Cunat S, et al. Estrogen receptor mediated inhibition of cancer cell invasion and motility: an overview. *J Steroid Biochem Mol Biol.* 1998 Apr;65(1–6):163–8.
326. Guttilla IK, Adams BD, White BA. ER α , microRNAs, and the epithelial–mesenchymal transition in breast cancer. *Trends Endocrinol Metab.* 2012 Feb;23(2):73–82.
327. Sisci D, Maris P, Cesario MG, Anselmo W, Coroniti R, Trombino GE, et al. The estrogen receptor α is the key regulator of the bifunctional role of FoxO3a transcription factor in breast cancer motility and invasiveness. *Cell Cycle Georget Tex.* 2013 Nov 1;12(21):3405–20.

328. Chandrasekharan S, Kandasamy KK, Dayalan P, Ramamurthy V. Estrogen induced concentration dependent differential gene expression in human breast cancer (MCF7) cells: Role of transcription factors. *Biochem Biophys Res Commun.* 2013 Aug 2;437(3):475–81.
329. Sartorius CA, Groshong SD, Miller LA, Powell RL, Tung L, Takimoto GS, et al. New T47D breast cancer cell lines for the independent study of progesterone B-and A-receptors: only antiprogesterin-occupied B-receptors are switched to transcriptional agonists by cAMP. *Cancer Res.* 1994;54(14):3868–77.
330. Wilson BJ, Giguère V. Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway. *Mol Cancer.* 2008;7(1):49.
331. Yan W, Cao QJ, Arenas RB, Bentley B, Shao R. GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition. *J Biol Chem.* 2010;285(18):14042–51.
332. Dhasarathy A, Kajita M, Wade PA. The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor- α . *Mol Endocrinol.* 2007;21(12):2907–18.
333. Ye Y, Xiao Y, Wang W, Yearsley K, Gao J, Shetuni B, et al. ER α signaling through slug regulates E-cadherin and EMT. *Oncogene.* 2010;29(10):1451–62.
334. Mishell DR. Pharmacokinetics of depot medroxyprogesterone acetate contraception. *J Reprod Med.* 1996 May;41(5 Suppl):381–90.
335. Osborne CK. *Endocrine Therapies in Breast and Prostate Cancer* [Internet]. Springer US; 1988. (Cancer treatment and research). Available from: <https://books.google.com/books?id=gW0eBAAAQBAJ>

336. Taylor MA, Parvani JG, Schiemann WP. The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor- β in normal and malignant mammary epithelial cells. *J Mammary Gland Biol Neoplasia*. 2010;15(2):169–90.
337. Wang X, Belguise K, O’neill CF, Sánchez-Morgan N, Romagnoli M, Eddy SF, et al. RelB NF- κ B represses estrogen receptor α expression via induction of the zinc finger protein Blimp1. *Mol Cell Biol*. 2009;29(14):3832–44.
338. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. *Nat Med*. 2004 Jan;10(1):33–9.
339. Hardy DB, Janowski BA, Corey DR, Mendelson CR. Progesterone receptor plays a major antiinflammatory role in human myometrial cells by antagonism of nuclear factor- κ B activation of cyclooxygenase 2 expression. *Mol Endocrinol*. 2006;20(11):2724–33.
340. Wu Y, Shi X, Guo S-W. The knockdown of progesterone receptor isoform B (PR-B) promotes proliferation in immortalized endometrial stromal cells. *Fertil Steril*. 2008;90(4):1320–3.
341. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. *Breast Cancer Res*. 2007;9(1):R6.
342. Ogba N, Manning NG, Bliesner BS, Ambler SK, Haughian JM, Pinto MP, et al. Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells. *Breast Cancer Res*. 2014;16(6):489.
343. Sumida T, Itahana Y, Hamakawa H, Desprez P-Y. Reduction of human metastatic breast cancer cell aggressiveness on introduction of either form A or B of the progesterone receptor and then treatment with progestins. *Cancer Res*. 2004;64(21):7886–92.
344. Test Guide historical References Ranges: Progesterone. 2014.

345. Dai D, Wolf DM, Litman ES, White MJ, Leslie KK. Progesterone inhibits human endometrial cancer cell growth and invasiveness. *Cancer Res.* 2002;62(3):881–6.
346. Bakker G, Setyono-Han B, Portengen H, De Jong F, Foekens J, Klijn J. Treatment of breast cancer with different antiprogestins: preclinical and clinical studies. *J Steroid Biochem Mol Biol.* 1990;37(6):789–94.
347. Di Leva G, Piovan C, Gasparini P, Nganheu A, Taccioli C, Briskin D, et al. Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. *PLoS Genet.* 2013;9(3):e1003311.
348. Wickramasinghe NS, Manavalan TT, Dougherty SM, Riggs KA, Li Y, Klinge CM. Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. *Nucleic Acids Res.* 2009 May;37(8):2584–95.
349. Maillot G, Lacroix-Triki M, Pierredon S, Gratadou L, Schmidt S, Bénès V, et al. Widespread estrogen-dependent repression of micromas involved in breast tumor cell growth. *Cancer Res.* 2009;69(21):8332–40.
350. Guttilla IK, Adams BD, White BA. ER α , microRNAs, and the epithelial–mesenchymal transition in breast cancer. *Trends Endocrinol Metab.* 2012;23(2):73–82.
351. Yamashita H, Gunduz P. Breast Cancer - Carcinogenesis, Cell Growth and Signalling Pathways. In Rijeka, Croatia: InTech; 2011.
352. Kent O, Mendell J. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. *Oncogene.* 2006;25(46):6188–96.
353. Oetken K. THE EFFECTS OF DIFFERENT ESTRADIOL DELIVERY METHODS ON PLASMA ESTRADIOL LEVELS IN MICE. 2013;

354. Nakada D, Oguro H, Levi BP, Ryan N, Kitano A, Saitoh Y, et al. Oestrogen increases haematopoietic stem-cell self-renewal in females and during pregnancy. *Nature*. 2014;505(7484):555–8.
355. Nilsson S, Möller C, Jirström K, Lee A, Busch S, Lamb R, et al. Downregulation of miR-92a is associated with aggressive breast cancer features and increased tumour macrophage infiltration. *PLoS One*. 2012;7(4):e36051.
356. Si H, Sun X, Chen Y, Cao Y, Chen S, Wang H, et al. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. *J Cancer Res Clin Oncol*. 2013 Feb 1;139(2):223–9.
357. Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. *Cell*. 2008;133(2):217–22.
358. Tan S, Ding K, Li R, Zhang W, Li G, Kong X, et al. Identification of miR-26 as a key mediator of estrogen stimulated cell proliferation by targeting CHD1, GREB1 and KPNA2. *Breast Cancer Res*. 2014;16(2):R40.
359. Zhu A, Kang N, He L, Li X, Xu X, Zhang H. MiR-221 and miR-26b Regulate Chemotactic Migration of MSCs Toward HGF Through Activation of Akt and FAK. *J Cell Biochem*. 2016;117(6):1370–83.
360. Miyamoto K, Seki N, Matsushita R, Yonemori M, Yoshino H, Nakagawa M, et al. Tumour-suppressive miRNA-26a-5p and miR-26b-5p inhibit cell aggressiveness by regulating PLOD2 in bladder cancer. *Br J Cancer*. 2016;115(3):354–63.

ABSTRACT**MECHANISMS OF HORMONAL REGULATION OF INVASIVENESS AND METASTASIS OF LUMINAL BREAST CANCER**

by

THOMAS MCFALL**December 2017****Advisor:** Dr. Manohar Ratnam**Major:** Cancer Biology**Degree:** Doctor of Philosophy

Over 20% of breast cancer cases present with distal metastasis and they are predominantly of luminal subtypes. As luminal breast cancer is relatively indolent, it is believed that progression to metastasis must occur over many years, generally well into post-menopausal years. Unfortunately, very little is known about the mechanisms by which these hormone receptor positive tumors metastasize, likely in part due to their slow metastatic rates in animal model systems as well. Moreover, the literature lacks adequate mechanistic understanding of cross talk between estradiol (E₂) and progesterone, particularly in the context of breast cancer invasion and metastasis. In this thesis, we sought to investigate the roles of estrogen and progesterone and their nuclear receptors to better understand hormonal regulation of metastasis at physiologically relevant hormone levels both pre- and post-menopause. The novelty of our experimental approach and study design is three-fold: 1. exploration of the isoform-specific actions of the progesterone receptor; 2. investigation of selective micro RNA mediated pathways of cross talk between estrogen and progesterone and 3. development of a quantitative lymph node infiltration assay to monitor metastasis of luminal breast cancer in xenograft models.

AUTOBIOGRAPHICAL STATEMENT

Thomas McFall was born in Kalamazoo Michigan in 1985. Graduated from Northern Michigan University with a B.S. in Biology/Human Physiology in 2008 and an M.S. in Biology in 2012.